Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.23.46 - memapsin 2

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abscess
Hidradenitis Suppurativa: Proposal of Classification in Two Endotypes with Two-Step Cluster Analysis.
Acute Kidney Injury
Targeted gamma-secretase inhibition of Notch signaling activation in acute renal injury.
Acute Lung Injury
Gamma-Secretase Inhibitors Attenuate Neurotrauma and Neurogenic Acute Lung Injury in Rats by Rescuing the Accumulation of Hypertrophic Microglia.
Adenocarcinoma
Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles.
Gamma-secretase complexes regulate the responses of human pancreatic ductal adenocarcinoma cells to taxanes.
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma.
Pathogenesis of Barrett's esophagus: bile acids inhibit the Notch signaling pathway with induction of CDX2 gene expression in human esophageal cells.
Adenocarcinoma of Lung
Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma.
Albuminuria
The pathogenic role of notch activation in podocytes.
Alzheimer Disease
(S)-N-(5-Chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol a Notch-1-sparing gamma-secretase inhibitor.
1,3-Oxazines as BACE1 and/or BACE2 inhibitors: a patent evaluation (WO2012156284).
1,4-Oxazine ?-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads.
1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
2,6-Disubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.
3-Substituted gem-cyclohexane sulfone based gamma-secretase inhibitors for Alzheimer's disease: conformational analysis and biological activity.
3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice.
4-substituted cyclohexyl sulfones as potent, orally active gamma-secretase inhibitors.
6beta-acetoxy nortropane regulated processing of amyloid precursor protein in CHOm1 cells and rat brain.
7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease.
?-Secretase activity in rat astrocytes: translational block of BACE1 and modulation of BACE2 expression.
?-secretase BACE1 is required for normal cochlear function.
?-Secretase BACE1 Regulates Hippocampal and Reconstituted M-Currents in a ?-Subunit-Like Fashion.
?-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification.
?-Secretase: its biology as a therapeutic target in diseases.
?-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces A?5-X peptides through alternative amyloid precursor protein cleavage.
?-Site APP-cleaving enzyme 1 (BACE1) cleaves cerebellar Na+ channel ?4-subunit and promotes Purkinje cell firing by slowing the decay of resurgent Na+ current.
?-Site APP-cleaving enzyme 1 trafficking and Alzheimer's disease pathogenesis.
A Canine Model to Evaluate Efficacy and Safety of ?-Secretase Inhibitors and Modulators.
A Case of Early-Onset Alzheimer's Disease Mimicking Schizophrenia in a Patient with Presenilin 1 Mutation (S170P).
A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.
A continuous time-resolved fluorescence assay for identification of BACE1 inhibitors.
A copper-binding site in the cytoplasmic domain of BACE1 identifies a possible link to metal homoeostasis and oxidative stress in Alzheimer's disease.
A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families.
A function for EHD family proteins in unidirectional retrograde dendritic transport of BACE1 and Alzheimer's disease A? production.
A further presenilin 1 mutation in the exon 8 cluster in familial Alzheimer's disease.
A G-Rich element forms a G-quadruplex and regulates BACE1 mRNA alternative splicing.
A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish.
A Glycosaminoglycan Extract from Portunus pelagicus Inhibits BACE1, the ? Secretase Implicated in Alzheimer's Disease.
A GPCR/secretase complex regulates beta- and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis.
A helix-to-coil transition at the epsilon-cut site in the transmembrane dimer of the amyloid precursor protein is required for proteolysis.
A Hypothesis and Evidence That Mercury May be an Etiological Factor in Alzheimer's Disease.
A Method for Induced-Fit Docking, Scoring, and Ranking of Flexible Ligands. Application to Peptidic and Pseudopeptidic beta-secretase (BACE 1) Inhibitors.
A Miniaturized 1536-Well Format gamma-Secretase Assay *
A molecular dynamics study of the BACE1 conformational change from Apo to closed form induced by hydroxyethylamine derived compounds.
A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer's disease.
A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin-1 gene.
A myristoylated calcium-binding protein that preferentially interacts with the Alzheimer's disease presenilin 2 protein.
A new and simple approach for genotyping Alzheimer's disease presenilin-1 mutant knock-in mice.
A New Decision Tree to Solve the Puzzle of Alzheimer's Disease Pathogenesis Through Standard Diagnosis Scoring System.
A New Presenilin 1 (Psen1) Mutation (p.Cys263Trp) as a Cause of Both Early and Late-Onset Alzheimer's Disease in a Large Italian Family.
A new presenilin Alzheimer's disease case confirms the helical alignment of pathogenic mutations in transmembrane domain 5.
A new series of potent benzodiazepine gamma-secretase inhibitors.
A nine-transmembrane domain topology for presenilin 1.
A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.
A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease.
A novel Leu171Pro mutation in presenilin-1 gene in a Mexican family with early onset Alzheimer disease.
A novel missense mutation (G209R) in exon 8 of the presenilin 1 gene in a Japanese family with presenile familial Alzheimer's disease. Mutation in brief no. 254. Online.
A novel missense mutation in the presenilin-1 gene in a familial Alzheimer's disease pedigree with abundant amyloid angiopathy.
A novel mutation (G217D) in the Presenilin 1 gene ( PSEN1) in a Japanese family: presenile dementia and parkinsonism are associated with cotton wool plaques in the cortex and striatum.
A novel mutation (L250V) in the presenilin 1 gene in a Japanese familial Alzheimer's disease with myoclonus and generalized convulsion.
A novel mutation (Thr116Ile) in the presenilin 1 gene in a patient with early-onset Alzheimer's disease.
A novel mutation (V89L) in the presenilin 1 gene in a family with early onset Alzheimer's disease and marked behavioural disturbances.
A novel mutation in PSEN1 (p.Arg41Ser) in an Argentinian woman with early onset Parkinsonism.
A novel mutation in the PSEN2 gene (T430M) associated with variable expression in a family with early-onset Alzheimer disease.
A novel mutation of presenilin 1 in familial Alzheimer's disease in Israel detected by denaturing gradient gel electrophoresis.
A novel pathogenic mutation (Leu262Phe) found in the presenilin 1 gene in early-onset Alzheimer's disease.
A novel Polish presenilin-1 mutation (P117L) is associated with familial Alzheimer's disease and leads to death as early as the age of 28 years.
A novel presenilin 1 deletion (p.L166del) associated with early onset familial Alzheimer's disease.
A novel presenilin 1 duplication mutation (Ile168dup) causing Alzheimer's disease associated with myoclonus, seizures and pyramidal features.
A novel presenilin 1 L166H mutation in a pseudo-sporadic case of early-onset Alzheimer's disease.
A novel presenilin 1 missense mutation (L153V) segregating with early-onset autosomal dominant Alzheimer's disease.
A novel presenilin 1 mutation (Ala275Val) as cause of early-onset familial Alzheimer disease.
A novel presenilin 1 mutation (F388L) identified in a Chinese family with early-onset Alzheimer's disease.
A novel presenilin 1 mutation (L174 M) in a large Cuban family with early onset Alzheimer disease.
A novel presenilin 1 mutation (L282F) in familial Alzheimer's disease.
A novel presenilin 1 mutation (Leu166Arg) associated with early-onset Alzheimer disease.
A novel presenilin 1 mutation (Ser169del) in a Chinese family with early-onset Alzheimer's disease.
A novel presenilin 1 mutation (V261L) associated with presenile Alzheimer's disease and spastic paraparesis.
A novel presenilin 1 mutation (Y154N) in a patient with early onset Alzheimer's disease with spastic paraparesis.
A Novel Presenilin 1 Mutation in Early-Onset Alzheimer's Disease With Prominent Frontal Features.
A novel presenilin 1 mutation resulting in familial Alzheimer's disease with an onset age of 29 years.
A novel presenilin 1 mutation, I202F occurring at a previously predicted pathogenic site causing autosomal dominant Alzheimer's disease.
A novel presenilin mutation (M233V) causing very early onset Alzheimer's disease with Lewy bodies.
A novel presenilin-1 mutation (Leu85Pro) in early-onset Alzheimer disease with spastic paraparesis.
A novel presenilin-2 splice variant in human Alzheimer's disease brain tissue.
A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease.
A novel PSEN1 H163P mutation in a patient with early-onset Alzheimer's disease: clinical, neuroimaging, and neuropathological findings.
A Novel PSEN1 K311R Mutation Discovered in Chinese Families with Late-Onset Alzheimer's Disease Affects Amyloid-? Production and Tau Phosphorylation.
A novel PSENEN mutation in a patient with complaints of memory loss and a family history of dementia.
A novel role for {gamma}-secretase: selective regulation of spontaneous neurotransmitter release from hippocampal neurons.
A novel sorting nexin modulates endocytic trafficking and alpha-secretase cleavage of the amyloid precursor protein.
A novel substrate for analyzing Alzheimer's disease gamma-secretase.
A novel V272D presenilin mutation associated with logopenia, disorientation, and apraxia in an autosomal-dominant Alzheimer's disease family.
A Nuclear Function for the Presenilin 1 Neuronal Partner NPRAP/?-Catenin.
A pathogenic presenilin-1 deletion causes abberrant Abeta 42 production in the absence of congophilic amyloid plaques.
A pathogenic PSEN1 Trp165Cys mutation associated with early-onset Alzheimer's disease.
A pathogenic PSEN2 p.His169Asn mutation associated with early-onset Alzheimer's disease.
A patient with posterior cortical atrophy possesses a novel mutation in the presenilin 1 gene.
A pedigree with a novel presenilin 1 mutation at a residue that is not conserved in presenilin 2.
A physicochemical descriptor based method for effective and rapid screening of dual inhibitors against BACE-1 and GSK-3? as targets for Alzheimer's disease.
A PM7 dynamic residue-ligand interactions energy landscape of the BACE1 inhibitory pathway by hydroxyethylamine compounds. Part I: The flap closure process.
A Polish pedigree with Alzheimer's disease determined by a novel mutation in exon 12 of the presenilin 1 gene: clinical and molecular characterization.
A polymorphism in the presenilin 1 gene does not modify risk for Alzheimer's disease in a cohort with sporadic early onset.
A presenilin 1 mutation (Arg278Ser) associated with early onset Alzheimer's disease and spastic paraparesis.
A presenilin 1 mutation (L420R) in a family with early onset Alzheimer disease, seizures and cotton wool plaques, but not spastic paraparesis.
A presenilin 1 mutation in the first case of Alzheimer's disease.
A presenilin 1 mutation in the first case of Alzheimer's disease: revisited.
A presenilin-1 mutation (T245P) in transmembrane domain 6 causes early onset Alzheimer's disease.
A presenilin-1 mutation causes Alzheimer disease without affecting Notch signaling.
A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity.
A presenilin-1 mutation in a Japanese family with Alzheimer's disease and distinctive abnormalities on cranial MRI.
A presenilin-1 mutation renders neurons vulnerable to isoflurane toxicity.
A presenilin-1 Thr116Asn substitution in a family with early-onset Alzheimer's disease.
A presenilin-1 truncating mutation is present in two cases with autopsy-confirmed early-onset Alzheimer disease.
A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain.
A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions.
A promising, novel, and unique BACE1 inhibitor emerges in the quest to prevent Alzheimer's disease.
A protective role of the low density lipoprotein receptor-related protein against amyloid beta-protein toxicity.
A quantitative autoradiographic study of [3H]cAMP binding to cytosolic and particulate protein kinase A in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits.
A Rare Variation in the 3' Untranslated Region of the Presenilin 2 Gene Is Linked to Alzheimer's Disease.
A reversible form of lysine acetylation in the ER and Golgi lumen controls the molecular stabilization of BACE1.
A Review of the Familial Alzheimer's Disease Locus PRESENILIN 2 and Its Relationship to PRESENILIN 1.
A RIP tide in neuronal signal transduction.
A secreted type of beta1,6 N-acetylglucosaminyltransferase V (GnT-V), a novel angiogenesis inducer, is regulated by gamma-secretase.
A sensitive and quantitative assay for measuring cleavage of presenilin substrates.
A strategy focused on MAPT, APP, NCSTN and BACE1 to build blood classifiers for Alzheimer's disease.
A Study On Cytogenetic And Molecular Analysis Of Presenilin 1 (Ps1) Gene In Alzheimer's Disease.
A surface plasmon resonance-based biosensor with full-length BACE1 in a reconstituted membrane.
A synthetic substrate assay for the gamma-secretase of the beta-A4 amyloid of Alzheimer's disease.
A system for enhancing genome-wide coexpression dynamics study.
A systematic review on anti-Alzheimer's disease activity of prescription Kangen-karyu.
A therapeutic antibody targeting BACE1 inhibits amyloid-? production in vivo.
A unifying model for functional difference and redundancy of presenilin-1 and -2 in cell apoptosis and differentiation.
A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1.
A? reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level.
A?42 oligomers modulate ?-secretase through an XBP-1s-dependent pathway involving HRD1.
A?42/A?40 Ratios of Presenilin 1 Mutations Correlate with Clinical Onset of Alzheimer's Disease.
A?43-producing PS1 FAD mutants cause altered substrate interactions and respond to ?-secretase modulation.
A?PP/PS1 Transgenic Mice Show Sex Differences in the Cerebellum Associated with Aging.
Aberrant accentuation of neurofibrillary degeneration in the hippocampus of Alzheimer's disease with amyloid precursor protein 717 and presenilin-1 gene mutations.
Aberrant amyloid precursor protein (APP) processing in hereditary forms of Alzheimer disease caused by APP familial Alzheimer disease mutations can be rescued by mutations in the APP GxxxG motif.
Aberrant expressions of pathogenic phenotype in Alzheimer's diseased transgenic mice carrying NSE-controlled APPsw.
Aberrant induction of Par-4 is involved in apoptosis of hippocampal neurons in presenilin-1 M146V mutant knock-in mice.
Aberrant presenilin-1 expression downregulates LDL receptor-related protein (LRP): is LRP central to Alzheimer's disease pathogenesis?
Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer's disease by increased Abeta42 secretion.
Abeta 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis.
Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease.
Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain.
Abnormal blood vessel development in mice lacking presenilin-1.
Abnormal cross-talk between mutant presenilin 1 (I143T, G384A) and glycosphingolipid biosynthesis.
Abnormal gel-electrophoretic behavior of presenilin 1 and it's fragment.
Accelerated acquisition of permeability barrier function in the skin of presenilin-1-deficient embryos.
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes.
Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins.
Accelerated long-term forgetting is a BACE1 inhibitor-reversible incipient cognitive phenotype in Alzheimer's disease model mice.
Accumulation of murine amyloidbeta42 in a gene-dosage-dependent manner in PS1 'knock-in' mice.
Accurate determination of carboxyl-terminal fragment of Presenilin 1 in various tissues from rat and cell lines.
Activating transcription factor 6 reduces A?1-42 and restores memory in Alzheimer's disease model mice.
Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation.
Activation of Liver X Receptor Decreases BACE1 Expression and Activity by Reducing Membrane Cholesterol Levels.
Activation of PKR causes amyloid ß-peptide accumulation via de-repression of BACE1 expression.
Activity of gamma-secretase on substrates other than APP.
Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway.
Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease.
Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets.
Acylguanidines as small-molecule beta-secretase inhibitors.
ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons.
ADAM19 is tightly associated with constitutive Alzheimer's disease APP alpha-secretase in A172 cells.
ADAM19/adamalysin 19 structure, function, and role as a putative target in tumors and inflammatory diseases.
ADAMs family members as amyloid precursor protein alpha-secretases.
Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid beta-protein.
Age-dependent impairment of spine morphology and synaptic plasticity in hippocampal CA1 neurons of a presenilin 1 transgenic mouse model of Alzheimer's disease.
Age-Dependent, Non-Cell-Autonomous Deposition of Amyloid from Synthesis of ?-Amyloid by Cells Other Than Excitatory Neurons.
Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss.
Age-related impairment of cerebral blood flow response to KATP channel opener in Alzheimer's disease mice with presenilin-1 mutation.
Age-related progressive synaptic dysfunction: the critical role of presenilin 1.
Age-related vascular pathology in transgenic mice expressing presenilin 1-associated familial Alzheimer's disease mutations.
Akt activity in presenilin 1 wild-type and mutation transfected human SH-SY5Y neuroblastoma cells after serum deprivation and high glucose stress.
Alcadein cleavages by APP {alpha}-and {gamma}-secretases generate small peptides p3-Alcs indicating Alzheimer disease-related {gamma}-secretase dysfunction.
Alleles at the Nicastrin locus modify presenilin 1- deficiency phenotype.
Allosteric inhibition of BACE1 by an exosite-binding antibody.
Allosteric Modulation of Intact ?-Secretase Structural Dynamics.
Alpha, beta-and gamma-secretases in Alzheimer's disease.
alpha- and beta-secretase: profound changes in Alzheimer's disease.
Alpha-secretase activation--an approach to Alzheimer's disease therapy.
Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment.
Alpha-secretase as a therapeutic target.
alpha-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential.
alpha-secretase mediated conversion of the Amyloid Precursor Protein derived membrane stub C99 to C83 limits Abeta generation.
Alpha-secretase-derived product of beta-amyloid precursor protein is decreased by presenilin 1 mutations linked to familial Alzheimer's disease.
Alteration in brain presenilin 1 mRNA expression in early onset familial Alzheimer's disease.
Alteration in brain presenilin-1 mRNA expression in sporadic Alzheimer's disease.
Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice.
Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease.
Alterations in excitotoxicity and prostaglandin metabolism in a transgenic mouse model of Alzheimer's disease.
Alterations in presenilin 1 processing by amyloid-beta peptide in the rat retina.
Alterations in Striatal microRNA-mRNA Networks Contribute to Neuroinflammation in Multiple System Atrophy.
Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice.
Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain.
Altered binding of mutated presenilin with cytoskeleton-interacting proteins.
Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1 mutant mice.
Altered Cholesterol Intracellular Trafficking and the Development of Pathological Hallmarks of Sporadic AD.
Altered expression of apolipoprotein E, amyloid precursor protein and presenilin-1 is associated with chronic reactive gliosis in rat cortical tissue.
Altered morphological and electrophysiological properties of Cajal-Retzius cells in cerebral cortex of embryonic Presenilin-1 knockout mice.
Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease.
Alternative processing of ?-secretase substrates in common forms of mild cognitive impairment and Alzheimer's disease: evidence for ?-secretase dysfunction.
Alternative splicing in a presenilin 2 variant associated with Alzheimer disease.
Alternative splicing in the N-terminus of Alzheimer's presenilin 1.
Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts.
Alzheimer disease gamma-secretase: a complex story of GxGD-type presenilin proteases.
Alzheimer disease: BACE1 branches out.
Alzheimer disease: BACE1 inhibition could block CSF tau increase.
Alzheimer disease: BACE1 inhibitor reduces ?-amyloid production in humans.
Alzheimer disease: BACE1 inhibitors block new A? plaque formation.
Alzheimer disease: update on basic mechanisms.
Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation.
Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase.
Alzheimer's Disease and Hippocampal Adult Neurogenesis; Exploring Shared Mechanisms.
Alzheimer's disease and Notch signaling.
Alzheimer's Disease Associated Presenilin 1 and 2 Genes Dysregulation in Neonatal Lymphocytes Following Perinatal Asphyxia.
Alzheimer's disease associated presenilin 1 interacts with HC5 and ZETA, subunits of the catalytic 20S proteasome.
Alzheimer's disease associated presenilin-1 holoprotein and its 18-20 kDa C-terminal fragment are death substrates for proteases of the caspase family.
Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme.
Alzheimer's disease BIN1 coding variants increase intracellular A? levels by interfering with BACE1 recycling.
Alzheimer's disease due to an intronic presenilin-1 (PSEN1 intron 4) mutation: A clinicopathological study.
Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2.
Alzheimer's disease presenilin-1 exon 9 deletion and L250S mutations sensitize SH-SY5Y neuroblastoma cells to hyperosmotic stress-induced apoptosis.
Alzheimer's disease presenilin-1 expression modulates the assembly of neurofilaments.
Alzheimer's Disease Presenilin-1 Mutation Sensitizes Neurons to Impaired Autophagy Flux and Propofol Neurotoxicity: Role of Calcium Dysregulation.
Alzheimer's disease with spastic paresis and cotton wool type plaques.
Alzheimer's Disease, Drosophila melanogaster and Polyphenols.
Alzheimer's disease-associated presenilins 1 and 2: accelerated amyloid fibril formation of mutant 410 Cys-->Tyr and 141 Asn-->Ile peptides.
Alzheimer's disease-causing proline substitutions lead to presenilin 1 aggregation and malfunction.
Alzheimer's disease-like alterations in peripheral cells from presenilin-1 transgenic mice.
Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified ?-secretase complexes.
Alzheimer's disease-related gene expression in the brain of senescence accelerated mouse.
Alzheimer's disease. Closing in on gamma-secretase.
Alzheimer's disease. In search of gamma-secretase.
Alzheimer's disease. Molecular consequences of presenilin-1 mutation.
Alzheimer's Disease: APP, Gamma Secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and Their Relationships with Herpes Simplex, C. Pneumoniae, Other Suspect Pathogens, and the Immune System.
Alzheimer's disease: from pathology to therapeutic approaches.
Alzheimer's disease: genetic studies and transgenic models.
Alzheimer's disease: Selectively tuning gamma-secretase.
Alzheimer's presenilin 1 causes chromosome missegregation and aneuploidy.
Alzheimer's presenilin 1 is a putative membrane receptor for rab GDP dissociation inhibitor.
Alzheimer's presenilin 1 modulates sorting of APP and its carboxyl-terminal fragments in cerebral neurons in vivo.
Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals.
Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta-peptide.
Alzheimer's secretases regulate voltage-gated sodium channels.
Alzheimer-associated C allele of the promoter polymorphism -22C>T causes a critical neuron-specific decrease of presenilin 1 expression.
Alzheimer-associated presenilin-2 confers increased sensitivity to apoptosis in PC12 cells.
Ameliorative effects of a non-competitive BACE1 inhibitor TAK-070 on A? peptide levels and impaired learning behavior in aged rats.
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1.
Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques.
Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality.
Amyloid ? aggregation inhibitory activity of triterpene saponins from the cactus Stenocereus pruinosus.
Amyloid ? production along the neuronal secretory pathway: Dangerous liaisons in the Golgi?
Amyloid ?-protein oligomers upregulate the ?-secretase, BACE1, through a post-translational mechanism involving its altered subcellular distribution in neurons.
Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease.
Amyloid angiopathy in a Volga German family with Alzheimer's disease and a presenilin-2 mutation (N141I).
Amyloid at the cutting edge: activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model.
Amyloid beta secretase gene (BACE) is neither mutated in nor associated with early-onset Alzheimer's disease.
Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages.
Amyloid precursor protein associates with a nicastrin-dependent docking site on the presenilin 1-gamma-secretase complex in cells demonstrated by fluorescence lifetime imaging.
Amyloid precursor protein gene analysis in familial Alzheimer's disease cases: a lack of mutations in exons 16 and 17.
Amyloid precursor protein heat shock response in lymphoblastoid cell lines bearing presenilin-1 mutations.
Amyloid precursor protein processing in human neurons with an allelic series of the PSEN1 intron 4 deletion mutation and total presenilin-1 knockout.
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.
Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease.
Amyloid protein-mediated differential DNA methylation status regulates gene expression in Alzheimer's disease model cell line.
Amyloid-? precursor protein processing and oxidative stress are altered in human iPSC-derived neuron and astrocyte co-cultures carrying presenillin-1 gene mutations following spontaneous differentiation.
Amyloid-beta reduction by memapsin 2 (beta-secretase) immunization.
Amyloid-beta, BACE, and oxidative stress in Alzheimer's disease, a commentary on "The different aggregation state of beta-amyloid 1-42 mediates different effects on oxidative stress, neurodegeneration and BACE-1 expression".
Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
Amyloidogenic processing of human amyloid precursor protein in hippocampal neurons devoid of cathepsin D.
An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease.
An alternative spliced mouse presenilin-2 mRNA encodes a novel gamma-secretase inhibitor.
An Alzheimer's disease-linked PS1 variant rescues the developmental abnormalities of PS1-deficient embryos.
An APP inhibitory domain containing the Flemish mutation residue modulates gamma-secretase activity for Abeta production.
An atomic structure of human ?-secretase.
An empirical model of gamma-secretase activity.
An exo-cell assay for examining real-time gamma-secretase activity and inhibition.
An intronic polymorphism in the presenilin-1 gene does not influence the amount or molecular form of the amyloid beta protein deposited in Alzheimer's disease.
An NSAID-like compound, FT-9, preferentially inhibits gamma-secretase cleavage of APP compared to its effect on APLP1.
An Orally Available BACE1 Inhibitor That Affords Robust CNS A? Reduction without Cardiovascular Liabilities.
Anagliptin protects neuronal cells against endogenous amyloid ? (A?)-induced cytotoxicity and apoptosis.
Analysis of alteration of p75NTR processing and signalling by PS2 mutation and gamma-secretase inhibition.
Analysis of presenilin 1 and presenilin 2 expression and processing by newly developed monoclonal antibodies.
Analysis of the 5' sequence, genomic structure, and alternative splicing of the presenilin-1 gene (PSEN1) associated with early onset Alzheimer disease.
Angela R.: a familial Alzheimer's disease case in the days of Auguste D.
Antisense inhibition at the beta-secretase-site of beta-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576.
Antisense-induced reduction of presenilin 1 expression selectively increases the production of amyloid beta42 in transfected cells.
AP-2 reduces amyloidogenesis by promoting BACE1 trafficking and degradation in neurons.
Apolipoprotein E and amyloidogenesis.
Apolipoprotein E and intronic polymorphism of presenilin 1 and alpha-1-antichymotrypsin in Alzheimer's disease and vascular dementia.
Apolipoprotein E and presenilin-1 allelic variation and Alzheimer's disease in India.
Apolipoprotein E and presenilin-1 genotypes in Huntington's disease.
Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred.
Apoptogenic interactions of plasmalemmal type-1 VDAC and A? peptides via GxxxG motifs induce Alzheimer's disease - a basic model of apoptosis?
Apoptotic proteolytic cleavage of the presenilins by caspases.
APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease.
APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1.
APP substitutions V715F and L720P alter PS1 conformation and differentially affect Abeta and AICD generation.
APP transgenic mice and their application to drug discovery.
APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases.
Application of a Bioinformatics-Based Approach to Identify Novel Putative in vivo BACE1 Substrates.
Application of BACE1 immobilized enzyme reactor for the characterization of multifunctional alkaloids from Corydalis cava (Fumariaceae) as Alzheimer's disease targets.
Application of molecular framework-based data-mining method in the search for beta-secretase 1 inhibitors through drug repurposing.
Application of quantitative LC-MS surrogate peptide methodology in the analysis of the amyloid beta peptide (Abeta) biosynthetic intermediate protein APP-betaCTF.
Approaches for detecting lysosomal alkalinization and impaired degradation in fresh and cultured RPE cells: evidence for a role in retinal degenerations.
Aryl sulfones: a new class of gamma-secretase inhibitors.
Aspartate mutations in presenilin and gamma-secretase inhibitors both impair notch1 proteolysis and nuclear translocation with relative preservation of notch1 signaling.
Aspartic proteases involved in Alzheimer's disease.
Aspartyl protease inhibitor pepstatin binds to the presenilins of Alzheimer's disease.
Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease.
Assembly, trafficking and function of gamma-secretase.
Association between a PS-1 intronic polymorphism and late onset Alzheimer's disease.
Association between presenilin 1 intronic polymorphism and late onset Alzheimer's disease in the North Chinese population.
Association between presenilin-1 Glu318Gly mutation and familial Alzheimer's disease in the Australian population.
Association between the presenilin-1 mutation Glu318Gly and complaints of memory impairment.
Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype.
Association of apolipoprotein E genotype and intronic polymorphism of the presenilin-1 gene with Alzheimer's disease in elderly Taiwan Chinese.
Association of BACE1 gene polymorphism with Alzheimer's disease in Asian populations: meta-analysis including Korean samples.
Association of presenilin-1 polymorphism with cerebral amyloid angiopathy in the elderly.
Association of PS1 1/2, ACE I/D, and LRP C/T polymorphisms with Alzheimer's disease in the Chinese population: a meta-analysis of case-control studies.
Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome.
Association study and meta-analysis of Alzheimer's disease risk and presenilin-1 intronic polymorphism.
Association study between Alzheimer's disease and genes involved in Abeta biosynthesis, aggregation and degradation: suggestive results with BACE1.
Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred: A Cross-sectional Study.
Astragaloside IV, a Natural PPAR? Agonist, Reduces A? Production in Alzheimer's Disease Through Inhibition of BACE1.
Asymptomatic Carriers of Presenilin-1 E318G Variant Show no Cerebrospinal Fluid Biochemical Signs Suggestive of Alzheimer's disease in a Family with Late-onset Dementia.
At the frontline of Alzheimer's disease treatment: gamma-secretase inhibitor/modulator mechanism.
ATF4 regulates gamma-secretase activity during amino acid imbalance.
Attenuated presenilin-1 endoproteolysis enhances store-operated calcium currents in neuronal cells.
Attitudes and knowledge about genetic testing before and after finding the disease-causing mutation among individuals at high risk for familial, early-onset Alzheimer's disease.
Atypical early-onset Alzheimer's disease caused by the Iranian APP mutation.
Atypical presentation of a novel Presenilin 1 R377W mutation: sporadic, late-onset Alzheimer disease with epilepsy and frontotemporal atrophy.
Autophagy impairment stimulates PS1 expression and gamma-secretase activity.
Autophagy Induction by Bexarotene Promotes Mitophagy in Presenilin 1 Familial Alzheimer's Disease iPSC-Derived Neural Stem Cells.
Autophagy-mediated Regulation of BACE1 Protein Trafficking and Degradation.
Autopsy-confirmed familial early-onset Alzheimer disease caused by the l153V presenilin 1 mutation.
Avoidance of Apoptosis in Alzheimer's Disease.
Axonal and Schwann Cell BACE1 Is Equally Required for Remyelination of Peripheral Nerves.
Axonal BACE1 dynamics and targeting in hippocampal neurons: a role for Rab11 GTPase.
AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease.
BACE inhibitor treatment of mice induces hyperactivity in a Seizure-related gene 6 family dependent manner without altering learning and memory.
BACE-1 and ?-Secretase as Therapeutic Targets for Alzheimer's Disease.
BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296.
BACE-1 inhibitors part 1: identification of novel hydroxy ethylamines (HEAs).
BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease.
BACE-1 is expressed in the blood-brain barrier endothelium and is upregulated in a murine model of Alzheimer's disease.
BACE1 (?-secretase) inhibitors for the treatment of Alzheimer's disease.
BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes.
BACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and rats.
BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
BACE1 activity is modulated by cell-associated sphingosine-1-phosphate.
BACE1 activity regulates cell surface contactin-2 levels.
BACE1 and BACE2 enzymatic activities in Alzheimer's disease.
BACE1 and Other Alzheimer's-Related Biomarkers in Cerebrospinal Fluid and Plasma Distinguish Alzheimer's Disease Patients from Cognitively-Impaired Neurosyphilis Patients.
BACE1 and presenilin/?-secretase regulate proteolytic processing of KCNE1 and 2, auxiliary subunits of voltage-gated potassium channels.
BACE1 and presenilin: two unusual aspartyl proteases involved in Alzheimer's disease.
BACE1 as a Potential Biomarker for Alzheimer's Disease.
BACE1 as a Therapeutic Target in Alzheimer's Disease: Rationale and Current Status.
BACE1 controls synaptic function through modulating release of synaptic vesicles.
BACE1 Deficiency Causes Abnormal Neuronal Clustering in the Dentate Gyrus.
BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease.
BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions.
BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.
BACE1 Elevation is Involved in Amyloid Plaque Development in the Triple Transgenic Model of Alzheimer's Disease: Differential A? Antibody Labeling of Early-Onset Axon Terminal Pathology.
BACE1 expression and activity: relevance in Alzheimer's disease.
BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology.
BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease.
BACE1 gene promoter single-nucleotide polymorphisms in Alzheimer's disease.
BACE1 gene variants do not influence BACE1 activity, levels of APP or A? isoforms in CSF in Alzheimer's disease.
BACE1 in Alzheimer's disease.
BACE1 in the retina: a sensitive biomarker for monitoring early pathological changes in Alzheimer's disease.
BACE1 inhibition as a therapeutic strategy for Alzheimer's disease.
BACE1 inhibition induces a specific cerebrospinal fluid ?-amyloid pattern that identifies drug effects in the central nervous system.
BACE1 inhibition more effectively suppresses initiation than progression of ?-amyloid pathology.
BACE1 Inhibition Using 2'-OMePS Steric Blocking Antisense Oligonucleotides.
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease.
BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease.
BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and ?-amyloid production in Alzheimer's disease.
BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus.
BACE1 levels are increased in plasma of Alzheimer's disease patients compared with matched cognitively healthy controls.
BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains.
BACE1 Levels Correlate with Phospho-Tau Levels in Human Cerebrospinal Fluid.
BACE1 modulates filopodia-like protrusions induced by sodium channel beta4 subunit.
BACE1 modulates gating of KCNQ1 (Kv7.1) and cardiac delayed rectifier KCNQ1/KCNE1 (IKs).
BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides.
BACE1 mRNA Expression in Alzheimer's Disease Postmortem Brain Tissue.
BACE1 partial deletion induces synaptic plasticity deficit in adult mice.
BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
BACE1 polymorphisms do not influence platelet membrane beta-secretase activity or genetic susceptibility for Alzheimer's disease in the Northern Irish population.
BACE1 regulates hippocampal astrogenesis via the Jagged1-Notch pathway.
BACE1 regulates voltage-gated sodium channels and neuronal activity.
BACE1 RNA interference improves spatial memory and attenuates A? burden in a streptozotocin-induced tau hyperphosphorylated rat model.
BACE1 RNAi Restores the Composition of Phosphatidylethanolamine-Derivates Related to Memory Improvement in Aged 3xTg-AD Mice.
BACE1 role in Alzheimer's disease and other dementias: from the theory to the practice.
BACE1 structure and function in health and Alzheimer's disease.
BACE1 SUMOylation increases its stability and escalates the protease activity in Alzheimer's disease.
BACE1 Translation: At the Crossroads Between Alzheimer's Disease Neurodegeneration and Memory Consolidation.
BACE1-/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization.
BACE1: from biomarker to Alzheimer's disease therapeutical target.
BACE1: the beta-secretase enzyme in Alzheimer's disease.
BACE2 as a new diabetes target: a patent review 2010 - 2012.
BACE2 degradation is mediated by both the proteasome and lysosome pathways.
BACE2 distribution in major brain cell types and identification of novel substrates.
BACE2 is stored in secretory granules of mouse and rat pancreatic beta cells.
Baculoviruses expressing the human familial Alzheimer's disease presenilin 1 mutation lacking exon 9 increase levels of an amyloid beta-like protein in Sf9 cells.
BAG-1M co-activates BACE1 transcription through NF-?B and accelerates A? production and memory deficit in Alzheimer's disease mouse model.
Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1.
Behavioral and neurochemical characterization of transgenic mice carrying the human presenilin-1 gene with or without the leucine-to-proline mutation at codon 235.
Beneficial effects of the ?-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression.
Benzolactam (BL) enhances sAPP secretion in fibroblasts and in PC12 cells.
Bepridil and amiodarone simultaneously target the Alzheimer's disease beta- and gamma-secretase via distinct mechanisms.
beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase.
Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease.
Beta-catenin expression in human neural cell lines following exposure to cytokines and growth factors.
Beta-galactoside alpha2,6-sialyltransferase I cleavage by BACE1 enhances the sialylation of soluble glycoproteins. A novel regulatory mechanism for alpha2,6-sialylation.
Beta-Secretase 1 Underlies Reactive Astrocytes and Endothelial Disruption in Neurodegeneration.
Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors.
beta-Secretase inhibitor potency is decreased by aberrant beta-cleavage location of the "Swedish mutant" amyloid precursor protein.
Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain.
Beta-secretase processing of the Alzheimer's amyloid protein precursor (APP).
Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development.
Beta-secretase: structure, function, and evolution.
Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6.
Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis.
Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo.
Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains.
Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways.
Bidirectional regulation of A? levels by Presenilin 1.
Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage.
Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.
Binding partners of Alzheimer's disease proteins: are they physiologically relevant?
Bioactive polycyclic polyprenylated acylphloroglucinols from Hypericum perforatum.
Biochemical and immunocytochemical characterization of calsenilin in mouse brain.
Biochemical and structural characterization of the interaction of memapsin 2 (beta-secretase) cytosolic domain with the VHS domain of GGA proteins.
Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides.
Biochemical properties of endogenous presenilin 1 and presenilin 2 in cultured human B-lymphocytes.
Biogenesis of gamma-secretase early in the secretory pathway.
Biological actions and mechanism of action of calbindin in the process of apoptosis.
Biological Evaluation of Newly Synthesized Biaryl Guanidine Derivatives to Arrest ?-Secretase Enzymatic Activity Involved in Alzheimer's Disease.
Biomarkers of Alzheimer disease, insulin resistance, and obesity in childhood.
Blood-brain barrier-penetrating siRNA nanomedicine for Alzheimer's disease therapy.
Bone Marrow-Derived Macrophages from A?PP/PS1 Mice are Sensitized to the Effects of Inflammatory Stimuli.
Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease.
Both N-terminal and C-terminal fragments of presenilin 1 colocalize with neurofibrillary tangles in neurons and dystrophic neurites of senile plaques in Alzheimer's disease.
Brain 18F-Florbetapir PET/CT Findings in an Early-onset Alzheimer Disease Patient Carrying Presenilin-1 G378E Mutation.
Brain A? load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD.
Brain expression of presenilins in sporadic and early-onset, familial Alzheimer's disease.
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.
Brain Pyroglutamate Amyloid-Beta is Produced by Cathepsin B and is Reduced by the Cysteine Protease Inhibitor E64d, Representing a Potential Alzheimer's Disease Therapeutic.
Brain-Targeted Delivery of Pre-miR-29b Using Lactoferrin-Stearic Acid-Modified-Chitosan/Polyethyleneimine Polyplexes.
Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer's disease alleviates amyloid-related pathologies in mice.
Branched Diacylglycerol-Lactones as Potent Protein Kinase C Ligands and alpha-Secretase Activators.
C-terminal 37 residues of LRP promote the amyloidogenic processing of APP independent of FE65.
C-terminal maturation fragments of presenilin 1 and 2 control secretion of APP alpha and A beta by human cells and are degraded by proteasome.
Ca(2+) dysregulation in neurons from transgenic mice expressing mutant presenilin 2.
Ca(2+) stores and capacitative Ca(2+) entry in human neuroblastoma (SH-SY5Y) cells expressing a familial Alzheimer's disease presenilin-1 mutation.
CA1 hippocampal neuronal loss in familial Alzheimer's disease presenilin-1 E280A mutation is related to epilepsy.
Caffeine Reverses Cognitive Impairment and Decreases Brain Amyloid-beta Levels in Aged Alzheimer's Disease Mice.
Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: reduced oxidative stress and preserved mitochondrial function.
Calcium enhances the proteolytic activity of BACE1: An in vitro biophysical and biochemical characterization of the BACE1-calcium interaction.
Calcium ion transients in neutrophils from patients with sporadic Alzheimer's disease.
Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease.
Calsenilin: a calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment.
Capacitative calcium entry induces hippocampal long term potentiation in the absence of presenilin-1.
Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers.
Carboxyl-terminal fragments of presenilin-1 are closely related to cytoskeletal abnormalities in Alzheimer's brains.
Case-control study of presenilin-1 intronic polymorphism in sporadic early and late onset Alzheimer's disease.
Casein Kinase 2 dependent phosphorylation of eIF4B regulates BACE1 expression in Alzheimer's disease.
Cases of Alzheimer's disease due to deletion of exon 9 of the presenilin-1 gene show an unusual but characteristic beta-amyloid pathology known as 'cotton wool' plaques.
Caspase-4 is partially cleaved by calpain via the impairment of Ca2+ homeostasis under the ER stress.
Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages.
CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production.
CD147, a gamma-secretase associated protein is upregulated in Alzheimer's disease brain and its cellular trafficking is affected by presenilin-2.
Cdk5 Protein Inhibition and A?42 Increase BACE1 Protein Level in Primary Neurons by a Post-transcriptional Mechanism: IMPLICATIONS OF CDK5 AS A THERAPEUTIC TARGET FOR ALZHEIMER DISEASE.
Cell and molecular neurobiology of presenilins: a role for the endoplasmic reticulum in the pathogenesis of Alzheimer's disease?
Cell cycle-driven neuronal apoptosis specifically linked to amyloid peptide Abeta1-42 exposure is not exacerbated in a mouse model of presenilin-1 familial Alzheimer's disease.
Cell-type-specific enhancement of amyloid-beta deposition in a novel presenilin-1 mutation (P117L).
Cellular consequences of the expression of Alzheimer's disease-causing presenilin 1 mutations in human neuroblastoma (SH-SY5Y) cells.
Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis.
Cerebellar dysfunction in a family harboring the PSEN1 mutation co-segregating with a Cathepsin D variant p.A58V.
Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's disease due to a novel presenilin 1 mutation.
Cerebrospinal fluid BACE1 activity and brain amyloid load in Alzheimer's disease.
Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease.
Cerebrospinal Fluid BACE1 Activity and sA?PP? as Biomarker Candidates of Alzheimer's Disease.
Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer's disease.
Challenges in diffusion MRI meta-analysis: A discussion of "Genetic influences on white matter and metabolism abnormal change in Alzheimer's disease: Meta-analysis for neuroimaging research on presenilin 1 mutation".
Changes in Chemokines and Chemokine Receptors Expression in a Mouse Model of Alzheimer's Disease.
Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.
Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.
Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1.
Characterization and molecular profiling of PSEN1 familial Alzheimer's disease iPSC-derived neural progenitors.
Characterization of alpha 2,6-sialyltransferase cleavage by Alzheimer's beta -secretase (BACE1).
Characterization of an atypical gamma-secretase complex from hematopoietic origin.
Characterization of beta-amyloid peptide precursor processing by the yeast Yap3 and Mkc7 proteases.
Characterization of Cerebrospinal Fluid BACE1 Species.
Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
Characterization of detergent-insoluble complexes containing the familial Alzheimer's disease-associated presenilins.
Characterization of human presenilin 1 transgenic rats: increased sensitivity to apoptosis in primary neuronal cultures.
Characterization of human presenilin 1 using N-terminal specific monoclonal antibodies: Evidence that Alzheimer mutations affect proteolytic processing.
Characterization of mouse Ire1 alpha: cloning, mRNA localization in the brain and functional analysis in a neural cell line.
Characterization of presenilin complexes from mouse and human brain using Blue Native gel electrophoresis reveals high expression in embryonic brain and minimal change in complex mobility with pathogenic presenilin mutations.
Characterization of recombinant, soluble beta-secretase from an insect cell expression system.
Characterization of the Photophysical, Thermodynamic, and Structural Properties of the Terbium(III)-DREAM Complex.
Characterization of the reconstituted gamma-secretase complex from Sf9 cells co-expressing presenilin 1, nicastrin [correction of nacastrin], aph-1a, and pen-2.
Chemical cross-linking provides a model of the gamma-secretase complex subunit architecture and evidence for close proximity of the C-terminal fragment of presenilin with APH-1.
Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of ?-secretase inhibitors.
CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.
CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease.
Chinese Presenilin-1 V97L mutation enhanced Abeta42 levels in SH-SY5Y neuroblastoma cells.
Cholesterol accumulation in Niemann Pick type C (NPC) model cells causes a shift in APP localization to lipid rafts.
Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and A beta production.
Cholesterol-depletion corrects APP and BACE1 misstrafficking in NPC1-deficient cells.
Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients.
Choroidal Proteins Involved in Cerebrospinal Fluid Production may be Potential Drug Targets for Alzheimer's Disease Therapy.
Chromosome 14 familial Alzheimer's disease: the clinical and neuropathological characteristics of a family with a leucine-->serine (L250S) substitution at codon 250 of the presenilin 1 gene.
Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation.
Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-A?PPswe Mice Without Inducing Microhemorrhage.
Chronicles in drug discovery.
Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1.
Click Chemistry-mediated Biotinylation Reveals a Function for the Protease BACE1 in Modulating the Neuronal Surface Glycoproteome.
Clinical and biomarker investigation of a patient with a novel presenilin-1 mutation (A431V) in the mild cognitive impairment stage of Alzheimer's disease.
Clinical and genetic analysis of a Chilean family with early-onset autosomal dominant Alzheimer's disease.
Clinical and molecular studies reveal a PSEN1 mutation (L153V) in a Peruvian family with early-onset Alzheimer's disease.
Clinical and neuropathological findings in a patient with familial Alzheimer disease showing a mutation in the PSEN1 gene.
Clinical Association of White Matter Hyperintensities Localization in a Mexican Family with Spastic Paraparesis Carrying the PSEN1 A431E Mutation.
Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer's disease in the third decade of life.
Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation.
Clinical Phenotype of G206D Mutation in the Presenilin 1 Gene in Pathologically Confirmed Familial Alzheimer's Disease.
Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene.
Clinical Presentation of Early-Onset Alzheimer's Disease as a Result of Mutation in Exon 12 of the PSEN-1 Gene.
Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease.
Clinical, neuropathologic, and biochemical profile of the amyloid precursor protein I716F mutation.
Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations.
Clinical-Genetic Correlations in Familial Alzheimer's Disease Caused by Presenilin 1 Mutations.
Clinical-genetic correlations in familial Alzheimer's disease caused by presenilin 1 mutations.
Clinicopathological correlations and cholinesterase expression in early-onset familial Alzheimer's disease with the presenilin 1 mutation, Leu235Pro.
Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene. Pedigree but not mutation specific age at onset provides evidence for a further genetic factor.
Cloning and characterization of the presenilin-2 gene promoter.
Cloning and expression of the rat BACE1 promoter.
Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination.
Co-expression of nicastrin and presenilin rescues a loss of function mutant of APH-1.
Cognitive decline in patients with familial Alzheimer's disease associated with E280a presenilin-1 mutation: a longitudinal study.
Combined association of Presenilin-1 and Apolipoprotein E polymorphisms with maternal meiosis II error in Down syndrome births.
Combining Dyad Protonation and Active Site Plasticity in BACE-1 Structure-Based Drug Design.
Combining NMR and X-ray Crystallography in Fragment-Based Drug Discovery: Discovery of Highly Potent and Selective BACE-1 Inhibitors.
Comparative molecular docking studies of lupeol and lupenone isolated from Pueraria lobata that inhibits BACE1: Probable remedies for Alzheimer's disease.
Comparative study of the effects of phosphatidylcholine rich in DHA and EPA on Alzheimer's disease and the possible mechanisms in CHO-APP/PS1 cells and SAMP8 mice.
Comparison of clinical and pathological phenotypes in two ethnically and geographically unrelated pedigrees segregating an equivalent presenilin 1 mutation.
Complete analysis of the presenilin 1 gene in early onset Alzheimer's disease.
Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12.
Complex translational regulation of BACE1 involves upstream AUGs and stimulatory elements within the 5' untranslated region.
Computational analysis of Alzheimer-causing mutations in amyloid precursor protein and presenilin 1.
Computing the Pathogenicity of Alzheimer's Disease Presenilin 1 Mutations.
Conformational Changes in Transmembrane Domain 4 of Presenilin 1 Are Associated with Altered Amyloid-? 42 Production.
Conformational Dynamics and Binding Free Energies of Inhibitors of BACE-1: From the Perspective of Protonation Equilibria.
Conformational dynamics of cathepsin D and binding to a small-molecule BACE1 inhibitor.
Conformational dynamics of transmembrane domain 3 of presenilin 1 is associated with the trimming activity of ?-secretase.
Conformational transition in the substrate binding domain of ?-secretase exploited by NMA and its implication in inhibitor recognition: BACE1-myricetin a case study.
Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function.
Conserved residues within the putative active site of gamma-secretase differentially influence enzyme activity and inhibitor binding.
Continuing strategies for inhibiting Alzheimer's gamma-secretase.
Contrasting role of presenilin-1 and presenilin-2 in neuronal differentiation in vitro.
Contribution of the proteasome to the alpha-secretase pathway in Alzheimer's disease.
Control of amyloid-beta-peptide generation by subcellular trafficking of the beta-amyloid precursor protein and beta-secretase.
Control of peripheral nerve myelination by the beta-secretase BACE1.
Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease.
Conversion of the LXR-agonist TO-901317--from inverse to normal modulation of gamma-secretase by addition of a carboxylic acid and a lipophilic anchor.
Core Refinement towards Permeable ß-Secretase (BACE-1) Inhibitors with Low hERG Activity.
Correction for Bao et al., BACE1 SUMOylation increases its stability and escalates the protease activity in Alzheimer's disease.
Correction: Mild Oxidative Stress Induces Redistribution of BACE1 in Non-Apoptotic Conditions and Promotes the Amyloidogenic Processing of Alzheimer's Disease Amyloid Precursor Protein.
Correction: MiR-124 acts as a target for Alzheimer's disease by regulating BACE1.
Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers.
Corticobasal Syndrome in a Family with Early-Onset Alzheimer's Disease Linked to a Presenilin-1 Gene Mutation.
Cotton wool plaques in non-familial late-onset Alzheimer disease.
cPLA2 and desaturases underlie the tau hyperphosphorylation offset induced by BACE knock-down in neuronal primary cultures.
Creation of Novel Cores for ?-Secretase (BACE-1) Inhibitors: A Multiparameter Lead Generation Strategy.
Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor.
CSF BACE1 activity is increased in CJD and Alzheimer disease other dementias.
CSF biomarkers for mild cognitive impairment.
CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease.
CSF markers for incipient Alzheimer's disease.
CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry.
CSF Presenilin-1 complexes are increased in Alzheimer's disease.
CSF studies facilitate DNA diagnosis in familial Alzheimer's disease due to a presenilin-1 mutation.
Curcumin mediates presenilin-1 activity to reduce ?-amyloid production in a model of Alzheimer's Disease.
Current and future implications of basic and translational research on amyloid-? peptide production and removal pathways.
Cyanobacterial peptides as a prototype for the design of potent ?-secretase inhibitors and the development of selective chemical probes for other aspartic proteases.
Cyclin-dependent kinase-5/p35 phosphorylates Presenilin 1 to regulate carboxy-terminal fragment stability.
Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity.
Cyclooxygenase-2 and presenilin-1 gene expression induced by interleukin-1beta and amyloid beta 42 peptide is potentiated by hypoxia in primary human neural cells.
Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway.
Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimer's disease.
De novo presenilin 1 mutations are rare in clinically sporadic, early onset Alzheimer's disease cases. French Alzheimer's Disease Study Group.
De Novo PS1 Mutation (Pro436Gln) in a Very Early-Onset Posterior Variant of Alzheimer's Disease Associated with Spasticity: A Case Report.
Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects.
Decrease in brain soluble amyloid precursor protein ? (sAPP?) in Alzheimer's disease cortex.
Decreased Abeta secretion by cells expressing familial Alzheimer's disease-linked mutant presenilin 1.
Decreased Deposition of Beta-Amyloid 1-38 and Increased Deposition of Beta-Amyloid 1-42 in Brain Tissue of Presenilin-1 E280A Familial Alzheimer's Disease Patients.
Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice.
Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease.
Deducing the transmembrane domain organization of presenilin-1 in gamma-secretase by cysteine disulfide cross-linking.
Defects of immune regulation in the presenilin-1 mutant knockin mouse.
Deficiency of Neuronal p38? MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1.
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein.
Deficiency of the Copper Chaperone for Superoxide Dismutase Increases Amyloid-? Production.
Deficits in Enrichment-Dependent Neurogenesis and Enhanced Anxiety Behaviors Mediated by Expression of Alzheimer's Disease-Linked Ps1 Variants Are Rescued by Microglial Depletion.
Degenerative alterations in noradrenergic neurons of the locus coeruleus in Alzheimer's disease.
Deletion of exons 9 and 10 of the Presenilin 1 gene in a patient with Early-onset Alzheimer Disease generates longer amyloid seeds.
Deletion of presenilin 1 hydrophilic loop sequence leads to impaired gamma-secretase activity and exacerbated amyloid pathology.
Deletion of the neuron-specific protein delta-catenin leads to severe cognitive and synaptic dysfunction.
Delivery of BACE1 siRNA mediated by TARBP-BTP fusion protein reduces ?-amyloid deposits in a transgenic mouse model of Alzheimer's disease.
Delivery of Quantum Dot-siRNA Nanoplexes in SK-N-SH Cells for BACE1 Gene Silencing and Intracellular Imaging.
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.
delta-catenin is a nervous system-specific adherens junction protein which undergoes dynamic relocalization during development.
Delta-catenin is required for the maintenance of neural structure and function in mature cortex in vivo.
Densin-180 interacts with delta-catenin/neural plakophilin-related armadillo repeat protein at synapses.
Deposition of BACE-1 Protein in the Brains of APP/PS1 Double Transgenic Mice.
Deposition of Hyperphosphorylated Tau in Cerebellum of PS1 E280A Alzheimer's Disease.
Derivation of induced pluripotent stem cells from a familial Alzheimer's disease patient carrying the L282F mutation in presenilin 1.
Design and synthesis of 1,4-dihydropyridine derivatives as BACE-1 inhibitors.
Design and synthesis of benzoazepinone-derived cyclic malonamides and aminoamides as potent gamma-secretase inhibitors.
Design and synthesis of highly potent benzodiazepine gamma-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4- hydroxy-N-((3S)-1-methyl-2-oxo-5- phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangement.
Design and synthesis of novel arylisoxazole-chromenone carboxamides: Investigation of biological activities associated with Alzheimer's disease.
Design, synthesis and biological evaluation of tasiamide B derivatives as BACE1 inhibitors.
Design, Synthesis and Evaluation of 2,4,6-substituted Pyrimidine Derivatives as BACE-1 inhibitor: Plausible lead for Alzheimer's Disease.
Design, synthesis and in vitro evaluation studies of sulfonyl-amino-acetamides as small molecule BACE-1 inhibitors.
Design, synthesis and SAR analysis of potent BACE1 inhibitors: Possible lead drug candidates for Alzheimer's disease.
Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activity.
Design, synthesis, and evaluation of tetrahydroquinoline and pyrrolidine sulfonamide carbamates as gamma-secretase inhibitors.
Designing of Selective ?-Secretase Inhibitory Benzenesulfonamides through Comparative In Vitro and In Silico Analysis.
Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis.
Detection of the presenilin 1 COOH-terminal fragment in the extracellular compartment: a release enhanced by apoptosis.
Detection of the presenilin 1 gene mutation (M139T) in early-onset familial Alzheimer disease in Spain.
Determination of a cleavage site of presenilin 2 protein in stably transfected SH-SY5Y human neuroblastoma cell lines.
Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry.
Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design.
Determination of the protonation state for the catalytic dyad in ?-secretase when bound to hydroxyethylamine transition state analogue inhibitors: A molecular dynamics simulation study.
Development and characterization of beta-secretase monolithic micro-immobilized enzyme reactor for on-line high-performance liquid chromatography studies.
Development and validation of sensitive and selective LC-MS/MS methods for the determination of BMS-708163, a gamma-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions.
Development of 2-aminooxazoline 3-azaxanthene ?-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D.
Development of a high-throughput assay for screening of gamma-secretase inhibitor with endogenous human, mouse or drosophila gamma-secretase.
Development of a specific ELISA to measure BACE1 levels in human tissues.
Development of an efficient enzyme production and structure-based discovery platform for BACE1 inhibitors.
Development of BACE1 inhibitors for Alzheimer's disease.
Development of molecular tools for diagnosis of Alzheimer's disease that are based on detection of amyloidogenic proteins.
Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.
Developmental regulation and possible alternative cleavage of presenilin 1 in the rat retina.
DGGE method for the mutational analysis of the coding and proximal promoter regions of the Alzheimer's disease presenilin-1 gene: two novel mutations.
Diagnostic accuracy of CERAD total score in a Colombian cohort with mild cognitive impairment and Alzheimer's disease affected by E280A mutation on presenilin-1 gene.
Dictyostelium possesses highly diverged presenilin/gamma-secretase that regulates growth and cell-fate specification and can accurately process human APP: a system for functional studies of the presenilin/gamma-secretase complex.
Different clinical phenotypes in siblings with a presenilin-1 P264L mutation.
Different effects of Alzheimer-associated mutations of presenilin 1 on its processing.
Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo.
Differential contributions of ApoE4 and female sex to BACE1 activity and expression mediate A? deposition and learning and memory in mouse models of Alzheimer's disease.
Differential display analysis of presenilin 1-deficient mouse brains.
Differential distribution of presenilin-1, Bax, and Bcl-X(L) in Alzheimer's disease and frontotemporal dementia.
Differential effects of transforming growth factor-beta(s) and glial cell line-derived neurotrophic factor on gene expression of presenilin-1 in human post-mitotic neurons and astrocytes.
Differential expression of presenilin-alpha and -beta (PSalpha and PSbeta) in Xenopus laevis: embryonic phosphorylation of PSalpha.
Differential gene expression in ADAM10 and mutant ADAM10 transgenic mice.
Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides.
Differential regulation of neurogenesis in two neurogenic regions of APPswe/PS1dE9 transgenic mice.
Differential utilization of upstream AUGs in the beta-secretase mRNA suggests that a shunting mechanism regulates translation.
Differentially expressed genes in transgenic mice carrying human mutant presenilin-2 (N141I): correlation of selenoprotein M with Alzheimer's disease.
Difluoro ketone peptidomimetics suggest a large S1 pocket for Alzheimer's gamma-secretase: implications for inhibitor design.
Dimethyl Fumarate Exerts Neuroprotection by Modulating Calcineurin/NFAT1 and NF?B Dependent BACE1 Activity in a Neuronal Model of Alzheimer's Disease.
Direct association of presenilin-1 with beta-catenin.
Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons.
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease.
Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.
Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa.
Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase.
Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS A? Reduction.
Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease.
Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease.
Discovery of gamma-secretase inhibitors efficacious in a transgenic animal model of Alzheimer's disease.
Discovery of N-ethylpyridine-2-carboxamide derivatives as a novel scaffold for orally active ?-secretase modulators.
Discovery of novel scaffolds for ?-secretase modulators without an arylimidazole moiety.
Discovery of potent beta-secretase (bace-1) inhibitors by the synthesis of isophthalamide-containing hybrids.
Discovery of SCH 900229, a Potent Presenilin 1 Selective ?-Secretase Inhibitor for the Treatment of Alzheimer's Disease.
Discovery of Sulforaphane as a Potent BACE1 Inhibitor Based on Kinetics and Computational Studies.
Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators.
Disease-related mutations among Caribbean Hispanics with familial dementia.
Disrupted intracellular calcium regulates BACE1 gene expression via nuclear factor of activated T cells 1 (NFAT 1) signaling.
Dissecting the many genetic faces of schizophrenia.
Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's disease-linked presenilin-1 mutations.
Divalent cation tolerance protein binds to ?-secretase and inhibits the processing of amyloid precursor protein.
Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis.
DNA Damage does not Correlate with Amyloid-beta-Plaques and Neurofibrillary Tangles in Familial Alzheimer's Disease Presenilin-1 [E280A] Mutation.
DNA methylation of the 5'-untranslated region at +298 and +351 represses BACE1 expression in mouse BV-2 microglial cells.
DNA microarray profiling of developing PS1-deficient mouse brain reveals complex and coregulated expression changes.
Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3?.
Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease?
Dopa Responsive Parkinsonism in an Early Onset Alzheimer's Disease Patient with a Presenilin 1 Mutation (A434T).
Dose-dependent inhibition of BACE-1 by the monoterpenoid 2,3,4,4-tetramethyl-5-methylenecyclopent-2-enone in cellular and mouse models of Alzheimer's disease.
Downregulated miR-29c correlates with increased BACE1 expression in sporadic Alzheimer's disease.
Driving force to detect Alzheimer's disease biomarkers: application of a thioflavine T@Er-MOF ratiometric fluorescent sensor for smart detection of presenilin 1, amyloid ?-protein and acetylcholine.
Dual inhibition of BACE1 and A? aggregation by ?-ecdysone: Application of a phytoecdysteroid scaffold in Alzheimer's disease therapeutics.
Dual roles of proteasome in the metabolism of presenilin 1.
Dual Signal Amplification Electrochemical Biosensor for Monitoring the Activity and Inhibition of the Alzheimer's Related Protease ?-Secretase.
Dual Task Abilities as a Possible Preclinical Marker of Alzheimer's Disease in Carriers of the E280A Presenilin-1 Mutation.
Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR).
Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer's disease.
Dynamic Nature of presenilin1/?-Secretase: Implication for Alzheimer's Disease Pathogenesis.
Dynamic presenilin 1 and synaptotagmin 1 interaction modulates exocytosis and amyloid ? production.
Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease.
Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability.
Dysregulation of SREBP2 induces BACE1 expression.
E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles.
Ear2 deletion causes early memory and learning deficits in APP/PS1 mice.
Early onset Alzheimer's disease - a case study.
Early onset familial Alzheimer Disease with spastic paraparesis, dysarthria, and seizures and N135S mutation in PSEN1.
Early psychiatrics symptoms in familial Alzheimer's disease with presenilin 1 mutation (I83T).
Early structural changes in individuals at risk of familial Alzheimer's disease: a volumetry and magnetization transfer MR imaging study.
Early-onset Alzheimer disease in an Italian family with presenilin-1 double mutation E318G and G394V.
Early-onset Alzheimer's disease caused by a novel mutation at codon 219 of the presenilin-1 gene.
Early-onset Alzheimer's disease due to mutations of the presenilin-1 gene on chromosome 14: a 7-year follow-up of a patient with a mutation at codon 139.
Early-onset Alzheimer's disease with a de novo mutation in the presenilin 1 gene.
Early-onset Alzheimer's disease with a presenilin-1 mutation at the site corresponding to the Volga German presenilin-2 mutation.
Early-onset Alzheimer's disease with presenilin-1 M139V mutation: clinical, neuropsychological and neuropathological study.
Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695.
Early-Onset Familial Alzheimer Disease Variant PSEN2 N141I Heterozygosity is Associated with Altered Microglia Phenotype.
Early-onset familial Alzheimer's disease related to presenilin 1 mutation resembling autosomal dominant spinocerebellar ataxia.
Editorial: Implications for BACE1 Inhibitor Clinical Trials: Adult Conditional BACE1 Knockout Mice Exhibit Axonal Organization Defects in the Hippocampus.
EEG and Granular Osmiophilic Elements in Early-Onset Alzheimer's Disease.
EEG, Activity, and Sleep Architecture in a Transgenic A?PPSWE/PSEN1A246E Alzheimer's Disease Mouse.
Effect of a dominant-negative form of ADAM10 in a mouse model of Alzheimer's disease.
Effect of gamma-secretase inhibitors on muscarinic receptor-mediated calcium signaling in human salivary epithelial cells.
Effect of glycogen synthase kinase 3 ?-mediated presenilin 1 phosphorylation on amyloid ? production is negatively regulated by insulin receptor cleavage.
Effect of heparin on APP metabolism and Abeta production in cortical neurons.
Effect of sampling on BACE-1 ligands binding free energy predictions via MM-PBSA calculations.
Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE-1.
Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.
Effects of an inhibitor of alpha-secretase, which metabolizes the amyloid peptide precursor, on memory formation in rats.
Effects of curcuminoids identified in rhizomes of Curcuma longa on BACE-1 inhibitory and behavioral activity and lifespan of Alzheimer's disease Drosophila models.
Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease.
Effects of human presenilin 1 isoforms on proliferation and survival of rat pheochromocytoma cell line PC12.
Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice.
Effects of Mild and Severe Oxidative Stress on BACE1 Expression and APP Amyloidogenic Processing.
Effects of presenilin N-terminal fragments on production of amyloid beta peptide and accumulation of endogenous presenilins.
Effects of progesterone administration and APPswe+PSEN1Deltae9 mutation for cognitive performance of mid-aged mice.
Effects of RNA interference-mediated silencing of gamma-secretase complex components on cell sensitivity to caspase-3 activation.
Effects of short-term Western diet on cerebral oxidative stress and diabetes related factors in APP x PS1 knock-in mice.
Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models.
Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.
EHT0202 in Alzheimer's Disease: A 3-Month, Randomized, Placebo-Controlled, Double-Blind Study.
Electric Stimulation of Neurogenesis Improves Behavioral Recovery After Focal Ischemia in Aged Rats.
Electroacupuncture ameliorates beta-amyloid pathology and cognitive impairment in Alzheimer disease via a novel mechanism involving activation of TFEB (transcription factor EB).
Electrophoretic separation and immunoblotting of a?(1-40) and a? (1-42).
Elevated A?42 in Aged, Non-demented Individuals with Cerebral Atherosclerosis.
Elevated cellular cholesterol in Familial Alzheimer's presenilin 1 mutation is associated with lipid raft localization of ?-amyloid precursor protein.
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.
Elucidation of the BACE1 Regulating Factor GGA3 in Alzheimer's Disease.
Employing a superior BACE1 cleavage sequence to probe cellular APP processing.
Encompassing receptor flexibility in virtual screening using ensemble docking-based hybrid QSAR: discovery of novel phytochemicals for BACE1 inhibition.
Endogenous APP accumulates in synapses after BACE1 inhibition.
Endogenous presenilin 1 redistributes to the surface of lamellipodia upon adhesion of Jurkat cells to a collagen matrix.
Endogenous presenilin-1 targets to endocytic rather than biosynthetic compartments.
Endoproteolysis of beta-secretase (beta-site amyloid precursor protein-cleaving enzyme) within its catalytic domain. A potential mechanism for regulation.
Endoproteolysis of presenilin in vitro: inhibition by gamma-secretase inhibitors.
Endoproteolysis of the ER stress transducer ATF6 in the presence of functionally inactive presenilins.
Endoproteolytic processing and stabilization of wild-type and mutant presenilin.
Enhanced accumulation of phosphorylated alpha-synuclein and elevated beta-amyloid 42/40 ratio caused by expression of the presenilin-1 deltaT440 mutant associated with familial Lewy body disease and variant Alzheimer's disease.
Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years.
Enhanced delivery of gamma-secretase inhibitor DAPT into the brain via an ascorbic acid mediated strategy.
Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins.
Enhanced synaptic potentiation in transgenic mice expressing presenilin 1 familial Alzheimer's disease mutation is normalized with a benzodiazepine.
Enhancement of activation of caspases by presenilin 1 gene mutations and its inhibition by secretase inhibitors.
Enhancement of alpha-secretase cleavage of amyloid precursor protein by a metalloendopeptidase nardilysin.
Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease.
Enhancement of BACE1 Activity by p25/Cdk5-Mediated Phosphorylation in Alzheimer's Disease.
Enrichment of presenilin 1 peptides in neuronal large dense-core and somatodendritic clathrin-coated vesicles.
Environmental exposures and the etiopathogenesis of Alzheimer's disease: The potential role of BACE1 as a critical neurotoxic target.
Enzymic properties of recombinant BACE2.
Epicatechin Plus Treadmill Exercise are Neuroprotective Against Moderate-stage Amyloid Precursor Protein/Presenilin 1 Mice.
Epidermal Growth Factor Receptor and Notch Pathways Participate in the Tumor Suppressor Function of {gamma}-Secretase.
Epigenetic Changes and Its Intervention in Age-Related Neurodegenerative Diseases.
Epigenetic regulation of BACE1 in Alzheimer's disease patients and in transgenic mice.
ER stress is not elevated in the 5XFAD mouse model of Alzheimer's disease.
ERK1/2 is an endogenous negative regulator of the gamma-secretase activity.
Establishing the relationship between in vitro potency, pharmacokinetic and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived ?-secretase inhibitors.
Estimating diagnostic accuracy for clustered ordinal diagnostic groups in the three-class case-Application to the early diagnosis of Alzheimer disease.
Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease.
Estrogens stabilize mitochondrial function and protect neural cells against the pro-apoptotic action of mutant presenilin-1.
Etazolate improves performance in a foraging and homing task in aged rats.
Evaluation of an Allosteric BACE Inhibitor Peptide to Identify Mimetics that Can Interact with the Loop F Region of the Enzyme and Prevent APP Cleavage.
Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease.
Event-related potential markers of brain changes in preclinical familial Alzheimer disease.
Evidence for a six-transmembrane domain structure of presenilin 1.
Evidence for natural antisense transcript-mediated inhibition of microRNA function.
Evidence for phosphorylation and oligomeric assembly of presenilin 1.
Evidence for presenilin-1 involvement in amyloid angiopathy in the Alzheimer's disease-affected brain.
Evidence for the involvement of calbindin D28k in the presenilin 1 model of Alzheimer's disease.
Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype.
Evidence that gamma-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer's disease.
Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice.
Exacerbation of psoriatic skin lesions in a patient with Alzheimer disease receiving gamma-secretase inhibitor.
Excess of nicastrin in brain results in heterozygosity having no effect on endogenous APP processing and amyloid peptide levels in vivo.
Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein.
Exercise-mediated alteration of hippocampal Dicer mRNA and miRNAs is associated with lower BACE1 gene expression and A?1-42 in female 3xTg-AD mice.
Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575.
Exome sequencing identifies 2 novel presenilin 1 mutations (p.L166V and p.S230R) in British early-onset Alzheimer's disease.
Exploring the chemical space of gamma-secretase modulators.
Expressing mRNAs for presenilin-1 and amyloid precursor protein (APP-695) from same neuronal populations in rat hippocampus.
Expression analysis of BACE2 in brain and peripheral tissues.
Expression analysis of human ?-secretase in transgenic tomato fruits.
Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's disease.
Expression and analysis of presenilin 1 in a human neuronal system: localization in cell bodies and dendrites.
Expression of ?-site APP-cleaving enzyme 1 in the hippocampal tissue of an insulin-resistant rat model of Alzheimer's disease.
Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase.
Expression of Alzheimer's disease risk genes in ischemic brain degeneration.
Expression of Amyloid-Associated miRNAs in Both the Forebrain Cortex and Hippocampus of Middle-Aged Rat.
Expression of familial Alzheimer disease presenilin 1 gene attenuates vesicle traffic and reduces peptide secretion in cultured astrocytes devoid of pathologic tissue environment.
Expression of presenilin 1 and 2 (PS1 and PS2) in human and murine tissues.
Expression of presenilin 1 mRNA in rat peripheral organs and brain.
Expression of presenilin-1 and -2 mRNAs in rat and Alzheimer's disease brains.
Expression of the Alzheimer protease BACE1 is suppressed via its 5'-untranslated region.
Expression of the Alzheimer's Disease Mutations A?PP695sw and PSEN1M146I in Double-Transgenic Göttingen Minipigs.
Expressions of amyloid precursor protein, synaptophysin and presenilin-1 in the different areas of the developing cerebellum of rat.
Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation.
F175S change and a novel polymorphism in presenilin-1 gene in late-onset familial Alzheimer's disease.
Facilitation of glutamate, but not GABA, release in Familial Alzheimer's APP mutant Knock-in rats with increased ?-cleavage of APP.
FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gamma-secretase cleavage complex.
Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of ?-secretase.
Familial Alzheimer's disease co-segregates with a Met146I1e substitution in presenilin-1.
Familial Alzheimer's disease coding mutations reduce Presenilin-1 expression in a novel genomic locus reporter model.
Familial Alzheimer's disease genes in Japanese.
Familial Alzheimer's Disease Lymphocytes Respond Differently Than Sporadic Cells to Oxidative Stress: Upregulated p53-p21 Signaling Linked with Presenilin 1 Mutants.
Familial Alzheimer's Disease Mutations in Presenilin 1 Do Not Alter Levels of the Secreted Amyloid-beta Protein Precursor Generated by beta-Secretase Cleavage.
Familial Alzheimer's disease mutations in presenilin 1 do not alter levels of the secreted amyloid-beta protein precursor generated by beta-secretase cleavage.
Familial Alzheimer's Disease Mutations in PSEN1 Lead to Premature Human Stem Cell Neurogenesis.
Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment.
Familial Alzheimer's Disease Mutations within the Amyloid Precursor Protein Alter the Aggregation and Conformation of the Amyloid-? Peptide.
Familial Alzheimer's disease presenilin 1 mutation M146V increases gamma secretase cutting of p75NTR in vitro.
Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein.
Familial Alzheimer's disease presenilin-1 mutants potentiate cell cycle arrest.
Familial Alzheimer's disease presenilin-2 mutants affect Ca2+ homeostasis and brain network excitability.
Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo.
Familial Alzheimer's disease-linked presenilin-1 mutation M146V affects store-operated calcium entry: does gain look like loss?
Familial Alzheimer's disease: oxidative stress, beta-amyloid, presenilins, and cell death.
Familial cases presenting very early onset autosomal dominant Alzheimer's disease with I143T in presenilin-1 gene: implication for genotype-phenotype correlation.
Familial Creutzfeldt-Jakob disease in a patient carrying both a presenilin 1 missense substitution and a prion protein gene insertion.
Familial dementia with frontotemporal features associated with M146V presenilin-1 mutation.
Familial frontotemporal dementia-associated presenilin-1 c.548G>T mutation causes decreased mRNA expression and reduced presenilin function in knock-in mice.
Fatty acids increase presenilin-1 levels and [gamma]-secretase activity in PSwt-1 cells.
Fe65 stimulates proteolytic liberation of the beta-amyloid precursor protein intracellular domain.
Female preclinical presenilin-1 mutation carriers unaware of their genetic status have higher levels of depression than their non-mutation carrying kin.
Fenchylamine sulfonamide inhibitors of amyloid beta peptide production by the gamma-secretase proteolytic pathway: potential small-molecule therapeutic agents for the treatment of Alzheimer's disease.
Fibroblasts from FAD-linked presenilin 1 mutations display a normal unfolded protein response but overproduce Abeta42 in response to tunicamycin.
Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease beta-amyloid production.
Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features.
Florbetapir PET analysis of amyloid-? deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.
Flotillins bind to the Dileucine Sorting Motif of BACE1 and influence its endosomal Sorting.
Forebrain degeneration and ventricle enlargement caused by double knockout of Alzheimer's presenilin-1 and presenilin-2.
Forebrain depletion of Rheb GTPase elicits spatial memory deficits in mice.
Formation of stable complexes between two Alzheimer's disease gene products: presenilin-2 and beta-amyloid precursor protein.
Formation of Tau Inclusions in Knock-in Mice with Familial Alzheimer Disease (FAD) Mutation of Presenilin 1 (PS1).
Founder effect for the Ala431Glu mutation of the presenilin 1 gene causing early-onset Alzheimer's disease in Mexican families.
Fragment-Based Discovery of Nonpeptidic BACE-1 Inhibitors Using Tethering.
Fragment-guided approach to incorporating structural information into a CoMFA study: BACE-1 as an example.
Frequency and clinicopathological characteristics of presenilin 1 Gly206Ala mutation in Puerto Rican Hispanics with dementia.
From BACE1 inhibitor to multifunctionality of tryptoline and tryptamine triazole derivatives for Alzheimer's disease.
From presenilinase to gamma-secretase, cleave to capacitate.
From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects.
Full-length cellular ?-secretase has a trimeric subunit stoichiometry, and its sulfur-rich transmembrane interaction site modulates cytosolic copper compartmentalization.
Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects.
Functional characterization of novel presenilin-2 variants identified in human breast cancers.
Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain.
Functional implications of the presenilin dimerization: reconstitution of gamma-secretase activity by assembly of a catalytic site at the dimer interface of two catalytically inactive presenilins.
Functional interactions of APP with the apoE receptor family.
Functional phenotype in transgenic mice expressing mutant human presenilin-1.
Functions of the Alzheimer's Disease Protease BACE1 at the Synapse in the Central Nervous System.
Fyn knock-down increases A?, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice.
G Protein-Coupled Receptors (GPCRs) in Alzheimer's Disease: A Focus on BACE1 Related GPCRs.
G206D Mutation of Presenilin-1 Reduces Pen2 Interaction, Increases A?42/A?40 Ratio and Elevates ER Ca(2+) Accumulation.
Gadd153 and NF-?B Crosstalk Regulates 27-Hydroxycholesterol-Induced Increase in BACE1 and ?-Amyloid Production in Human Neuroblastoma SH-SY5Y Cells.
Gain of function by phosphorylation in Presenilin 1-mediated regulation of insulin signaling.
Gallic Acid is a Dual ?/?-Secretase Modulator that Reverses Cognitive Impairment and Remediates Pathology in Alzheimer Mice.
Gamma -secretase inhibitors repress thymocyte development.
Gamma secretase-activating protein is a substrate for caspase-3: implications for Alzheimer's disease.
gamma-cleavage-independent functions of presenilin, nicastrin, and Aph-1 regulate cell-junction organization and prevent tau toxicity in vivo.
Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.
Gamma-secretase activity is associated with a conformational change of nicastrin.
gamma-Secretase activity modulates store-operated Ca2+ entry into rat sensory neurons.
Gamma-secretase activity of presenilin 1 regulates acetylcholine muscarinic receptor-mediated signal transduction.
Gamma-secretase and the intramembrane proteolysis of Notch.
Gamma-secretase as a pharmacological target in Alzheimer disease research: when, why and how?
gamma-Secretase as a target for drug intervention in Alzheimer's disease.
Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease.
gamma-Secretase as a Therapeutic Target for Treatment of Alzheimer's Disease.
gamma-Secretase as a therapeutic target in Alzheimer's disease.
gamma-Secretase can cleave amyloid precursor protein fragments independent of alpha- and beta-secretase pre-cutting.
gamma-Secretase dependent production of intracellular domains is reduced in adult compared to embryonic rat brain membranes.
Gamma-secretase gene mutations link acne inversa (flexural, scarring acne) with Alzheimer's disease.
gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease.
gamma-Secretase in biology and medicine.
Gamma-secretase inhibition and modulation for Alzheimer's disease.
Gamma-secretase inhibition.
Gamma-secretase inhibitors and Alzheimer's disease.
gamma-Secretase inhibitors as molecular probes of presenilin function.
gamma-Secretase Inhibitors for Alzheimer's Disease : Balancing Efficacy and Toxicity.
gamma-Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State.
Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2.
Gamma-secretase modulation and its promise for Alzheimer's disease: a medicinal chemistry perspective.
Gamma-secretase modulation and its promise for Alzheimer's disease: a rationale for drug discovery.
gamma-Secretase modulators.
gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site.
Gamma-secretase subunit composition and distribution in the presenilin wild-type and mutant mouse brain.
gamma-Secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid beta peptides of varying length.
gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in?
Gamma-secretase--intramembrane protease with a complex.
Gamma-secretase-dependent and -independent effects of presenilin1 on beta-catenin.Tcf-4 transcriptional activity.
Gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila.
Gamma-secretase: a catalyst of Alzheimer disease and signal transduction.
Gamma-secretase: a complex target for Alzheimer's disease.
gamma-Secretase: characterization and implication for Alzheimer disease therapy.
Gamma-secretase: structure, function, and modulation for Alzheimer's disease.
gamma-secretases: from cell biology to therapeutic strategies.
Gastrodin suppresses BACE1 expression under oxidative stress condition via inhibition of the PKR/eIF2? pathway in Alzheimer's disease.
Gender- and age-dependent gamma-secretase activity in mouse brain and its implication in sporadic Alzheimer disease.
Gene expression in Alzheimer's disease.
Gene expression of Alzheimer-associated presenilin-2 in the frontal cortex of Alzheimer and aged control brain.
Gene Expression Profiles of APP and BACE1 in Tg SOD1G93A Cortical Cells.
Gene expression profiling in cells with enhanced gamma-secretase activity.
Gene mutations associated with early onset familial Alzheimer's disease in China: An overview and current status.
Gene polymorphism in apolipoprotein E and presenilin-1 in patients with late-onset Alzheimer's disease.
Generation and deposition of A?43 by the virtually inactive presenilin-1 L435F mutant contradicts the presenilin loss-of-function hypothesis of Alzheimer's disease.
Generation of a gene-corrected isogenic control hiPSC line derived from a familial Alzheimer's disease patient carrying a L150P mutation in presenilin 1.
Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation.
Generation of aggregation prone N-terminally truncated amyloid ? peptides by meprin ? depends on the sequence specificity at the cleavage site.
Generation of amyloid beta protein from a presenilin-1 and betaAPP complex.
Generation of an integration-free iPSC line, ICCSICi006-A, derived from a male Alzheimer's disease patient carrying the PSEN1-G206D mutation.
Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer's disease patient carrying a L150P mutation in PSEN-1.
Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer's disease patient carrying a M146I mutation in PSEN1.
Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer's disease patient carrying an A79V mutation in PSEN1.
Generation of induced pluripotent stem cells (IRMBi001-A) from an Alzheimer's disease patient carrying a G217D mutation in the PSEN1 gene.
Genes implicated in the pathogenesis of Alzheimer's disease.
Genes involved in cerebrospinal fluid production as candidate genes for late-onset Alzheimer's disease: a hypothesis.
Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation.
Genetic aspects of Alzheimer disease.
Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Alzheimer's Disease Collaborative Group.
Genetic association of BACE1 gene polymorphism C786G with late-onset Alzheimer's disease in Chinese.
Genetic association of the presenilin-1 regulatory region with early-onset Alzheimer's disease in a population-based sample.
Genetic association of two chromosome 14 genes (presenilin 1 and alpha 1-antichymotrypsin) with Alzheimer's disease.
Genetic complexity of Alzheimer's disease: successes and challenges.
Genetic counseling and presenilin-1 Alzheimer's disease: "Research Family" members share some thoughts.
Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves.
Genetic influences on white matter and metabolism abnormal change in Alzheimer's disease: Meta-analysis for neuroimaging research on presenilin 1 mutation.
Genetic inhibition of phosphorylation of the translation initiation factor eIF2? does not block A?-dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease.
Genetic markers in the diagnosis of Alzheimer's disease.
Genetic Markers of Alzheimer's Disease.
Genetic reductions of beta-site amyloid precursor protein-cleaving enzyme 1 and amyloid-beta ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice.
Genetic screening in early-onset Alzheimer's disease identified three novel presenilin mutations.
Genetic screening in two Iranian families with early-onset Alzheimer's disease identified a novel PSEN1 mutation.
Genetic studies of A2M and BACE1 genes in Chinese Han Alzheimer's disease patients.
Genetic variability at the amyloid-beta precursor protein locus may contribute to the risk of late-onset Alzheimer's disease.
Genetic variability in the regulatory region of presenilin 1 associated with risk for Alzheimer's disease and variable expression.
Genetics and pathology of alpha-secretase site AbetaPP mutations in the understanding of Alzheimer's disease.
Genetics of Alzheimer's disease.
Genomic structure, expression pattern, and chromosomal localization of the human calsenilin gene: no association between an exonic polymorphism and Alzheimer's disease.
Genotoxicity Studies of Titanium Dioxide Nanoparticles (TiO2NPs) in the Brain of Mice.
Genotype-phenotype analysis in early-onset Alzheimer's disease due to presenilin-1 mutations at codon 139.
Genotype-phenotype correlation in early-onset Alzheimer disease with presenilin 1 gene mutations.
Genotype-Phenotype Relationships of Presenilin-1 Mutations in Alzheimer's Disease: An Update.
Geriatric neurogenetics: oxymoron or reality?
Germline mutational analysis of presenilin 1 and APP genes in Jewish-Israeli individuals with familial or early-onset Alzheimer disease using denaturing gradient gel electrophoresis (DGGE).
GGA proteins mediate the recycling pathway of memapsin 2 (BACE).
GGA1 acts as a spatial switch altering amyloid precursor protein trafficking and processing.
GGA1 is expressed in the human brain and affects the generation of amyloid beta-peptide.
Gga3 deletion and a GGA3 rare variant associated with late onset Alzheimer's disease trigger BACE1 accumulation in axonal swellings.
Ginsenoside Rg1 attenuates ?-amyloid generation via suppressing PPAR?-regulated BACE1 activity in N2a-APP695 cells.
Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation.
Glycogen synthase kinase-3beta regulates presenilin 1 C-terminal fragment levels.
Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer's Disease ? Secretase, BACE1.
Got RIP? Presenilin-dependent intramembrane proteolysis in growth factor receptor signaling.
Grape seed polyphenols and curcumin reduce genomic instability events in a transgenic mouse model for Alzheimer's disease.
GSK3beta activity modifies the localization and function of presenilin 1.
High affinity, bioavailable 3-amino-1,4-benzodiazepine-based gamma-secretase inhibitors.
High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease.
High content analysis of gamma-secretase activity reveals variable dominance of presenilin mutations linked to familial Alzheimer's disease.
High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression.
High resolution imaging study of interactions between the 37 kDa/67 kDa laminin receptor and APP, beta-secretase and gamma-secretase in Alzheimer's disease.
High-fat diet exacerbates cognitive and metabolic abnormalities in neuronal BACE1 knock-in mice - partial prevention by Fenretinide.
Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment.
Highly Pathogenic Alzheimer's Disease Presenilin 1 P117R Mutation Causes a specific Increase in p53 and p21 Protein Levels and Cell Cycle Dysregulation in Human Lymphocytes.
Histological and Behavioral Phenotypes of a Novel Mutated APP Knock-In Mouse.
Histone acetyltransferase p300 mediates histone acetylation of PS1 and BACE1 in a cellular model of Alzheimer's disease.
HMGA1a induces alternative splicing of estrogen receptor alpha in MCF-7 human breast cancer cells.
HMGA1a trapping of U1 snRNP at an authentic 5' splice site induces aberrant exon skipping in sporadic Alzheimer's disease.
HMGA1a: sequence-specific RNA-binding factor causing sporadic Alzheimer's disease-linked exon skipping of presenilin-2 pre-mRNA.
Homozygosity of the autosomal dominant Alzheimer disease presenilin 1 E280A mutation.
Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.
Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network.
Human neuroblastoma cells transfected with two Chinese presenilin 1 mutations are sensitized to trophic factor withdrawal and protected by insulin-like growth factor-1.
Human presenilin-1, but not familial Alzheimer's disease (FAD) mutants, facilitate Caenorhabditis elegans Notch signalling independently of proteolytic processing.
Human wild presenilin-1 mimics the effect of the mutant presenilin-1 on the processing of Alzheimer's amyloid precursor protein in PC12D cells.
Human-Induced Neurons from Presenilin 1 Mutant Patients Model Aspects of Alzheimer's Disease Pathology.
Hybrid approach to sieve out natural compounds against dual targets in Alzheimer's Disease.
Hybrid Structure-Based Virtual Screening Protocol for the Identification of Novel BACE1 Inhibitors.
Hybrid structure-based virtual screening protocol for the identification of novel BACE1 inhibitors.
Hydrocephalus and abnormal subcommissural organ in mice lacking presenilin-1 in Wnt1 cell lineages.
Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase.
Hyperaccumulation of FAD-linked presenilin 1 variants in vivo.
Hypertension accelerates the progression of Alzheimer-like pathology in a mouse model of the disease.
Hypocapnia induces caspase-3 activation and increases Abeta production.
Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease.
Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression.
Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation.
Hypoxic remodelling of Ca2+ mobilization in type I cortical astrocytes: involvement of ROS and pro-amyloidogenic APP processing.
Ibuprofen rescues abnormalities in periodontal tissues in conditional presenilin 1 and presenilin 2 double knockout mice.
Icariin decreases the expression of APP and BACE-1 and reduces the ?-amyloid burden in an APP transgenic mouse model of Alzheimer's disease.
Identification of a BACE1 Binding Peptide Candidate for the Prevention of Amyloid Beta in Alzheimer's Disease.
Identification of a cis-acting element involved in the regulation of BACE1 mRNA alternative splicing.
Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein.
Identification of a novel 4.6-kb genomic deletion in presenilin-1 gene which results in exclusion of exon 9 in a Finnish early onset Alzheimer's disease family: an Alu core sequence-stimulated recombination?
Identification of a novel BACE1 inhibitor, timosaponin A-III, for treatment of Alzheimer's disease by a cell extraction and chemogenomics target knowledgebase-guided method.
Identification of a novel family of presenilin homologues.
Identification of a novel mutation (Leu282Arg) of the human presenilin 1 gene in Alzheimer's disease.
Identification of a novel mutation in the presenilin 1 gene in a Chinese Alzheimer's disease family.
Identification of a novel PSEN1 Gly111Val missense mutation in a Chinese pedigree with early-onset Alzheimer's disease.
Identification of a novel PSEN1 mutation (Leu232Pro) in a Korean patient with early-onset Alzheimer's disease and a family history of dementia.
Identification of a Pathogenic PSEN1 Ala285Val Mutation Associated with Early-Onset Alzheimer's Disease.
Identification of BACE1 inhibitors from Panax ginseng saponins-An Insilco approach.
Identification of beta-secretase (BACE1) substrates using quantitative proteomics.
Identification of distinct gamma-secretase complexes with different APH-1 variants.
Identification of gamma-secretase inhibitor potency determinants on presenilin.
Identification of Human Islet Amyloid Polypeptide as a BACE2 Substrate.
Identification of new BACE1 inhibitors for treating Alzheimer's disease.
Identification of new presenilin gene mutations in early-onset familial Alzheimer disease.
Identification of syntaxin 1A as a novel binding protein for presenilin-1.
Identification of tetrahydrocarbazoles as novel multifactorial drug candidates for treatment of Alzheimer's disease.
Identification of the presenilins in hematopoietic cells with localization of presenilin 1 to neutrophil and platelet granules.
Identification of the role of presenilins beyond Alzheimer's disease.
Identification of ubiquilin, a novel presenilin interactor that increases presenilin protein accumulation.
Identifying genes that interact with Drosophila presenilin and amyloid precursor protein.
Iminoheterocycle as a druggable motif: BACE1 inhibitors and beyond.
Immunocytochemical Characterization of Alzheimer Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid- ? Vaccine.
Immunocytochemical Characterization of Alzheimer's Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-? Vaccine.
Immunohistochemical analysis of presenilin 2 expression in the mouse brain: distribution pattern and co-localization with presenilin 1 protein.
Immunohistochemical analysis of presenilin-1 expression in the mouse brain.
Immunohistochemical characterization of gamma-secretase activating protein expression in Alzheimer's disease brains.
Immunomodulation of A?PP Processing Alleviates Amyloid-?-Related Pathology in Alzheimer's Disease Transgenic Mice.
Immunoreactivity of presenilin-1 and tau in Alzheimer's disease brain.
Impaired cell proliferation in the subventricular zone in an Alzheimer's disease model.
Impaired proteolytic processing of presenilin-1 in chromosome 14-linked familial Alzheimer's disease patient lymphocytes.
Impairment in hippocampal long-term potentiation in mice under-expressing the Alzheimer's disease related gene presenilin-1.
Implication of APP secretases in notch signaling.
Implications of presenilin 1 mutations in Alzheimer's disease.
In silico Analysis of Gamma-Secretase-Complex Mutations in Hidradenitis Suppurativa Demonstrates Disease-Specific Substrate Recognition and Cleavage Alterations.
In silico design of BACE1 inhibitor for Alzheimer's disease by traditional Chinese medicine.
In Silico Design of Beta-Secretase Inhibitors in Alzheimer's Disease.
In silico prediction and screening of gamma-secretase inhibitors by molecular descriptors and machine learning methods.
In silico screening of drugs to find potential gamma-secretase inhibitors using pharmacophore modeling, QSAR and molecular docking studies.
In situ hybridization analysis of presenilin 1 mRNA in Alzheimer disease and in lesioned rat brain.
In vitro and in vivo metabolism of a gamma-secretase inhibitor BMS-299897 and generation of active metabolites in milligram quantities with a microbial bioreactor.
In vitro biological activity of Salvia fruticosa Mill. infusion against amyloid ?-peptide-induced toxicity and inhibition of GSK-3?, CK-1?, and BACE-1 enzymes relevant to Alzheimer's disease.
In vitro characterization of a gamma-secretase radiotracer in mammalian brain.
In vitro gamma-secretase cleavage of the Alzheimer's amyloid precursor protein correlates to a subset of presenilin complexes and is inhibited by zinc.
In vitro reconstitution of gamma-secretase activity using yeast microsomes.
In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase.
In vivo manifestation of Notch related phenotypes in zebrafish treated with Alzheimer's amyloid reducing gamma-secretase inhibitors.
In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease.
In vivo Reconstitution of {gamma}-Secretase in Drosophila Results in Substrate Specificity.
Incomplete penetrance of familial Alzheimer's disease in a pedigree with a novel presenilin-1 gene mutation.
Increase in p53 protein levels by presenilin 1 gene mutations and its inhibition by secretase inhibitors.
Increase of BACE1, Brain-Renal Risk Factor, Contributes to Kidney Damage in an Alzheimer's Disease Mouse Model.
Increased Abeta42(43) from cell lines expressing presenilin 1 mutations.
Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain.
Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1.
Increased apoptosis arising from increased expression of the Alzheimer's disease-associated presenilin-2 mutation (N141I).
Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome.
Increased blood BACE1 activity as a potential common pathogenic factor of vascular dementia and late onset Alzheimer's disease.
Increased CSF- BACE1 Activity Associated with Decreased Hippocampus Volume in Alzheimer's Disease.
Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.
Increased expression of the gamma-secretase components presenilin-1 and nicastrin in activated astrocytes and microglia following traumatic brain injury.
Increased Foxo3a Nuclear Translocation and Activity is an Early Neuronal Response to ??-Secretase-Mediated Processing of the Amyloid-? Protein Precursor: Utility of an A?PP-GAL4 Reporter Assay.
Increased Inflammatory Response Both in Brain and in Periphery in Presenilins Conditional Double Knock-Out Mice.
Increased NF-?B signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.
Increased oxidative stress and astrogliosis responses in conditional double-knockout mice of Alzheimer-like presenilin-1 and presenilin-2.
Increased Phosphorylation of Tau and Synaptic Protein Loss in the Aged Transgenic Mice Expressing Familiar Alzheimer's Disease-Linked Presenilin 1 Mutation.
Increased sensitivity to mitochondrial toxin-induced apoptosis in neural cells expressing mutant presenilin-1 is linked to perturbed calcium homeostasis and enhanced oxyradical production.
Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1.
Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid beta-peptide toxicity: central roles of superoxide production and caspase activation.
Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase.
Independent inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered cholesterol levels.
Indirubin-3'-monoxime rescues spatial memory deficits and attenuates beta-amyloid-associated neuropathology in a mouse model of Alzheimer's disease.
Induced dimerization of the amyloid precursor protein leads to decreased amyloid-beta protein production.
Induced HMGA1a expression causes aberrant splicing of Presenilin-2 pre-mRNA in sporadic Alzheimer's disease.
Induction of neuronal death by ER stress in Alzheimer's disease.
Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease.
Influence of low frequency PSEN1 variants on familial Alzheimer's disease risk in Brazil.
Inherited Alzheimer's disease PS-1 olfactory function: a 10-year follow-up study.
Inhibiting amyloid precursor protein C-terminal cleavage promotes an interaction with presenilin 1.
Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease.
Inhibition and modulation of gamma-secretase for Alzheimer's disease.
Inhibition of ?-site amyloid precursor protein cleaving enzyme 1 and cholinesterases by pterosins via a specific structure-activity relationship with a strong BBB permeability.
Inhibition of Alzheimer's amyloid-?42 peptide aggregation by a bi-functional bis-tryptoline triazole: key insights from molecular dynamics simulations.
Inhibition of AMPA responses by mutated presenilin 1.
Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model.
Inhibition of BACE1 for therapeutic use in Alzheimer's disease.
Inhibition of BACE1, the ?-secretase implicated in Alzheimer's disease, by a chondroitin sulfate extract from Sardina pilchardus.
Inhibition of cyclooxygenase as potential novel therapeutic strategy in N141I presenilin-2 familial Alzheimer's disease.
Inhibition of gamma-Secretase Activity by Helical beta-Peptide Foldamers.
Inhibition of gamma-secretase activity reduces Abeta production, reduces oxidative stress, increases mitochondrial activity and leads to reduced vulnerability to apoptosis: Implications for the treatment of Alzheimer's disease.
Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies.
Inhibition of gamma-secretase by the CK1 inhibitor IC261 does not depend on CK1delta.
Inhibition of neurite outgrowth by familial Alzheimer's disease-linked presenilin-1 mutations.
Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression.
Inhibition of stress induced premature senescence in presenilin-1 mutated cells with water soluble Coenzyme Q10.
Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story.
Inhibitory effect of a presenilin 1 mutation on the Wnt signalling pathway by enhancement of beta-catenin phosphorylation.
Inhibitory effect of chloroquine derivatives on presenilin 1 and ubiquilin 1 expression in Alzheimer's disease [Retraction].
Inhibitory effect of chloroquine derivatives on presenilin 1 and ubiquilin 1 expression in Alzheimer's disease.
Injury induces presenilin-1 gene expression in mouse brain.
Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations.
Insight into the genetic etiology of Alzheimer's disease: A comprehensive review of the role of rare variants.
Insights from modeling the tertiary structure of human BACE2.
Insights into Alzheimer disease pathogenesis from studies in transgenic animal models.
Insulin Suppresses the Expression of Amyloid Precursor Protein, Presenilins, and Glycogen Synthase Kinase-3{beta} in Peripheral Blood Mononuclear Cells.
Insulysin Cleaves the APP Cytoplasmic Fragment at Multiple Sites.
Interaction between the APOE epsilon4 allele and the APH-1b c + 651T > G SNP in Alzheimer's disease.
Interaction of Alzheimer's presenilin-1 and presenilin-2 with Bcl-X(L). A potential role in modulating the threshold of cell death.
Interaction of the Presenilins with the Amyloid Precursor Protein (APP).
Interleukin-1 and the immunogenetics of Alzheimer disease.
Internalization of exogenously added memapsin 2 (beta-secretase) ectodomain by cells is mediated by amyloid precursor protein.
Intra- or intercomplex binding to the gamma-secretase enzyme. A model to differentiate inhibitor classes.
Intracellular calcium deficits in Drosophila cholinergic neurons expressing wild type or FAD-mutant presenilin.
Intracellularly generated amyloid-beta peptide counteracts the antiapoptotic function of its precursor protein and primes proapoptotic pathways for activation by other insults in neuroblastoma cells.
Intracerebroventricular transplantation of human amniotic epithelial cells ameliorates spatial memory deficit in the doubly transgenic mice coexpressing APPswe and PS1?E9-deleted genes.
Intramembrane proteolysis by gamma-secretase.
Intramembrane proteolysis by signal peptidepeptidases - a comparative discussion of GxGD -type aspartyl proteases.
Intramembrane proteolysis of GXGD-type aspartyl proteases is slowed by a familial Alzheimer disease-like mutation.
Intraneuronal advanced glycation endproducts in presenilin-1 Alzheimer's disease.
Investigation of naphthofuran moiety as potential dual inhibitor against BACE-1 and GSK-3?: molecular dynamics simulations, binding energy, and network analysis to identify first-in-class dual inhibitors against Alzheimer's disease.
Involvement of Gadd153 in the pathogenic action of presenilin-1 mutations.
Involvement of Insulin Signaling Disturbances in Bisphenol A-Induced Alzheimer's Disease-like Neurotoxicity.
Involvement of ubiquilin-1 transcript variants in protein degradation and accumulation.
Ion channel regulation by ?-secretase BACE1 - enzymatic and non-enzymatic effects beyond Alzheimer's disease.
Is Alzheimer's Disease a Disorder of Mitochondria-Associated Membranes?
Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
Is the presenilin-1 E318G missense mutation a risk factor for Alzheimer's disease?
Isolation and characterization of Drosophila presenilin homolog.
JLK isocoumarin inhibitors: selective gamma-secretase inhibitors that do not interfere with notch pathway in vitro or in vivo.
Kinetics and molecular docking studies of fucosterol and fucoxanthin, BACE1 inhibitors from brown algae Undaria pinnatifida and Ecklonia stolonifera.
Kinetics and molecular docking studies of loganin, morroniside and 7-O-galloyl-D-sedoheptulose derived from Corni fructus as cholinesterase and ?-secretase 1 inhibitors.
L655,240, acting as a competitive BACE1 inhibitor, efficiently decreases ?-amyloid peptide production in HEK293-APPswe cells.
Label-free quantitative analysis of the membrane proteome of Bace1 protease knock-out zebrafish brains.
Label-free Quantitative Proteomics of Mouse Cerebrospinal Fluid Detects ?-Site APP Cleaving Enzyme (BACE1) Protease Substrates In Vivo.
Lack of ?-amyloid cleaving enzyme-1 (BACE1) impairs long-term synaptic plasticity but enhances granule cell excitability and oscillatory activity in the dentate gyrus in vivo.
Lack of association between an intronic polymorphism in the presenilin-1 gene and sporadic late-onset Alzheimer disease in Polish patients.
Lack of association of presenilin-1 intron-8 polymorphism with neuropathological features of Alzheimer's disease.
Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease.
Lack of effect of Presenilin 1, betaAPP and their Alzheimer's disease-related mutated forms on Xenopus oocytes membrane currents.
Lack of human-like extracellular sortilin neuropathology in transgenic Alzheimer's disease model mice and macaques.
Lack of interactions between amyloid precursor protein and hydrophilic domains of presenilin 1 and 2 using the yeast two hybrid system.
Lack of specific association of presenilin 1 (PS-1) protein with plaques and tangles in Alzheimer's disease.
Lactic acid induces aberrant amyloid precursor protein processing by promoting its interaction with endoplasmic reticulum chaperone proteins.
Laminar distribution of ?-amyloid (A?) peptide deposits in the frontal lobe in familial and sporadic Alzheimer's disease.
Laminar specific loss of isocortical presenilin 1 immunoreactivity in Alzheimer's disease. Correlations with the amyloid load and the density of tau-positive neurofibrillary tangles.
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease.
Las noticias de Madrid (News from Madrid).
LDL receptor-related protein (LRP) in Alzheimer's disease: towards a unified theory of pathogenesis.
Lead neurotoxicity: exploring the potential impact of lead substitution in zinc-finger proteins on mental health.
Length and overall sequence of the PEN-2 C-terminal domain determines its function in the stabilization of presenilin fragments.
Lentivirus-expressed siRNA vectors against Alzheimer disease.
Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor.
Linear patterns of Alzheimer's disease mutations along alpha-helices of presenilins as a tool for PS-1 model construction.
Linking vascular disorders and Alzheimer's disease: Potential involvement of BACE1.
Lipid peroxidation up-regulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer's disease.
Liquid-liquid extraction of strongly protein bound BMS-299897 from human plasma and cerebrospinal fluid, followed by high-performance liquid chromatography/tandem mass spectrometry.
Localisation of presenilin 2 in human and rodent pancreatic islet beta-cells; Met239Val presenilin 2 variant is not associated with diabetes in man.
Localization and trafficking of endogenous anterior pharynx-defective 1, a component of Alzheimer's disease related gamma-secretase.
Localization of Alzheimer-associated presenilin 1 in transfected COS-7 cells.
Locomotor activity, emotionality, sensori-motor gating, learning and memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
Longitudinal observation on CSF Abeta42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice.
Loss of A?43 Production Caused by Presenilin-1 Mutations in the Knockin Mouse Brain.
Loss of endophilin-B1 exacerbates Alzheimer's disease pathology.
Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrane cholesterol homeostasis.
Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.
Loss of neuronal cell cycle control as a mechanism of neurodegeneration in the presenilin-1 Alzheimer's disease brain.
Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis.
Loss of presenilin function causes Alzheimer's disease-like neurodegeneration in the mouse.
Loss of stability and hydrophobicity of presenilin 1 mutations causing Alzheimer's disease.
Low brain ascorbic acid increases susceptibility to seizures in mouse models of decreased brain ascorbic acid transport and Alzheimer's disease.
Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.
Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway.
LRP1 Downregulates the Alzheimer's ?-Secretase BACE1 by Modulating Its Intraneuronal Trafficking(1,2,3).
LRRTM3 interacts with APP and BACE1 and has variants associating with late-onset Alzheimer's disease (LOAD).
LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease.
Luteolin Reduces BACE1 Expression through NF-?B and Estrogen Receptor Mediated Pathways in HEK293 and SH-SY5Y Cells.
Lysosomal alkalization and dysfunction in human fibroblasts with the Alzheimer's disease-linked presenilin 1 A246E mutation can be reversed with cAMP.
Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations.
Lysosomal TPCN (two pore segment channel) inhibition ameliorates beta-amyloid pathology and mitigates memory impairment in Alzheimer disease.
Machine learning models for predicting the activity of AChE and BACE1 dual inhibitors for the treatment of Alzheimer's disease.
Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads.
Magnesium Modulates Amyloid-beta Protein Precursor Trafficking and Processing.
Maladaptive exploratory behavior and neuropathology of the PS-1 P117L Alzheimer transgenic mice.
Male-specific association between a gamma-secretase polymorphism and premature coronary atherosclerosis.
Mapping the APP/presenilin (PS) binding domains: the hydrophilic N-terminus of PS2 is sufficient for interaction with APP and can displace APP/PS1 interaction.
Masking of transmembrane-based retention signals controls ER export of gamma-secretase.
Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase.
Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42.
Measuring human beta-secretase (BACE1) activity using homogeneous time-resolved fluorescence.
Mechanism of gamma-secretase cleavage activation: is gamma-secretase regulated through autoinhibition involving the presenilin-1 exon 9 loop?
Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein.
Mechanisms that lessen benefits of ?-secretase reduction in a mouse model of Alzheimer's disease.
Memapsin 2 (beta-secretase) as a therapeutic target.
Memapsin 2 (beta-secretase) cytosolic domain binds to the VHS domains of GGA1 and GGA2: implications on the endocytosis mechanism of memapsin 2.
Memapsin 2, a drug target for Alzheimer's disease.
Membrane topology of Alzheimer's disease-related presenilin 1. Evidence for the existence of a molecular species with a seven membrane-spanning and one membrane-embedded structure.
Membrane topology of gamma-secretase component PEN-2.
Membrane-Associated Effects of Glucocorticoid on BACE1 Upregulation and A? Generation: Involvement of Lipid Raft-Mediated CREB Activation.
Mental Disorders in Young Adults from Families with the Presenilin-1 Gene Mutation E280A in the Preclinical Stage of Alzheimer's Disease.
Meta-analysis of BACE1 gene rs638405 polymorphism and the risk of Alzheimer's disease in Caucasion and Asian population.
Mice expressing human mutant presenilin-1 exhibit decreased activation of NF-kappaB p50 in hippocampal neurons after injury.
Microglia and neuritic plaques in familial Alzheimer's disease induced by a new mutation of presenilin-1 gene. An ultrastructural study.
MicroRNA-149 is downregulated in Alzheimer's disease and inhibits ?-amyloid accumulation and ameliorates neuronal viability through targeting BACE1.
MicroRNA-195 downregulates Alzheimer's disease amyloid-? production by targeting BACE1.
Microsecond molecular dynamics simulation of A?42 and identification of a novel dual inhibitor of A?42 aggregation and BACE1 activity.
Microvesicles from cerebrospinal fluid of patients with Alzheimer's disease display reduced concentrations of tau and APP protein.
Mif1: a missing link between the unfolded protein response pathway and ER-associated protein degradation?
Mild oxidative stress induces redistribution of BACE1 in non-apoptotic conditions and promotes the amyloidogenic processing of Alzheimer's disease amyloid precursor protein.
MiR-124 acts as a target for Alzheimer's disease by regulating BACE1.
miR-124 downregulates BACE 1 and alters autophagy in APP/PS1 transgenic mice.
miR-15b represses BACE1 expression in sporadic Alzheimer's disease.
miR-16-5p and miR-19b-3p prevent amyloid ?-induced injury by targeting BACE1 in SH-SY5Y cells.
miR-186 in Alzheimer's disease: a big hope for a small RNA?
MiR-361-3p inhibits ?-amyloid accumulation and attenuates cognitive deficits through targeting BACE1 in Alzheimer's disease.
miRNA-31 Improves Cognition and Abolishes Amyloid-? Pathology by Targeting APP and BACE1 in an Animal Model of Alzheimer's Disease.
miRNA-Based Rapid Differentiation of Purified Neurons from hPSCs Advancestowards Quick Screening for Neuronal Disease Phenotypes In Vitro.
Missense mutation in exon 11 (Codon 378) of the presenilin-1 gene in a French family with early-onset Alzheimer's disease and transmission study by mismatch enhanced allele specific amplification. Mutations in brief no. 141. Online. besancon@rockefeller1.univ.lyon1.fr.
Missense mutations in the chromosome 14 familial Alzheimer's disease presenilin 1 gene.
Mitochondria-targeted catalase reduces abnormal APP processing, amyloid ? production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension.
Mitochondrial function in fibroblasts with aging in culture and/or Alzheimer's disease.
MMP13 inhibition rescues cognitive decline in Alzheimer transgenic mice via BACE1 regulation.
Model peptides uncover the role of the ?-secretase transmembrane sequence in metal ion mediated oligomerization.
Modeling the tertiary structure of human cathepsin-E.
Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities.
Modification of endoplasmic reticulum Ca2+ stores by select oxidants produces changes reminiscent of those in cells from patients with Alzheimer disease.
Modulation of BACE1 Activity by Chemically Modified Aptamers.
Modulation of gamma-secretase for the treatment of Alzheimer's disease.
Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease.
Modulation of in?vitro activity of zymogenic and mature recombinant human ?-secretase by dietary plants.
Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer's disease and related models.
Modulatory effect of acetyl-l-carnitine on amyloid precursor protein metabolism in hippocampal neurons.
Molecular analysis of the presenilin 1 (S182) gene in "sporadic" cases of Alzheimer's disease: identification and characterisation of unusual splice variants.
Molecular characterization and temporal expression profiling of presenilins in the developing porcine brain.
Molecular cloning and characterization of CALP/KChIP4, a novel EF-hand protein interacting with presenilin 2 and voltage-gated potassium channel subunit Kv4.
Molecular cloning and expression of the rat homologue of presenilin-1.
Molecular Docking and 3D Qsar Studies of C000000956 as a Potent Inhibitor of Bace-1.
Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease.
Molecular evidence of presenilin 1 mutation in familial early onset dementia.
Molecular Genetic Analysis of the APP, PSEN1, and PSEN2 Genes in Finnish Patients With Early-onset Alzheimer Disease and Frontotemporal Lobar Degeneration.
Molecular genetics of Alzheimer's disease.
Molecular genetics of Alzheimer's disease: presenilin 1 gene analysis in a cohort of patients from the Poznań region.
Molecular Models of the Interface between Anterior Pharynx-Defective Protein 1 (APH-1) and Presenilin Involving GxxxG Motifs.
Monogenic determinants of familial Alzheimer's disease: presenilin-1 mutations.
Monogenic determinants of familial Alzheimer's disease: presenilin-2 mutations.
Morphological change by overexpression of D385A dominant negative presenilin 1 in human neuroblastoma SH-SY5Y cells.
Mouse brain proteomics establishes MDGA1 and CACHD1 as in vivo substrates of the Alzheimer protease BACE1.
Multifunctional iminochromene-2H-carboxamide derivatives containing different aminomethylene triazole with BACE1 inhibitory, neuroprotective and metal chelating properties targeting Alzheimer's disease.
Multimodal Imaging in a Patient With Alzheimer Disease and Parkinsonism Because of a Presenilin-1 Mutation.
Multipotent AChE and BACE-1 inhibitors for the treatment of Alzheimer's disease: Design, synthesis and bio-analysis of 7-amino-1,4-dihydro-2H-isoquilin-3-one derivates.
Multitarget Approach to Drug Candidates against Alzheimer's Disease Related to AChE, SERT, BACE1 and GSK3? Protein Targets.
Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3? inhibitors.
Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors.
Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons.
Mutagenesis mapping of the presenilin 1 calcium leak conductance pore.
Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates Abeta1-42/43 expression.
Mutant presenilin (A260V) affects Rab8 in PC12D cell.
Mutant presenilin 1 expression in excitatory neurons impairs enrichment-mediated phenotypes of adult hippocampal progenitor cells.
Mutant presenilin 1 increases the expression and activity of BACE1.
Mutant presenilin 1 increases the levels of Alzheimer amyloid beta-peptide Abeta42 in late compartments of the constitutive secretory pathway.
Mutant presenilin 1 proteins induce cell death and reduce tau-dependent processes outgrowth.
Mutant presenilin-1 deregulated peripheral immunity exacerbates alzheimer-like pathology.
Mutant presenilin-1 induces apoptosis and downregulates Akt/PKB.
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase.
Mutation profile of APP, PSEN1, and PSEN2 in Chinese familial Alzheimer's disease.
Mutational analysis in early-onset familial Alzheimer's disease in Mainland China.
Mutational analysis in early-onset familial dementia in the Japanese population. The role of PSEN1 and MAPT R406W mutations.
Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease.
Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland.
Mutations in progranulin explain atypical phenotypes with variants in MAPT.
Mutations in the transmembrane domain of APP altering gamma-secretase specificity.
Myeloproliferative disease in mice with reduced presenilin gene dosage: effect of gamma-secretase blockage.
N-glycosylation of human nicastrin is required for interaction with the lectins from the secretory pathway calnexin and ERGIC-53.
N-Substituted carbazolyloxyacetic acids modulate Alzheimer associated gamma-secretase.
N141I mutant presenilin-2 gene enhances neuronal cell death and decreases bcl-2 expression.
NACP/alpha-synuclein, NAC, and beta-amyloid pathology of familial Alzheimer's disease with the E184D presenilin-1 mutation: a clinicopathological study of two autopsy cases.
Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease.
Natural antisense transcripts of Alzheimer's disease associated genes.
Natural Compounds with Anti-BACE1 Activity as Promising Therapeutic Drugs for Treating Alzheimer's Disease.
Natural Products based P-glycoprotein Activators for Improved ?-amyloid Clearance in Alzheimer's Disease: An in silico Approach.
Nav?2 knockdown improves cognition in APP/PS1 mice by partially inhibiting seizures and APP amyloid processing.
Neprilysin activity and expression are controlled by nicastrin.
Neurite-like structures induced by mevalonate pathway blockade are due to the stability of cell adhesion foci and are enhanced by the presence of APP.
Neuro-protective effects of aloperine in an Alzheimer's disease cellular model.
Neurodegeneration in Alzheimer disease: role of amyloid precursor protein and presenilin 1 intracellular signaling.
Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer's Disease: A Pilot Study.
Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling.
Neuronal and nonneuronal quantitative BACE immunocytochemical expression in the entorhinohippocampal and frontal regions in Alzheimer's disease.
Neuronal expression and intracellular localization of presenilins in normal and Alzheimer disease brains.
Neuronal human BACE1 knockin induces systemic diabetes in mice.
Neuronal localization of presenilin-1 and association with amyloid plaques and neurofibrillary tangles in Alzheimer's disease.
Neuronal Migration and Neurodegeneration: 2 Sides of the Same Coin.
Neuronal protein trafficking associated with Alzheimer disease: From APP and BACE1 to glutamate receptors.
Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease.
Neuropathological and clinical phenotype of an Italian Alzheimer family with M239V mutation of presenilin 2 gene.
Neuropathological, biochemical and genetic alterations in AD.
Neuropathology and biochemistry of early onset familial Alzheimer's disease caused by presenilin-1 missense mutation Thr116Asn.
Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features.
Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease.
Neuropsychological functions in variant Alzheimer's disease with spastic paraparesis.
Neuropsychological profile of a large kindred with familial Alzheimer's disease caused by the E280A single presenilin-1 mutation.
Neuropsychological profiles of familial Alzheimer's disease associated with mutations in the presenilin 1 and amyloid precursor protein genes.
Neuropsychological study of familial Alzheimer's disease caused by mutation E280A in the presenilin 1 gene.
Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation: oxidative stress, caspases, and the JNK pathway.
Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation.
New 1,2,3,4-tetrahydroisoquinoline derivatives as modulators of proteolytic cleavage of amyloid precursor proteins.
New 3,5-dimethylorsellinic acid-based meroterpenoids with BACE1 and AchE inhibitory activities from Aspergillus terreus.
New aminoimidazoles as ?-secretase (BACE-1) inhibitors showing amyloid-? (A?) lowering in brain.
New BACE1 Chimeric Peptide Inhibitors Selectively Prevent A?PP-? Cleavage Decreasing Amyloid-? Production and Accumulation in Alzheimer's Disease Models.
New developments in mild cognitive impairment and Alzheimer's disease.
New mutation in the PSEN1 (E120G) gene associated with early onset Alzheimer's disease.
New N(4)-substituted piperazine naphthamide derivatives as BACE-1 inhibitors.
New presenilin 1 mutation with Alzheimer disease and Lewy bodies.
NF-E2-related factor 2 activation boosts antioxidant defenses and ameliorates inflammatory and amyloid properties in human Presenilin-1 mutated Alzheimer's disease astrocytes.
NF{kappa}B-dependent Control of BACE1 Promoter Transactivation by A{beta}42.
Nicastrin binds to membrane-tethered Notch.
Nicastrin Is Dispensable for {gamma}-Secretase Protease Activity in the Presence of Specific Presenilin Mutations.
Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate Notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals.
Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria.
Nitrosylation of Vesicular Transporters in Brain of Amyloid Precursor Protein/Presenilin 1 Double Transgenic Mice.
No association between a polymorphism in the presenilin 1 gene and dementia with Lewy bodies.
No association between a presenilin 1 polymorphism and Alzheimer disease.
No association between an intronic polymorphism in the presenilin-1 gene and Alzheimer disease in a German population.
No association between an intronic polymorphism in the presenilin-1 gene and Alzheimer disease in a Tunisian population.
No association between an intronic polymorphism in the presenilin-1 gene and Alzheimer's disease.
No association between presenilin 1 (PS1) intronic polymorphism and sporadic Alzheimer's disease in Koreans.
No association between the intronic presenilin 1 polymorphism and Alzheimer's disease in the Chinese population.
No association between the intronic presenilin-1 polymorphism and Alzheimer's disease in clinic and population-based samples.
No association of presenilin-1 intronic polymorphism and Alzheimer's disease in Australia.
No association of spastic paraparesis genes in PSEN1 Alzheimer's disease with spastic paraparesis.
No association of the -48CT polymorphism of the presenilin 1 gene with Alzheimer disease in a late-onset sporadic population.
No association or linkage between an intronic polymorphism of presenilin-1 and sporadic or late-onset familial Alzheimer disease.
No detected mutations in the genes for the amyloid precursor protein and presenilins 1 and 2 in a swiss early-onset Alzheimer's disease family with a dominant mode of inheritance.
No replication of genetic association between candidate polymorphisms and Alzheimer's disease.
Non-proteolytic effect of beta-site APP-cleaving enzyme 1 (BACE1) on sodium channel function.
Normal distribution of presenilin-1 and nicastrin in skeletal muscle and the differential responses of these proteins after denervation.
Normal proteolytic processing of the presenilins.
Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer's therapy.
Notch is expressed in adult brain, is coexpressed with presenilin-1, and is altered in Alzheimer disease.
Notch-1 activation by familial Alzheimer's disease (FAD)-linked mutant forms of presenilin-1.
Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells.
Novel 'inflammatory plaque' pathology in presenilin-1 Alzheimer's disease.
Novel brain 14-3-3 interacting proteins involved in neurodegenerative disease.
Novel insertional presenilin 1 mutation causing Alzheimer disease with spastic paraparesis.
Novel intronic polymorphisms in the presenilin-2 gene and a case-control association study of Alzheimer's disease.
Novel orally active, dibenzazepinone-based gamma-secretase inhibitors.
Novel Plasma miRNAs as Biomarkers and Therapeutic Targets of Alzheimer's Disease at the Prodromal Stage.
Novel presenilin 1 mutation (Ile408Thr) in an Italian family with late-onset Alzheimer's disease.
Novel presenilin 1 mutation (p.F386I) in a Chinese family with early-onset Alzheimer's disease.
Novel presenilin 1 mutation (p.I83T) in Tunisian family with early-onset Alzheimer's disease.
Novel presenilin 1 mutation (p.Thr-Pro116-117Ser-Thr) in a Spanish family with early-onset Alzheimer's disease.
Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life.
Novel presenilin 1 mutation with profound neurofibrillary pathology in an indigenous Southern African family with early-onset Alzheimer's disease.
Novel presenilin 1 mutations associated with early onset of dementia in a family with both early-onset and late-onset Alzheimer disease.
Novel presenilin 1 variant (P117A) causing Alzheimer's disease in the fourth decade of life.
Novel presenilin-1 Y159F sequence variant associated with early-onset Alzheimer's disease.
Novel Presenilins mutations within Moroccan patients with Early Onset Alzheimer's Disease.
Novel PSEN1 mutations (H214N and R220P) associated with familial Alzheimer's disease identified by targeted exome sequencing.
Novel PSEN1 p.Gly417Ala mutation in a Korean patient with early-onset Alzheimer's disease with parkinsonism.
Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands.
Novel {gamma}-secretase inhibitors uncover a common nucleotide-binding site in JAK3, SIRT2, and PS1.
NRF2/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer's models.
NSAID-derived gamma-secretase modulators. Part III: Membrane anchoring.
Octapeptide repeat insertions in the prion protein gene and early onset dementia.
Oleic acid and linoleic acid from Tenebrio molitor larvae inhibit BACE1 activity in vitro: molecular docking studies.
One novel presenilin-1 gene mutation in a Chinese pedigree of familial Alzheimer's disease.
Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores - development of potential agents for the treatment of Alzheimer's disease.
Optimization and biological evaluation of imidazopyridine derivatives as a novel scaffold for ?-secretase modulators with oral efficacy against cognitive deficits in Alzheimer's disease model mice.
Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Oral treatment with a gamma-secretase inhibitor improves long-term potentiation in a mouse model of Alzheimer's disease.
Origin of the PSEN1 E280A mutation causing early-onset Alzheimer's disease.
Overactive BRCA1 Affects Presenilin 1 in Induced Pluripotent Stem Cell-Derived Neurons in Alzheimer's Disease.
Overexpression in neurons of human presenilin-1 or a presenilin-1 familial Alzheimer disease mutant does not enhance apoptosis.
Overexpression of presenilin-2 enhances apoptotic death of cultured cortical neurons.
Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice.
Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein.
Oxidative stress in synaptosomal proteins from mutant presenilin-1 knock-in mice: implications for familial Alzheimer's disease.
Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2? pathway.
Oxidative stress potentiates BACE1 gene expression and Abeta generation.
p300 activation by Presenilin 1 but not by its M146L mutant.
p35/cdk5 binds and phosphorylates beta-catenin and regulates beta-catenin/presenilin-1 interaction.
p53-dependent control of transactivation of the Pen2 promoter by presenilins.
p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas.
Palmitoylation of the C-terminal fragment of p75(NTR) regulates death signaling and is required for subsequent cleavage by gamma-secretase.
PAMP and PARL, two novel putative metalloproteases interacting with the COOH-terminus of Presenilin-1 and -2.
Partial BACE1 reduction in a Down syndrome mouse model blocks Alzheimer-related endosomal anomalies and cholinergic neurodegeneration: role of APP-CTF.
Partial loss of presenilins causes seborrheic keratosis and autoimmune disease in mice.
Partial purification and characterization of gamma-secretase from post-mortem human brain.
Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice.
Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice.
Partial, Rather than Full, BACE1 Inhibition May Be a Better Therapeutic Strategy for Alzheimer's Disease Due to Effects of Complete Loss of BACE1 Activity on Adult Hippocampal Neurogenesis.
Participation of Amyloid and Tau Protein in Post-Ischemic Neurodegeneration of the Hippocampus of a Nature Identical to Alzheimer's Disease.
Pathogenic presenilin 1 mutations (P436S & I143F) in early-onset Alzheimer's disease in the UK. Mutations in brief no. 223. Online.
Pathogenic PSEN1 Thr119Ile Mutation in Two Korean Patients with Early-Onset Alzheimer's Disease.
Pathological activity of familial Alzheimer's disease-associated mutant presenilin can be executed by six different gamma-secretase complexes.
Pathological and physiological functions of presenilins.
Pathological manifestation of the induced pluripotent stem cell-derived cortical neurons from an early-onset Alzheimer's disease patient carrying a presenilin-1 mutation (S170F).
Pathology of early-onset Alzheimer's disease cases bearing the Thr113-114ins presenilin-1 mutation.
Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics.
PCSK9 is Present in Human Cerebrospinal Fluid and is Maintained at Remarkably Constant Concentrations Throughout the Course of the Day.
PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.
PEDF Maintains RPE Function by Inhibiting VEGF-R2 Signaling Through {gamma}-Secretase.
Pen2 and presenilin-1 modulate the dynamic equilibrium of presenilin-1 and presenilin-2 gamma-secretase complexes.
PEN2 is not a genetic risk factor for Alzheimer's disease in a large family sample.
Peptide EphB2/CTF2 Generated by the gamma-secretase processing of EphB2 receptor promotes tyrosine phosphorylation and cell surface localization of N-methyl-D-aspartate receptors.
Peptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's disease.
Peripheral Activity and Central Substrates of BACE1: Therapeutic Implications for Alzheimer's Disease.
PERK mediates eIF2? phosphorylation responsible for BACE1 elevation, CREB dysfunction and neurodegeneration in a mouse model of Alzheimer's disease.
PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease.
pH-Dependent Population Shift Regulates BACE1 Activity and Inhibition.
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.
Pharmacological Inhibition of BACE1 Impairs Synaptic Plasticity and Cognitive Functions.
Pharmacological knock-down of the presenilin 1 heterodimer by a novel gamma -secretase inhibitor: implications for presenilin biology.
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.
Phenotypic analysis of images of zebrafish treated with Alzheimer's gamma-secretase inhibitors.
Phenotypic Profile of Early-Onset Familial Alzheimer's Disease Caused by Presenilin-1 E280A Mutation.
Phenotypic Variability in Autosomal Dominant Familial Alzheimer Disease due to the S170F Mutation of Presenilin-1.
Phosphorylation of presenilin-2 regulates its cleavage by caspases and retards progression of apoptosis.
Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis.
Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins.
Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1.
Physical evidence supporting a ribosomal shunting mechanism of translation initiation for BACE1 mRNA.
Physiological Control of Nitric Oxide on neuronal BACE1 Translation by Heme-Regulated Eif2-alpha Kinase HRI Induces Synaptogenesis.
Physiological Functions of the ?-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2.
Physiological functions of the amyloid precursor protein secretases ADAM10, BACE1, and Presenilin.
Physiologically generated presenilin 1 lacking exon 8 fails to rescue brain PS1-/- phenotype and forms complexes with wildtype PS1 and nicastrin.
Pick bodies in a family with presenilin-1 Alzheimer's disease.
Piperazinyl pyrimidine derivatives as potent gamma-secretase modulators.
Plasma ?-secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD.
Plasma Lipids as Biomarkers for Alzheimer's Disease: A Systematic Review.
Plasma long non-coding RNA BACE1 as a novel biomarker for diagnosis of Alzheimer disease.
Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study.
Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease.
Polymorphism of the regulatory region of the presenilin-2 gene in sporadic Alzheimer's disease: a case-control study.
Polymorphisms in the presenilin 1 and presenilin 2 genes and risk for sporadic Alzheimer's disease.
Polypharmacology of Berberine Based on Multi-Target Binding Motifs.
Population density analysis for determining the protonation state of the catalytic dyad in BACE1-tertiary carbinamine-based inhibitor complex.
Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques.
Post-Translational Modifications of BACE1 in Alzheimer's Disease.
Post-translational regulation of the ?-secretase BACE1.
Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.
Postsynaptic Target Specific Synaptic Dysfunctions in the CA3 Area of BACE1 Knockout Mice.
Posttranslational modification and plasma membrane localization of the Drosophila melanogaster presenilin.
Potential of Pueraria tuberosa (Willd.) DC. to rescue cognitive decline associated with BACE1 protein of Alzheimer's disease on Drosophila model: An integrated molecular modeling and in vivo approach.
Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study.
Precuneus Failures in Subjects of the PSEN1 E280A Family at Risk of Developing Alzheimer's Disease Detected Using Quantitative Electroencephalography.
Predicting memapsin 2 (?-secretase) hydrolytic activity.
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.
Preparation and biological evaluation of conformationally constrained BACE1 inhibitors.
Presenilin 1 and APP Gene Mutations in Early-Onset AD Families from a Southeast Region of China.
Presenilin 1 and cadherins: stabilization of cell-cell adhesion and proteolysis-dependent regulation of transcription.
Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau.
Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons.
Presenilin 1 deficiency suppresses autophagy in human neural stem cells through reducing ?-secretase-independent ERK/CREB signaling.
Presenilin 1 facilitates the constitutive turnover of beta-catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the beta-catenin-signaling pathway.
Presenilin 1 familial Alzheimer's disease mutation leads to defective associative learning and impaired adult neurogenesis.
Presenilin 1 gene mutation (M139I) in a patient with an early-onset Alzheimer's disease: clinical characteristics and genetic identification.
Presenilin 1 Gene Mutation (M139V) in a German Family with Early-Onset Alzheimer's Disease: A Case Report.
Presenilin 1 gene silencing by S-adenosylmethionine: a treatment for Alzheimer disease?
Presenilin 1 immunostaining using well-characterized antibodies in human tissues.
Presenilin 1 interacts with acetylcholinesterase and alters its enzymatic activity and glycosylation.
Presenilin 1 intronic polymorphism in sporadic Alzheimer's disease in a Northern Chinese population.
Presenilin 1 intronic polymorphism is not associated with Alzheimer type neuropathological changes or sporadic Alzheimer's disease.
Presenilin 1 is essential for cardiac morphogenesis.
Presenilin 1 is involved in maturation and trafficking of N-cadherin to the plasma membrane.
Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm.
Presenilin 1 Maintains Lysosomal Ca(2+) Homeostasis via TRPML1 by Regulating vATPase-Mediated Lysosome Acidification.
Presenilin 1 mediates retinoic acid-induced differentiation of SH-SY5Y cells through facilitation of Wnt signaling.
Presenilin 1 Met146Leu variant due to an A --> T transversion in an early-onset familial Alzheimer's disease pedigree from Argentina.
Presenilin 1 mRNA expression in hippocampi of sporadic Alzheimer's disease patients.
Presenilin 1 mutation decreases both calcium and contractile responses in cerebral arteries.
Presenilin 1 mutation in an african american family presenting with atypical Alzheimer dementia.
PRESENILIN 1 Mutations Causing Early-Onset Familial Alzheimer's Disease or Familial Acne Inversa Differ in Their Effects on Genes Facilitating Energy Metabolism and Signal Transduction.
Presenilin 1 mutations in Polish families with early-onset Alzheimer's disease.
Presenilin 1 mutations increase amyloid precursor protein production and proteolysis in Xenopus laevis oocytes.
Presenilin 1 mutations linked to familial Alzheimer's disease increase the intracellular levels of amyloid beta-protein 1-42 and its N-terminally truncated variant(s) which are generated at distinct sites.
Presenilin 1 overexpressions in Chinese hamster ovary (CHO) cells decreases the phosphorylation of retinoblastoma protein: relevance for neurodegeneration.
Presenilin 1 polymorphism associated with Alzheimer's disease in apolipoprotein E4 carriers.
Presenilin 1 promotes trypsin-induced neuroprotection via the PAR2/ERK signaling pathway. Effects of presenilin 1 FAD mutations.
Presenilin 1 regulates beta-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion.
Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway.
Presenilin 1 Regulates Membrane Homeostatic Pathways that are Dysregulated in Alzheimer's Disease.
Presenilin 1 Regulates NF-?B Activation via Association with Breakpoint Cluster Region and Casein Kinase II.
Presenilin 1 regulates pharmacologically distinct gamma -secretase activities. Implications for the role of presenilin in gamma -secretase cleavage.
Presenilin 1 Regulates [Ca2+]i and Mitochondria/ER Interaction in Cultured Rat Hippocampal Neurons.
Presenilin 1 stabilizes the C-terminal fragment of the amyloid precursor protein independently of gamma-secretase activity.
Presenilin 1 suppresses the function of c-Jun homodimers via interaction with QM/Jif-1.
Presenilin 1 transgene addition to amyloid precursor protein overexpressing transgenic rats increases amyloid beta 42 levels and results in loss of memory retention.
Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency.
Presenilin 2 expression in neuronal cells: induction during differentiation of embryonic carcinoma cells.
Presenilin 2 is secreted in mouse primary neurons: a release enhanced by apoptosis.
Presenilin 2 mutation accelerates the onset of impairment in trace eyeblink conditioning in a mouse model of Alzheimer's disease overexpressing human mutant amyloid precursor protein.
Presenilin 2 mutation R71W in an Italian early-onset sporadic Alzheimer's disease case.
Presenilin affects arm/beta-catenin localization and function in Drosophila.
Presenilin dependence of phospholipase C and protein kinase C signaling.
Presenilin E318G variant and Alzheimer's disease risk: the Cache County study.
Presenilin endoproteolysis mediated by an aspartyl protease activity pharmacologically distinct from gamma-secretase.
Presenilin function in APP processing.
Presenilin function: connections to Alzheimer's disease and signal transduction.
Presenilin I expression in yeast lowers secretion of the amyloid precursor protein.
Presenilin mediates neuroprotective functions of ephrinB and brain-derived neurotrophic factor and regulates ligand-induced internalization and metabolism of EphB2 and TrkB receptors.
Presenilin mutations line up along transmembrane alpha-helices.
Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels.
Presenilin transgenic mice as models of Alzheimer's disease.
Presenilin-1 280Glu-->Ala Mutation Alters C-Terminal APP Processing Yielding Longer Abeta Peptides: Implications for Alzheimer's Disease.
Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer's disease.
Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors.
Presenilin-1 and the amyloid precursor protein are transported bidirectionally in the sciatic nerve of adult rat.
Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 association, and regulates stability and function of the cadherin/catenin adhesion complex.
Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to ?-secretase modulators regardless of their potency and structure.
Presenilin-1 C410Y Alzheimer disease plaques contain synaptic proteins.
Presenilin-1 controls the growth and differentiation of endothelial progenitor cells through its beta-catenin-binding region.
Presenilin-1 deficiency impairs glutamate-evoked intracellular calcium responses in neurons.
Presenilin-1 deficiency leads to loss of Cajal-Retzius neurons and cortical dysplasia similar to human type 2 lissencephaly.
Presenilin-1 Delta E9 Mutant Induces STIM1-Driven Store-Operated Calcium Channel Hyperactivation in Hippocampal Neurons.
Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch.
Presenilin-1 exists in the axoplasm fraction in the brains of aged Down's syndrome subjects and non-demented individuals.
Presenilin-1 expression in Pick's disease.
Presenilin-1 familial Alzheimer's disease mutation alters hippocampal neurogenesis and memory function in CCL2 null mice.
Presenilin-1 gene intronic polymorphism and late-onset Alzheimer's disease.
Presenilin-1 gene intronic polymorphism in sporadic and familial Alzheimer's disease.
Presenilin-1 immunoreactivity is localized intracellularly in Alzheimer's disease brain, but not detected in amyloid plaques.
Presenilin-1 in late-onset depressive disorder.
Presenilin-1 intron 8 polymorphism is not associated with autopsy-confirmed late-onset Alzheimer's disease.
Presenilin-1 is associated with Alzheimer's disease amyloid.
Presenilin-1 is processed into two major cleavage products in neuronal cell lines.
Presenilin-1 Knockin Mice Reveal Loss-of-Function Mechanism for Familial Alzheimer's Disease.
Presenilin-1 mutation activates the signaling pathway of caspase-4 in endoplasmic reticulum stress-induced apoptosis.
Presenilin-1 mutation alters NGF-induced neurite outgrowth, calcium homeostasis, and transcription factor (AP-1) activation in PC12 cells.
Presenilin-1 mutation Alzheimer's disease: a genetic epilepsy syndrome?
Presenilin-1 mutation E318G and familial Alzheimer's disease in the Italian population.
Presenilin-1 mutation impairs cholinergic modulation of synaptic plasticity and suppresses NMDA currents in hippocampus slices.
Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: involvement of perturbed calcium homeostasis.
Presenilin-1 mutation is associated with a hippocampus defect in alzheimer's disease: Meta-Analysis for neuroimaging research.
Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer's disease with non-cored plaques and no neuritic dystrophy.
Presenilin-1 mutations alter K+ currents in the human neuroblastoma cell line, SH-SY5Y.
Presenilin-1 mutations and Alzheimer's disease.
Presenilin-1 mutations associated with familial Alzheimer's disease do not disrupt protein transport from the endoplasmic reticulum to the Golgi apparatus.
Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response.
Presenilin-1 mutations in Alzheimer's disease.
Presenilin-1 Mutations in Alzheimer's Disease: An Update on Genotype-Phenotype Relationships.
Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons.
Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production.
Presenilin-1 mutations sensitize neurons to DNA damage-induced death by a mechanism involving perturbed calcium homeostasis and activation of calpains and caspase-12.
Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability.
Presenilin-1 polymorphism and Alzheimer's disease.
Presenilin-1 polymorphism and Alzheimer's disease. The Alzheimer's Study Group.
Presenilin-1 polymorphism and Alzheimer's disease. The UK Alzheimer's Disease Collaborative Group.
Presenilin-1 polymorphism in Alzheimer's disease and vascular dementia.
Presenilin-1 polymorphism in patients with Alzheimer's disease, vascular dementia and alcohol-associated dementia in Japanese population.
Presenilin-1 protects against neuronal apoptosis caused by its interacting protein PAG.
Presenilin-1 protein expression in familial and sporadic Alzheimer's disease.
Presenilin-1 protein specifically expressed in Leydig cells with its expression level increased during rat testis development.
Presenilin-1 regulates induction of hypoxia inducible factor-1?: altered activation by a mutation associated with familial Alzheimer's disease.
Presenilin-1 regulates neuronal differentiation during neurogenesis.
Presenilin-1 regulates the constitutive turnover of the fibronectin matrix in endothelial cells.
Presenilin-1 Regulates the Expression of p62 to Govern p62-dependent Tau Degradation.
Presenilin-1 regulates the neuronal threshold to excitotoxicity both physiologically and pathologically.
Presenilin-1 Targeted Morpholino Induces Cognitive Deficits, Increased Brain A?1-42 and Decreased Synaptic Marker PSD-95 in Zebrafish Larvae.
Presenilin-1, amyloid precursor protein and amyloid precursor-like protein 2 mRNA levels in human superior frontal cortex during aging.
Presenilin-1-deficient neurons are nitric oxide-dependently killed by hydrogen peroxide in vitro.
Presenilin-1-dependent transcriptome changes.
Presenilin-1-immunoreactive neurons are preserved in late-onset Alzheimer's disease.
Presenilin-2 and Calcium Handling: Molecules, Organelles, Cells and Brain Networks.
Presenilin-2 dampens intracellular Ca(2+) stores by increasing Ca(2+) leakage and reducing Ca(2+) uptake.
Presenilin-2 in the cynomolgus monkey brain: investigation of age-related changes.
Presenilin-2 mutation and polymorphism in Japanese Alzheimer disease patients.
Presenilin-2 mutation causes early amyloid accumulation and memory impairment in a transgenic mouse model of Alzheimer's disease.
Presenilin-2 polymorphisms and risk of sporadic AD: evidence from a meta-analysis.
Presenilin-Deficient Neurons and Astrocytes Display Normal Mitochondrial Phenotypes.
Presenilin-dependent expression of STIM proteins and dysregulation of capacitative Ca(2+) entry in familial Alzheimer's disease.
Presenilin-dependent gamma-secretase activity modulates neurite outgrowth.
Presenilin-dependent intramembrane cleavage of ephrin-B1.
Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide.
Presenilin-dependent regulated intramembrane proteolysis and gamma-secretase activity.
Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP.
Presenilin-interacting proteins.
Presenilin1 familial Alzheimer disease mutants inactivate EFNB1- and BDNF-dependent neuroprotection against excitotoxicity by affecting neuroprotective complexes of N-methyl-d-aspartate receptor.
Presenilins and Alzheimer's disease: biological functions and pathogenic mechanisms.
Presenilins and Alzheimer's disease: the role of A beta 42.
Presenilins Are Enriched in Endoplasmic Reticulum Membranes Associated with Mitochondria.
Presenilins as Drug Targets for Alzheimer's Disease-Recent Insights from Cell Biology and Electrophysiology as Novel Opportunities in Drug Development.
Presenilins as therapeutic targets for the treatment of Alzheimer's disease.
Presenilins in memory, Alzheimer's disease, and therapy.
Presenilins in the heart: presenilin-2 expression is increased by low glucose and by hypoxia in cardiac cells.
Presenilins interact with armadillo proteins including neural-specific plakophilin-related protein and beta-catenin.
Presenilins interact with Rab11, a small GTPase involved in the regulation of vesicular transport.
Presenilins upregulate functional K+ channel currents in mammalian cells.
Presenilins, the endoplasmic reticulum, and neuronal apoptosis in Alzheimer's disease.
Presenilins: molecular switches between proteolysis and signal transduction.
Preservation of cell-survival mechanisms by the presenilin-1 K239N mutation may cause its milder clinical phenotype.
Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased A? generation in Alzheimer's disease.
Prevalence of pathogenic mutations in an Italian clinical series of patients with familial dementia.
Previously not recognized deletion in presenilin-1 (p.Leu174del.) in a patient with early-onset familial Alzheimer's disease.
Prion protein and Alzheimer disease.
Prion protein expression alters APP cleavage without interaction with BACE-1.
Proamyloidogenic effects of membrane type 1 matrix metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking.
Probable novel PSEN1 Gln222Leu mutation in a Chinese family with early-onset Alzheimer's disease.
Probing the Mint2 protein-protein interaction network with relevance for the pathophysiology of Alzheimer's disease.
Processing of amyloid precursor protein as a biochemical link between atherosclerosis and Alzheimer's disease.
Processing of Notch and amyloid precursor protein by gamma-secretase is spatially distinct.
Processing of presenilin 1 in brains of patients with Alzheimer's disease and controls.
Processing of the Alzheimer's disease amyloid precursor protein in Pichia pastoris: immunodetection of alpha-, beta-, and gamma-secretase products.
Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimer's Disease.
Progress toward a practical BACE-1 inhibitor.
Progressive Age-Related Impairment of the Late Long-Term Potentiation in Alzheimer's Disease Presenilin-1 Mutant Knock-in Mice.
Progressive age-related impairment of the late long-term potentiation in Alzheimer's disease presenilin-1 mutant knock-in mice.
Prominent behavioural and psychiatric symptoms in early-onset Alzheimer's disease in a sib pair with the presenilin-1 gene R269G mutation.
Prominent expression of presenilin-1 in senile plaques and reactive astrocytes in Alzheimer's disease brain.
Prominent neuroleptic sensitivity in a case of early-onset Alzheimer disease due to presenilin-1 G206A mutation.
Promising anti-Alzheimer's dimer bis(7)-tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity.
Promising multifunctional anti-Alzheimer's dimer bis(7)-Cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 concurrently.
Promoter polymorphisms which modulate BACE1 expression are associated with sporadic Alzheimer's disease.
Proprotein convertase activity contributes to the processing of the Alzheimer's beta-amyloid precursor protein in human cells: evidence for a role of the prohormone convertase PC7 in the constitutive alpha-secretase pathway.
Proteasome inhibitors prevent the degradation of familial Alzheimer's disease-linked presenilin 1 and potentiate A beta 42 recovery from human cells.
Protective effects of BACE1 inhibitory ligand molecules against amyloid beta-induced synaptic and mitochondrial toxicities in Alzheimer's disease.
Protective effects of ferulic acid in amyloid precursor protein plus presenilin-1 transgenic mouse model of Alzheimer disease.
Protein Expression of BACE1 is Downregulated by Donepezil in Alzheimer's Disease Platelets.
Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients.
Protein markers for Alzheimer disease in the frontal cortex and cerebellum.
Protein Predictive Modeling and Simulation of Mutations of Presenilin-1 Familial Alzheimer's Disease on the Orthosteric Site.
Proteolytic fragments of Alzheimer's disease-associated presenilin 1 are present in synaptic organelles and growth cone membranes of rat brain.
Proteolytic processing and degradation of human presenilin-1 expressed in yeast.
Proteolytic processing of Neuregulin-1.
Proteolytic Processing of Neurexins by Presenilins Sustains Synaptic Vesicle Release.
Proteolytic processing of presenilin-1 (PS-1) is not associated with Alzheimer's disease with or without PS-1 mutations.
Proteolytic processing of the amyloid-beta protein precursor of Alzheimer's disease.
Proteomic identification of sorting nexin 6 as a negative regulator of BACE1-mediated APP processing.
Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements.
PSEN2 (presenilin 2) mutants linked to familial Alzheimer disease impair autophagy by altering Ca2+ homeostasis.
Psychiatric Disorders in Alzheimer Disease With the Presenilin-1 L226F Mutation.
Psychosis in a Middle-aged Woman: A Case of Presenilin-1 p.Gly206Ala Alzheimer Disease.
Pulse Pressure: An Emerging Therapeutic Target for Dementia.
Purine derivatives as potent gamma-secretase modulators.
Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase.
Quantification of presenilin-1 mRNA in Alzheimer's disease brains.
Quantitative interaction proteomics of neurodegenerative disease proteins.
Quantum mechanics study of the hydroxyethylamines-BACE-1 active site interaction energies.
Rab6 membrane association is dependent of Presenilin 1 and cellular phosphorylation events.
RAGE regulates BACE1 and A{beta} generation via NFAT1 activation in Alzheimer's disease animal model.
Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Rapid and Direct Transport of Cell Surface APP to the Lysosome defines a novel selective pathway.
Rapid cell death is preceded by amyloid plaque-mediated oxidative stress.
Rapid Notch1 nuclear translocation after ligand binding depends on presenilin-associated gamma-secretase activity.
Rapid purification of active gamma-secretase, an intramembrane protease implicated in Alzheimer's disease.
Rapid stimulation of amyloid precursor protein release by epidermal growth factor: role of protein kinase C.
Rare autosomal copy number variations in early-onset familial Alzheimer's disease.
Rat brain gamma-secretase activity is highly influenced by detergents.
Rational Design of Novel 1,3-Oxazine Based ?-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust A? Reduction in the Brain.
Rational design, synthesis and in vitro evaluation of allylidene hydrazinecarboximidamide derivatives as BACE-1 inhibitors.
RCAN1 Inhibits BACE2 Turnover by Attenuating Proteasome-Mediated BACE2 Degradation.
Recent Advances in the Identification of gamma-Secretase Inhibitors To Clinically Test the Abeta Oligomer Hypothesis of Alzheimer's Disease.
Recent Studies on Design and Development of Drugs Against Alzheimer's Disease (AD) Based on Inhibition of BACE-1 and Other AD-causative Agents.
Reconstitution of gamma-secretase activity.
Reduced expression of amyloid precursor protein, presenilin-1 and rab3a in cortical brain regions in Alzheimer's disease.
Reduced Sodium Channel Nav1.1 Levels in BACE1-null Mice.
Reduction BACE1 expression via suppressing NF-?B mediated signaling by Tamibarotene in a mouse model of Alzheimer's disease.
Reduction of Ca2+ stores and capacitative Ca2+ entry is associated with the familial Alzheimer's disease presenilin-2 T122R mutation and anticipates the onset of dementia.
Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid.
Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
Refractory epilepsy in PSEN 1 mutation (I83T).
Regional and cellular presenilin 1 gene expression in human and rat tissues.
Regional brain evaluation of acetylcholinesterase activity in PS1/A246E transgenic mice.
Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and alpha1-antichymotrypsin type A allele in Alzheimer's disease.
Regional distribution of presenilin-1 messenger RNA in the embryonic rat brain: comparison with beta-amyloid precursor protein messenger RNA localization.
Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease.
Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase.
Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I.
Regulation of amyloid beta-protein precursor by phosphorylation and protein interactions.
Regulation of apoptosis by presenilin 1.
Regulation of brain G-protein go by Alzheimer's disease gene presenilin-1.
Regulation of gamma-secretase activity in Alzheimer's disease.
Regulation of secretases by all-trans-retinoic acid.
Regulation of Synaptic Amyloid-? Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.
Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain.
Relationship between neuronal loss and 'inflammatory plaques' in early onset Alzheimer's disease.
Relationship between the polymorphism in exon 5 of BACE1 gene and Alzheimer's disease.
Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Relative ratio and level of amyloid-? 42 surrogate in cerebrospinal fluid of familial Alzheimer disease patients with presenilin 1 mutations.
Release of a membrane-bound death domain by gamma-secretase processing of the p75NTR homolog NRADD.
Remodelling of Ca2+ homeostasis in type I cortical astrocytes by hypoxia: evidence for association with Alzheimer's disease.
Repurposing bromocriptine for A? metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations.
Requirement for small side chain residues within the GxGD-motif of presenilin for gamma-secretase substrate cleavage.
Residues at P2-P1 positions of varepsilon- and zeta-cleavage sites are important in formation of beta-amyloid peptide.
Restricted growth and insulin-like growth factor-1 deficiency in mice lacking presenilin-1 in the neural crest cell lineage.
Retention of the Alzheimer's amyloid precursor fragment C99 in the endoplasmic reticulum prevents formation of amyloid beta-peptide.
Reticulons RTN3 and RTN4-B/C interact with BACE1 and inhibit its ability to produce amyloid beta-protein.
RNA aptamers selectively modulate protein recruitment to the cytoplasmic domain of beta-secretase BACE1 in vitro.
RNA interference in silencing of genes of Alzheimer's disease in cellular and rat brain models.
Role of presenilin-1 in cortical lamination and survival of Cajal-Retzius neurons.
Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease.
Role of tyrosine phosphorylation in the antioxidant effects of the p75 neurotrophin receptor.
RVG-Peptide-Linked Trimethylated Chitosan for Delivery of siRNA to the Brain.
S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10.
sA?PP? is a Potent Endogenous Inhibitor of BACE1.
Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects.
Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators.
SCF(Fbx2) -E3-ligase-mediated degradation of BACE1 attenuates Alzheimer's disease amyloidosis and improves synaptic function.
Scope of ?-Secretase (BACE1)-Targeted Therapy in Alzheimer's Disease: Emphasizing the Flavonoid Based Natural Scaffold for BACE1 Inhibition.
Screening for presenilin-1 gene mutations by PCR-SSCP analysis in patients with early-onset Alzheimer's disease.
Searching for the Multi-Target-Directed Ligands against Alzheimer's disease: discovery of quinoxaline-based hybrid compounds with AChE, H?R and BACE 1 inhibitory activities.
Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent.
Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.
Second generation of hydroxyethylamine BACE-1 inhibitors: optimizing potency and oral bioavailability.
Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.
Secreted beta-amyloid precursor protein counteracts the proapoptotic action of mutant presenilin-1 by activation of NF-kappaB and stabilization of calcium homeostasis.
Secretion of long Abeta-related peptides processed at epsilon-cleavage site is dependent on the alpha-secretase pre-cutting.
Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons.
Seizure protein 6 controls glycosylation and trafficking of kainate receptor subunits GluK2 and GluK3.
Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease.
Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism.
Selecting cells with different Alzheimer's disease gamma-secretase activity using FACS. Differential effect on presenilin exon 9 gamma- and epsilon-cleavage.
Self-refinement of Notch activity through the transmembrane protein Crumbs: modulation of gamma-secretase activity.
Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.
Semi-synthetic isoflavones as BACE-1 inhibitors against Alzheimer's disease.
Sequence analysis of presenilin-1 gene mutation in Japanese Alzheimer's disease patients.
Serpents on the road to dementia and death. Accumulating evidence from several studies points to the normal function of presenilin 1 and suggests how the mutant protein contributes to deposition of amyloid plaques in Alzheimer's disease.
Serum Beta Secretase 1 (BACE1) activity increases in patients with mild cognitive impairment.
Sex Differences in Cognitive Abilities Among Children With the Autosomal Dominant Alzheimer Disease Presenilin 1 E280A Variant From a Colombian Cohort.
Signal peptide peptidase and gamma-secretase share equivalent inhibitor binding pharmacology.
Signal peptide peptidase dependent cleavage of type II transmembrane substrates releases intracellular and extracellular signals.
Signal peptide peptidase: biochemical properties and modulation by nonsteroidal antiinflammatory drugs.
Signaling effect of amyloid-beta(42) on the processing of AbetaPP.
Significance of intracellular Abeta42 accumulation in Alzheimer's disease.
Significance of transcytosis in Alzheimer's disease: BACE1 takes the scenic route to axons.
Similar mechanisms regulated by gamma-secretase are involved in both directions of the bi-directional Notch-Delta signaling pathway as well as play a potential role in signaling events involving type 1 transmembrane proteins.
Simple structure-based approach for predicting the activity of inhibitors of beta-secretase (BACE1) associated with Alzheimer's disease.
Simultaneous quantitation of the BACE1 inhibitor AZD3293 and its metabolite AZ13569724 in human matrices by LC-MS/MS.
Single chain variable fragment against nicastrin inhibits the gamma-secretase activity.
Single-entity heparan sulfate glycomimetic clusters for therapeutic applications.
Skeletal and CNS defects in Presenilin-1-deficient mice.
Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011).
Sodium channel cleavage is associated with aberrant neuronal activity and cognitive deficits in a mouse model of Alzheimer's disease.
Soluble amyloid precursor protein alpha inhibits tau phosphorylation through modulation of GSK3? signaling pathway.
Soluble BACE-1 Activity and sA?PP? Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.
Solution-phase parallel synthesis of carbamates as gamma-secretase inhibitors.
Somatic mutation analysis of the APP and Presenilin 1 and 2 genes in Alzheimer's disease brains.
Sorting out the cell biology of Alzheimer's disease: focus on BACE1 and APP.
Spastic paraplegia preceding PSEN1-related familial Alzheimer's disease.
Spatial learning in transgenic mice expressing human presenilin 1 (PS1) transgenes.
Spatial patterns of ?-amyloid (A?) deposits in familial and sporadic Alzheimer's disease.
Specific BACE1 genotypes provide additional risk for late-onset Alzheimer disease in APOE epsilon 4 carriers.
Specific deficit of colour-colour short-term memory binding in sporadic and familial Alzheimer's disease.
Specific mutations in presenilin 1 cause conformational changes in ?-secretase to modulate amyloid ? trimming.
Specificity of memapsin 1 and its implications on the design of memapsin 2 (beta-secretase) inhibitor selectivity.
Specificity of presenilin-1- and presenilin-2-dependent ?-secretases towards substrate processing.
Spectral Analysis of EEG in Familial Alzheimer's Disease with E280A Presenilin-1 Mutation Gene.
Sphingosylphosphorylcholine Attenuated ?-Amyloid Production by Reducing BACE1 Expression and Catalysis in PC12 Cells.
Spirocyclic Sulfamides as BACE-1 Inhibitors for the Treatment of Alzheimer's Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies to Identify Centrally Efficacious Inhibitors.
Spirocyclic ß-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: From Hit to Lowering of Cerebrospinal Fluid (CSF) Amyloid Beta in a Higher Species.
Splice variants of the Alzheimer's disease beta-secretase, BACE1.
Splicing mutation of presenilin-1 gene for early-onset familial Alzheimer's disease.
Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging.
Stable association of presenilin derivatives and absence of presenilin interactions with APP.
Statins and the Squalene Synthase Inhibitor Zaragozic Acid Stimulate the Non-Amyloidogenic Pathway of Amyloid-beta Protein Precursor Processing by Suppression of Cholesterol Synthesis.
Staurosporine-induced activation of caspase-3 is potentiated by presenilin 1 familial Alzheimer's disease mutations in human neuroglioma cells.
Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs.
Stereoselective synthesis of constrained azacyclic hydroxyethylene isosteres as aspartic protease inhibitors: dipolar cycloaddition and related methodologies toward branched pyrrolidine and pyrrolidinone carboxylic acids.
Stereoselective synthesis of constrained oxacyclic hydroxyethylene isosteres of aspartic protease inhibitors: aldol and Mukaiyama aldol methodologies for branched tetrahydrofuran 2-carboxylic acids.
Structural and Functional Determinants of gamma-Secretase, an Intramembrane Protease Implicated in Alzheimer's Disease.
Structural features of human memapsin 2 (beta-secretase) and their biological and pathological implications.
Structural investigation of the C-terminal catalytic fragment of presenilin 1.
Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (beta-secretase).
Structure and alternative splicing of the presenilin-2 gene.
Structure and function of gamma-secretase.
Structure of the catalytic pore of gamma-secretase probed by the accessibility of substituted cysteines.
Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor.
Structure, mechanism and inhibition of gamma-secretase and presenilin-like proteases.
Structure-activity relationship of memapsin 2: implications on physiological functions and Alzheimer's disease.
Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective ?-Secretase (BACE1) Inhibitors over BACE2.
Structure-Based Design of Selective ?-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2.
Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase).
Structure-Based Survey of the Binding Modes of BACE1 Inhibitors.
Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.
Study of memapsin 2 (beta-secretase) and strategy of inhibitor design.
Subcellular distribution and turnover of presenilins in transfected cells.
Subcellular localization of presenilin 2 endoproteolytic C-terminal fragments.
Subcellular localization of presenilins during mouse preimplantation development.
Subcellular mechanisms of presenilin-mediated enhancement of calcium signaling.
Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design.
Substituted 2-oxo-azepane derivatives are potent, orally active gamma-secretase inhibitors.
Substituted thiazolamide coupled to a redox delivery system: a new gamma-secretase inhibitor with enhanced pharmacokinetic profile.
Substitution of a glycogen synthase kinase-3beta phosphorylation site in presenilin 1 separates presenilin function from beta-catenin signaling.
Substrate specificity of gamma-secretase and other intramembrane proteases.
Substrate-targeting gamma-secretase modulators.
Sulfonamido-derivatives of unsubstituted carbazoles as BACE1 inhibitors.
Sulfuretin exerts diversified functions in the processing of amyloid precursor protein.
SUMO1 modulates A? generation via BACE1 accumulation.
Superimposing the 27 crystal protein/inhibitor complexes of ?-secretase to calculate the binding affinities by the linear interaction energy method.
Superoxide free radical and intracellular calcium mediate A beta(1-42) induced endothelial toxicity.
Superoxide mediates the cell-death-enhancing action of presenilin-1 mutations.
Supplementation with apple juice attenuates presenilin-1 overexpression during dietary and genetically-induced oxidative stress.
Suppressor Mutations for Presenilin 1 Familial Alzheimer Disease Mutants Modulate ?-Secretase Activities.
Susceptibility to cellular stress in PS1 mutant N2a cells is associated with mitochondrial defects and altered calcium homeostasis.
Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein.
Swedish mutant APP-based BACE1 binding site peptide reduces APP ?-cleavage and cerebral A? levels in Alzheimer's mice.
Synaptic activity prompts gamma-secretase-mediated cleavage of EphA4 and dendritic spine formation.
Synaptic and endosomal localization of active gamma-secretase in rat brain.
Synaptic transmission and hippocampal long-term potentiation in transgenic mice expressing FAD-linked presenilin 1.
Synergistic Deleterious Effect of Chronic Stress and Sodium Azide in the Mouse Hippocampus.
Synthesis and evaluation of arylquinones as BACE1 inhibitors, ?-amyloid peptide aggregation inhibitors, and destabilizers of preformed ?-amyloid fibrils.
Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.
Synthesis and structure-activity relationship of a novel series of heterocyclic sulfonamide gamma-secretase inhibitors.
Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease.
Systematic genetic study of Alzheimer disease in Latin America: mutation frequencies of the amyloid beta precursor protein and presenilin genes in Colombia.
Systematic substrate identification indicates a central role for the metalloprotease ADAM10 in axon targeting and synapse function.
Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease.
T/G polymorphism at intron 9 of presenilin 1 gene is associated with, but not responsible for sporadic late-onset Alzheimer's disease in Japanese population.
Target specific proteochemometric model development for BACE1 - protein flexibility and structural water are critical in virtual screening.
Targeting ADAM10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein.
Targeting antigen-specific receptors on B lymphocytes to generate high yields of specific monoclonal antibodies directed against biologically active lower antigenic peptides within presenilin 1.
Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model.
Targeting Cannabinoid Receptor Activation and BACE-1 Activity Counteracts TgAPP Mice Memory Impairment and Alzheimer's Disease Lymphoblast Alterations.
Targeting the ? secretase BACE1 for Alzheimer's disease therapy.
TASTPM Mice Expressing Amyloid Precursor Protein and Presenilin-1 Mutant Transgenes Are Sensitive to gamma-Secretase Modulation and Amyloid-beta(42) Lowering by GSM-10h.
Tau deletion reduces plaque-associated BACE1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease.
Tau load is associated with apolipoprotein E genotype and the amount of amyloid beta protein, Abeta40, in sporadic and familial Alzheimer's disease.
Tau negative frontal lobe dementia at 17q21: significant finemapping of the candidate region to a 4.8 cM interval.
Tau phosphorylation in cells transfected with wild-type or an Alzheimer's disease mutant Presenilin 1.
Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells.
Temporal Effects of Neuron-specific beta-secretase 1 (BACE1) Knock-in on the Mouse Brain Metabolome: Implications for Alzheimer's Disease.
Temporal-spatial expression of presenilin 1 and the production of amyloid-beta after acute spinal cord injury in adult rat.
Tetrahydroquinoline sulfonamides as gamma-secretase inhibitors.
Tetrapeptides, as small-sized peptidic inhibitors; synthesis and their inhibitory activity against BACE1.
The β-Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimer's Disease.
The -22c/t polymorphism in presenilin 1 gene is not connected with late-onset and early-onset familial Alzheimer's disease in Poland.
The -48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Abeta load in brain.
The 1239G/C polymorphism in exon 5 of BACE1 gene may be associated with sporadic Alzheimer's disease in Chinese Hans.
The 4,752 C/T polymorphism in the presenilin 1 gene increases the risk of Alzheimer's disease in apolipoprotein E4 carriers.
The ?-Secretase BACE1 in Alzheimer's Disease.
The ?-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease.
The Alzheimer disease-related calcium-binding protein Calmyrin is present in human forebrain with an altered distribution in Alzheimer's as compared to normal ageing brains.
The Alzheimer's disease beta-secretase enzyme, BACE1.
The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.
The Alzheimer-related gene presenilin 1 facilitates notch 1 in primary mammalian neurons.
The amyloid beta-protein precursor of Alzheimer's disease is degraded extracellularly by a Kunitz protease inhibitor domain-sensitive trypsin-like serine protease in cultures of chick sympathetic neurons.
The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression.
The association of the regulatory region of the presenilin-2 gene with Alzheimer's disease in the Northern Han Chinese population.
The association of three BACE1 gene polymorphisms (exon5 C/G, intron 5 T/G and 3'UTR T/A) with sporadic Alzheimer's disease susceptibility: a meta-analysis.
The BACE inhibitor NB-360 in preclinical models: From ?-amyloid reduction to downstream disease-relevant effects.
The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS ?-amyloid in animal models and in Alzheimer's disease patients.
The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.
The biochemistry of Alzheimer disease.
The biochemistry of Alzheimer's disease.
The biological and pathological function of the presenilin-1 Deltaexon 9 mutation is independent of its defect to undergo proteolytic processing.
The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase.
The C-terminal region of CHD3/ZFH interacts with the CIDD region of the Ets transcription factor ERM and represses transcription of the human presenilin 1 gene.
The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1.
The clinical phenotype of two missense mutations in the presenilin I gene in Japanese patients.
The coat protein complex II, COPII, protein Sec13 directly interacts with presenilin-1.
The Cysteine Protease Inhibitor, E64d, Reduces Brain Amyloid-? and Improves Memory Deficits in Alzheimer's Disease Animal Models by Inhibiting Cathepsin B, but not BACE1, ?-Secretase Activity.
The cytosolic inclusion bodies that consist of splice variants that lack exon 5 of the presenilin-2 gene differ obviously from Hirano bodies observed in the brain from sporadic cases of Alzheimer's disease patients.
The cytosolic loop of the gamma-secretase component presenilin enhancer 2 protects zebrafish embryos from apoptosis.
The cytosolic N-terminus of presenilin-1 potentiates mouse ryanodine receptor single channel activity.
The discovery and role of CD147 as a subunit of gamma-secretase complex.
The dynamic mechanism of presenilin-1 function: Sensitive gate dynamics and loop unplugging control protein access.
The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology.
The E318G substitution in PSEN1 gene is not connected with Alzheimer's disease in a large Polish cohort.
The effects of dietary restriction and aging on amyloid precursor protein and presenilin-1 mRNA and protein expression in rat brain.
The Endosome-associated Deubiquitinating Enzyme USP8 Regulates BACE1 Enzyme Ubiquitination and Degradation.
The expression of HMGA1a is increased in lymphoblastoid cell lines from schizophrenia patients.
The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1.
The expression of presenilin 1 mRNA in skin fibroblasts and brains from sporadic Alzheimer's disease.
The expression of presenilin-1 mRNA in skin fibroblasts from Alzheimer's disease.
The expression of the nicotinic acetylcholine receptor ?3 subunit in the brains of patients with Alzheimer's disease and its effects on ?- and ?-secretases and Notch signal transduction in SH-SY5Y cells.
The gamma-secretase complex: machinery for intramembrane proteolysis.
The gamma-secretase-generated intracellular domain of beta-amyloid precursor protein binds Numb and inhibits Notch signaling.
The gamma/epsilon-Secretase-Derived APP Intracellular Domain Fragments Regulate p53.
The gene encoding nicastrin, a major gamma-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample.
The genetics of Alzheimer disease: current status and future prospects.
The genetics of Alzheimer's disease.
The genotype 2/2 of the presenilin-1 polymorphism is decreased in Spanish early-onset Alzheimer's disease.
The Glu318Gly mutation of the presenilin-1 gene does not necessarily cause Alzheimer's disease.
The Glu318Gly substitution in presenilin 1 is not causally related to Alzheimer disease.
The Golgi-Localized ?-Ear-Containing ARF-Binding (GGA) Proteins Alter Amyloid-? Precursor Protein (APP) Processing through Interaction of Their GAE Domain with the Beta-Site APP Cleaving Enzyme 1 (BACE1).
The GxGD motif of presenilin contributes to catalytic function and substrate identification of gamma-secretase.
The Identification of Biochanin A as a Potent and Selective ?-Site App-Cleaving Enzyme 1 (Bace1) Inhibitor.
The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors.
The increased activity of BACE1 correlates with oxidative stress in Alzheimer's disease.
The inhibition of gamma-secretase as a therapeutic approach to Alzheimer's disease.
The initial substrate-binding site of gamma-secretase is located on presenilin near the active site.
The L392V mutation of presenilin 1 associated with autosomal dominant early-onset Alzheimer's disease alters the secondary structure of the hydrophilic loop.
The large hydrophilic loop of presenilin 1 is important for regulating gamma-secretase complex assembly and dictating the amyloid beta peptide (Abeta) Profile without affecting Notch processing.
The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease.
The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases.
The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate.
The mechanism of gamma-secretase activities through high molecular weight complex formation of presenilins is conserved in Drosophila melanogaster and mammals.
The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer's Disease and Beyond.
The Metalloprotease Meprin ? Is an Alternative ?-Secretase of APP.
The modeling of Alzheimer's disease by the overexpression of mutant Presenilin 1 in human embryonic stem cells.
The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice.
The N-terminus of presenilin-2 increases single channel activity of brain ryanodine receptors through direct protein-protein interaction.
The Neural Cell Adhesion Molecules L1 and CHL1 Are Cleaved by BACE1 Protease in Vivo.
The nonconserved hydrophilic loop domain of presenilin (PS) is not required for PS endoproteolysis or enhanced abeta 42 production mediated by familial early onset Alzheimer's disease-linked PS variants.
The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease.
The pathogenic L392V mutation of presenilin 1 decreases the affinity to glycogen synthase kinase-3 beta.
The physical approximation of APP and BACE-1: A key event in alzheimer's disease pathogenesis.
The possible effect of microRNA-155 (miR-155) and BACE1 inhibitors in the memory of patients with down syndrome and Alzheimer's disease: Design, synthesis, virtual screening, molecular modeling and biological evaluations.
The potent BACE1 inhibitor LY2886721 elicits robust central A? pharmacodynamic responses in mice, dogs, and humans.
The potential for BACE1 inhibitors in the treatment of Alzheimer's disease.
The presenilin 1 C92S mutation increases abeta 42 production.
The presenilin 1 deltaE9 mutation gives enhanced basal phospholipase C activity and a resultant increase in intracellular calcium concentrations.
The presenilin 1 mutation (M146V) linked to familial Alzheimer's disease attenuates the neuronal differentiation of NTera 2 cells.
The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer's disease in Hispanics in Florida.
The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice.
The presenilin-1 familial Alzheimer's disease mutation P117L decreases neuronal differentiation of embryonic murine neural progenitor cells.
The presenilins and Alzheimer's disease.
The processing and biological function of the human amyloid precursor protein (APP): lessons from different cellular models.
The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.
The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation.
The R269H mutation in presenilin-1 presenting as late-onset autosomal dominant Alzheimer's disease.
The regulation of presenilin-1 by nerve growth factor.
The role of Alzheimer's disease-related presenilin 1 in intercellular adhesion.
The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology.
The role of beta-catenin stability in mutant PS1-associated apoptosis.
The Role of Cathepsin B in the Degradation of A? and in the Production of A? Peptides Starting With Ala2 in Cultured Astrocytes.
The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease.
The role of heparan sulfate in the generation of Abeta.
The role of low-density receptor-related protein 1 (LRP1) as a competitive substrate of the amyloid precursor protein (APP) for BACE1.
The role of membrane trafficking in the processing of amyloid precursor protein and production of amyloid peptides in Alzheimer's disease.
The role of presenilin 1 in the genetics of Alzheimer's disease.
The role of presenilin-1 in the gamma-secretase cleavage of the amyloid precursor protein of Alzheimer's disease.
The role of the presenilin-1 homologue gene sel-12 of Caenorhabditis elegans in apoptotic activities.
The Selective BACE1 Inhibitor VIa Reduces Amyloid-? Production in Cell and Mouse Models of Alzheimer's Disease.
The sterol carrier protein SCP-x/pro-SCP-2 gene has transcriptional activity and regulates the Alzheimer disease gamma-secretase.
The Structure and Function of ?, ? and ?-Secretase as Therapeutic Target Enzymes in the Development of Alzheimer's Disease: A Review.
The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Alzheimer's Disease Collaborative Group.
The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing.
The synergy factor: a statistic to measure interactions in complex diseases.
The transcription factor Yin Yang 1 is an activator of BACE1 expression.
The two-hydrophobic domain tertiary structure of reticulon proteins is critical for modulation of beta-secretase BACE1.
The Ups and Downs of BACE1: Walking a Fine Line between Neurocognitive and Other Psychiatric Symptoms of Alzheimer's Disease.
The Variations of Presenilin 1 Promoter are Associated with Sporadic Alzheimer's Disease.
Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and A? expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer's disease: A pilot study.
Therapeutic potential of cyanobacterial pigment protein phycoerythrin: in silico and in vitro study of BACE1 interaction and in vivo A? reduction.
Therapeutic potential of gamma-secretase inhibitors and modulators.
Therapeutic targeting of the alpha-secretase pathway to treat Alzheimer's disease.
Thiamine deficiency alters APP but not presenilin-1 immunoreactivity in vulnerable brain regions.
Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer's disease brain.
Three different mutations of presenilin 1 gene in early-onset Alzheimer's disease families.
Three novel presenilin 1 mutations marking the wide spectrum of age at onset and clinical patterns in familial Alzheimer's disease.
Three-amino acid spacing of presenilin endoproteolysis suggests a general stepwise cleavage of gamma-secretase-mediated intramembrane proteolysis.
Three-year follow-up of a patient with early-onset Alzheimer's disease with presenilin-2 N141I mutation - case report and review of the literature.
Time-domain fluorescent plate reader for cell based protein-protein interaction and protein conformation assays.
Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers.
Topology of the C-terminal fragment of human presenilin 1.
Toward ?-Secretase-1 Inhibitors with Improved Isoform Selectivity.
Trans-dominant negative effects of pathogenic PSEN1 mutations on ?-secretase activity and A? production.
Transcriptional and post-transcriptional profile of human chromosome 21.
Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer's disease.
Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1.
Transcriptional regulation of the murine Presenilin-2 gene reveals similarities and differences to its human orthologue.
Transcriptional regulation of the presenilin-1 gene: implication in Alzheimer's disease.
Transferrin is responsible for mediating the effects of iron ions on the regulation of anterior pharynx-defective-1?/? and Presenilin 1 expression via PGE2 and PGD2 at the early stage of Alzheimer's Disease.
Transgenic expression of the amyloid-beta precursor protein-intracellular domain does not induce Alzheimer's Disease-like traits in vivo.
Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation.
Transition-state analogue gamma-secretase inhibitors stabilize a 900 kDa presenilin/nicastrin complex.
Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1.
Translational control of BACE1 may go awry in Alzheimer's disease.
Translational regulation of BACE-1 expression in neuronal and non-neuronal cells.
Transmembrane domain 9 of presenilin determines the dynamic conformation of the catalytic site of gamma-secretase.
Transmembrane structures of amyloid precursor protein dimer predicted by replica-exchange molecular dynamics simulations.
Trientine Reduces BACE1 Activity and Mitigates Amyloidosis via the AGE/RAGE/NF-kappa B Pathway in a Transgenic Mouse Model of Alzheimer's Disease.
Tripchlorolide Attenuates ?-amyloid Generation via Suppressing PPAR?-Regulated BACE1 Activity in N2a/APP695 Cells.
Triptolide treatment reduces Alzheimer's disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD.
Turmeric and curcumin suppress presenilin 1 protein expression in Jurkat cells.
Twenty-nine missense mutations linked with familial Alzheimer's disease alter the processing of presenilin 1.
Two domains within the first putative transmembrane domain of presenilin 1 differentially influence presenilinase and gamma-secretase activity.
Two endoplasmic reticulum (ER)/ER Golgi intermediate compartment-based lysine acetyltransferases post-translationally regulate BACE1 levels.
Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype.
Two Novel Mutations and a de novo Mutation in PSEN1 in Early-onset Alzheimer's Disease.
Two Novel Mutations in the First Transmembrane Domain of Presenilin1 Cause Young-Onset Alzheimer's Disease.
Two novel presenilin 1 gene mutations connected with frontotemporal dementia-like clinical phenotype: genetic and bioinformatic assessment.
Two novel presenilin-1 mutations (I249L and P433S) in early onset Chinese Alzheimer's pedigrees and their functional characterization.
Two novel presenilin-1 mutations (Ser169Leu and Pro436Gln) associated with very early onset Alzheimer's disease.
Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer's disease.
Two polymorphisms of presenilin-2 gene (PSEN2) 5' regulatory region are not associated with Alzheimer's disease (AD) in the Polish population.
Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity.
Tyramine fragment binding to BACE-1.
Ubiquitin regulates GGA3-mediated degradation of BACE1.
Ubiquitin-proteasome pathway mediates degradation of APH-1.
Ultrastructure evidence of necrotic neural cell death in familial Alzheimer's disease brains bearing presenilin-1 E280A mutation.
Understanding BACE1: essential protease for amyloid-beta production in Alzheimer's disease.
Unfolded protein response signaling by transcription factor XBP-1 regulates ADAM10 and is affected in Alzheimer's disease.
Unnatural amino acid-substituted (hydroxyethyl)urea peptidomimetics inhibit gamma-secretase and promote the neuronal differentiation of neuroblastoma cells.
Unravelling the molecular basis of AM-6494 high potency at BACE1 in Alzheimer's disease: an integrated dynamic interaction investigation.
Unveiling a novel transient druggable pocket in BACE-1 through molecular simulations: Conformational analysis and binding mode of multisite inhibitors.
Upregulation of BACE1 and beta-Amyloid Protein Mediated by Chronic Cerebral Hypoperfusion Contributes to Cognitive Impairment and Pathogenesis of Alzheimer's Disease.
Upregulation of Presenilin 1 in Brains of Sporadic, Late-Onset Alzheimer's Disease.
Using a genetically targeted sensor to investigate the role of presenilin-1 in ER Ca(2+) levels and dynamics.
Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice.
Val97Leu mutant presenilin-1 induces tau hyperphosphorylation and spatial memory deficit in mice and the underlying mechanisms.
Variable expression of presenilin 1 is not a major determinant of risk for late-onset Alzheimer's disease.
Variable phenotype of Alzheimer's disease with spastic paraparesis.
Variant Alzheimer disease with spastic paraparesis: a rare presenilin-1 mutation.
Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype.
Variant Alzheimer's disease with spastic paraparesis: clinical characterization.
Variation in RTN3 and PPIL2 Genes Does not Influence Platelet Membrane beta-Secretase Activity or Susceptibility to Alzheimer's Disease in the Northern Irish Population.
Variations in the neuropathology of familial Alzheimer's disease.
Vasopressin and bradykinin regulate secretory processing of the amyloid protein precursor of Alzheimer's disease.
Very early onset AD with a de novo mutation in the presenilin 1 gene (Met 233 Leu).
Very early onset Alzheimer's disease with spastic paraparesis associated with a novel presenilin 1 mutation (Phe237Ile).
Very early-onset familial Alzheimer's disease: a novel presenilin 1 mutation.
Very early-onset sporadic Alzheimer's disease with a de novo mutation in the PSEN1 gene.
Visual short-term memory binding deficit in familial Alzheimer's disease.
Visual short-term memory binding deficits in familial Alzheimer's disease.
Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway.
Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
Voltage-dependent Na+ channels as targets of BACE1 - implications for neuronal firing and beyond.
What is 'early onset dementia'?
When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease.
When sporadic disease is not sporadic: the potential for genetic etiology.
Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease.
Why Did Tarenflurbil Fail in Alzheimer's Disease?
Wide range of disease onset in a family with Alzheimer disease and a His163Tyr mutation in the presenilin-1 gene.
Widespread distribution of reticulon-3 in various neurodegenerative diseases.
Widespread gamma-secretase activity in the cell, but do we need it at the mitochondria?
Widespread neuronal expression of the presenilin-1 early-onset Alzheimer's disease gene in the murine brain.
Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology.
WITHDRAWN: Mental Disorders in Young Adults from Families with the Presenilin-1 Gene Mutation E280A in the Preclinical Stage of Alzheimer's Disease.
Workflow and methods of high-content time-lapse analysis for quantifying intracellular calcium signals.
Worldwide distribution of PSEN1 Met146Leu mutation: a large variability for a founder mutation.
YAC fragmentation with repetitive and single-copy sequences: detailed physical mapping of the presenilin 1 gene on chromosome 14.
Yeast growth selection system for the identification of cell-active inhibitors of beta-secretase.
Young investigator award recipient.
Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss.
Zinc enhances synthesis of presenilin 1 in mouse primary cortical culture.
[A Japanese family with familial Alzheimer's disease associated with presenilin 1 mutation: relationship between younger age of onset and ApoE gene polymorphism]
[A study on mutation of exon 5 of presenilin-1 in Alzheimer's disease]
[alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients.
[Alzheimer's disease treatment by inhibition/modulation of the gamma-secretase activity]
[Alzheimer's disease: focus on beta-amyloid and gamma-secretase]
[Analysis of intrusive errors in a memory test as possible pre-clinical marker of familial Alzheimer disease, in E280A presenilin-1 mutation carrier]
[Biochemistry of presenilin 1]
[Clinical characteristics of a family with early-onset Alzheimer's disease associated with a presenilin 1 mutation (M139T)]
[Detection of antibodies to beta-amyloid in carriers of E280A mutation in the presenilin-1 gene]
[Effect of an inhibitor of alpha-secretase metabolizing amyloid precursor protein on memory in rats]
[Effect of hyperforin on learning and memory abilities and A?????, ?APP and BACE1 protein expressions in hippocampus of Alzheimer's disease model mice].
[Effects of huannao yicong recipe extract on the learning and memory and related factors of Abeta generation in the brain of APP transgenic mice].
[Effects of vitamin E on expression of PS-1 and production of Abeta in the hippocampus of female senile rats].
[Expression of presenilin 1 on the cell surface in motile polarized cells]
[Familial Alzheimer's disease mutations in the presenilin 1 gene reduce cell-cell adhesion in transfected fibroblasts].
[Genetics of dementia].
[Gly(14)]-Humanin improved the learning and memory impairment induced by scopolamine in vivo.
[Identification and clone of human Alzheimer's disease related gene nicastrin promoter]
[Molecular genetics of Alzheimer's disease--presenilin and other genes]
[Mutation site of presenilin-1 gene in familial Alzheimer's disease]
[Pathogenesis of Alzheimer's disease: implications from amyloid research front]
[Pathology of familial Parkinson's disease]
[Potential role of presenilin 1 in regulation of synaptic function].
[Presenilin-1 (S182) causative gene of early-onset familial Alzheimer's disease]
[Recent progress in 'HMGA1a' which causes aberrant splicing of Presenilin-2 pre-mRNA in sporadic Alzheimer's disease]
[Study on expression of PS1 in APP-PS1 double gene stably transfected cell lines and its relation to gamma-secretase]
[Study on mutation of presenilin-1 gene in familial Alzheimer's disease]
[Study on the etiology of Alzheimer's disease caused by missense mutations in presenilin 1]
[Targeting the structure and function relationships of the gamma-secretase for the development of Alzheimer's disease]
[The effect of PNS on the content and activity of alpha-secretase in the brains of SAMP8 mice with alzheimer's disease].
[The effect of two newly Chinese presenilin-1 mutations on the sensitivity to trophic factor withdrawal in human neuroblastoma cells]
{gamma}-Secretase Substrate Concentration Modulates the Abeta42/Abeta40 Ratio: IMPLICATIONS FOR ALZHEIMER DISEASE.
{gamma}-Secretase-dependent cleavage of amyloid precursor protein regulates osteoblast behavior.
{gamma}-Secretase: Successive Tripeptide and Tetrapeptide Release from the Transmembrane Domain of {beta}-Carboxyl Terminal Fragment.
Amnesia
Anti-amnesic activity of neferine with antioxidant and anti-inflammatory capacities, as well as inhibition of ChEs and BACE1.
Presenilin-1 mutation associated with amnesia, ataxia, and medial temporal lobe T2 signal changes.
Amyloidosis
5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease.
A bell-shaped dependence between amyloidosis and GABA accumulation in astrocytes in a mouse model of Alzheimer's disease.
A study of long-term potentiation in transgenic mice over-expressing mutant forms of both amyloid precursor protein and presenilin-1.
Astrocytes & Astrocyte derived Extracellular Vesicles in Morphine Induced Amyloidopathy: Implications for Cognitive Deficits in Opiate Abusers.
AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice.
BACE1 and mutated presenilin-1 differently modulate Abeta40 and Abeta42 levels and cerebral amyloidosis in APPDutch transgenic mice.
BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions.
Brain Abeta amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau.
Changes in the brain and plasma A? peptide levels with age and its relationship with cognitive impairment in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
Combined treatment with the phenolics (-)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice.
Cytosolic proteins lose solubility as amyloid deposits in a transgenic mouse model of Alzheimer-type amyloidosis.
Diversity in A? deposit morphology and secondary proteome insolubility across models of Alzheimer-type amyloidosis.
Early functional connectivity deficits and progressive microstructural alterations in the TgF344-AD rat model of Alzheimer's Disease: A longitudinal MRI study.
Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional A? deposition rate and plaque burden at treatment initiation.
Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities.
Ferulic acid is a nutraceutical ?-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice.
Gallic Acid is a Dual ?/?-Secretase Modulator that Reverses Cognitive Impairment and Remediates Pathology in Alzheimer Mice.
Genetically altered transgenic models of Alzheimer's disease.
Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease.
Modeling an anti-amyloid combination therapy for Alzheimer's disease.
Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities.
Multiple Low-Dose Infusions of Human Umbilical Cord Blood Cells Improve Cognitive Impairments and Reduce Amyloid-?-Associated Neuropathology in Alzheimer Mice.
Non-neuronal and neuronal BACE1 elevation in association with angiopathic and leptomeningeal ?-amyloid deposition in the human brain.
Presence of soluble and cell-surface B-cell maturation antigen in systemic light-chain amyloidosis and its modulation by gamma-secretase inhibition.
Presenilin-1 polymorphism and hereditary cerebral hemorrhage with amyloidosis, Dutch type.
Regulation of forkhead transcription factor FoxO3a contributes to calorie restriction-induced prevention of Alzheimer's disease-type amyloid neuropathology and spatial memory deterioration.
SCF(Fbx2) -E3-ligase-mediated degradation of BACE1 attenuates Alzheimer's disease amyloidosis and improves synaptic function.
Swedish mutant APP-based BACE1 binding site peptide reduces APP ?-cleavage and cerebral A? levels in Alzheimer's mice.
Tannic Acid Is a Natural ?-Secretase Inhibitor That Prevents Cognitive Impairment and Mitigates Alzheimer-like Pathology in Transgenic Mice.
Trientine Reduces BACE1 Activity and Mitigates Amyloidosis via the AGE/RAGE/NF-kappa B Pathway in a Transgenic Mouse Model of Alzheimer's Disease.
YXQN Reduces Alzheimer's Disease-Like Pathology and Cognitive Decline in APPswePS1dE9 Transgenic Mice.
Amyotrophic Lateral Sclerosis
Genotyping of presenilin-1 polymorphism in amyotrophic lateral sclerosis.
Aphasia
Presenilin-1 Mutations in Alzheimer's Disease: An Update on Genotype-Phenotype Relationships.
Aphasia, Primary Progressive
The presenilin 1 P264L mutation presenting as non-fluent/agrammatic primary progressive aphasia.
Astrocytoma
A?-induced Ca(2+) influx regulates astrocytic BACE1 expression via calcineurin/NFAT4 signals.
Constitutive and cytokine-regulated expression of presenilin-1 and presenilin-2 genes in human neural cell lines.
Differential effects of transforming growth factor-beta(s) and glial cell line-derived neurotrophic factor on gene expression of presenilin-1 in human post-mitotic neurons and astrocytes.
Glial expression of presenilin epitopes in human brain with cerebral infarction and in astrocytoma.
Localization of presenilin-1 mRNA in rat brain.
The effects of alpha-secretase ADAM10 on the proteolysis of neuregulin-1.
Ataxia
Familial Alzheimer's disease-associated presenilin-1 alters cerebellar activity and calcium homeostasis.
Presenilin-1 mutation associated with amnesia, ataxia, and medial temporal lobe T2 signal changes.
Atherosclerosis
Corrigendum to title "Expression of Bace1 is positive with the progress of atherosclerosis and formation of foam cell" [Biochem. Biophys. Res. Commun. 528 (3) (2020) 440-446].
Elevated A?42 in Aged, Non-demented Individuals with Cerebral Atherosclerosis.
Expression of Bace1 is positive with the progress of atherosclerosis and formation of foam cell.
gamma-Secretase inhibitor reduces diet-induced atherosclerosis in apolipoprotein E-deficient mice.
Male-specific association between a gamma-secretase polymorphism and premature coronary atherosclerosis.
TNF-? regulates the proteolytic degradation of ST6Gal-1 and endothelial cell-cell junctions through upregulating expression of BACE1.
Autoimmune Diseases
Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development.
Avitaminosis
Changes in Presenilin 1 gene methylation pattern in diet-induced B vitamin deficiency.
S-adenosylmethionine reduces the progress of the Alzheimer-like features induced by B-vitamin deficiency in mice.
beta-1,4-mannosyl-glycoprotein 4-beta-n-acetylglucosaminyltransferase deficiency
Bisecting GlcNAc modification stabilizes BACE1 protein under oxidative stress conditions.
Brain Diseases
Early onset autosomal dominant dementia with ataxia, extrapyramidal features, and epilepsy.
Increased expression of the gamma-secretase components presenilin-1 and nicastrin in activated astrocytes and microglia following traumatic brain injury.
Brain Injuries
Exacerbation of poststroke dementia by type 2 diabetes is associated with synergistic increases of beta-site amyloid precursor protein-cleaving enzyme activation and beta-amyloid generation in rat brains.
Penetrating Ballistic-Like Brain Injury Leads to MicroRNA Dysregulation, BACE1 Upregulation, and Amyloid Precursor Protein Loss in Lesioned Rat Brain Tissues.
Regulation of BACE1 expression after injury is linked to the p75 neurotrophin receptor.
Shared Genomic and Proteomic Contribution of Amyloid and Tau Protein Characteristic of Alzheimer's Disease to Brain Ischemia.
Brain Injuries, Traumatic
Increased expression of the gamma-secretase components presenilin-1 and nicastrin in activated astrocytes and microglia following traumatic brain injury.
Lithium Reduces BACE1 Overexpression, Beta Amyloid Accumulation, and Spatial Learning Deficits in Mice with Traumatic Brain Injury.
Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma.
Brain Ischemia
Alzheimer-associated presenilin 2 gene is dysregulated in rat medial temporal lobe cortex after complete brain ischemia due to cardiac arrest.
Dysregulation of Amyloid-? Protein Precursor, ?-Secretase, Presenilin 1 and 2 Genes in the Rat Selectively Vulnerable CA1 Subfield of Hippocampus Following Transient Global Brain Ischemia.
Electric Stimulation of Neurogenesis Improves Behavioral Recovery After Focal Ischemia in Aged Rats.
Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation.
Mild cognitive impairment: animal models.
Oxygen-glucose deprivation regulates BACE1 expression through induction of autophagy in Neuro-2a/APP695 cells.
The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha.
Toward prevention of Alzheimers disease--potential nutraceutical strategies for suppressing the production of amyloid beta peptides.
Upregulation of BACE1 and beta-Amyloid Protein Mediated by Chronic Cerebral Hypoperfusion Contributes to Cognitive Impairment and Pathogenesis of Alzheimer's Disease.
[mRNA expression and activity of ADAM17 in hippocampus after chronic cerebral hypoperfusion: experiment with aged rats]
Brain Neoplasms
A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma.
Breast Neoplasms
?-secretase components as predictors of breast cancer outcome.
A study on Notch signaling in human breast cancer.
Beta-Secretase 1 (BACE1) Is Down-Regulated in Invasive Ductal Carcinoma of Breast.
Cancer stem cells in breast cancer.
De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model.
Down regulation of CSL activity inhibits cell proliferation in prostate and breast cancer cells.
Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer.
ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Functional characterization of novel presenilin-2 variants identified in human breast cancers.
Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer.
High-level JAG1 mRNA and protein predict poor outcome in breast cancer.
Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells.
Mammary stem cells and breast cancer--role of Notch signalling.
Modeling the tertiary structure of human cathepsin-E.
Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials.
Presenilin 1/gamma-secretase is associated with cadmium-induced E-cadherin cleavage and COX-2 gene expression in T47D breast cancer cells.
Secretase-dependent tyrosine phosphorylation of Mdm2 by the ErbB-4 intracellular domain fragment.
Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer.
The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition.
The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium.
The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation.
Carcinogenesis
gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.
Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis.
Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities.
Phenotypic analysis of images of zebrafish treated with Alzheimer's gamma-secretase inhibitors.
Suppression of colon carcinogenesis by targeting Notch signaling.
The expression of presenilin 1 enhances carcinogenesis and metastasis in gastric cancer.
Carcinoma
Differential roles of Hath1, MUC2 and P27Kip1 in relation with gamma-secretase inhibition in human colonic carcinomas: a translational study.
Epidermal Growth Factor Receptor and Notch Pathways Participate in the Tumor Suppressor Function of {gamma}-Secretase.
Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles.
gamma-secretase inhibitors exerts antitumor activity via down-regulation of Notch and Nuclear factor kappa B in human tongue carcinoma cells.
Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities.
Morphologic and Immunohistochemical Appraisal of Primary Gastric Carcinomas.
Presenilin 1 is frequently overexpressed and positively associates with epidermal growth factor receptor expression in head and neck squamous cell carcinoma.
The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition.
[Expression of Notch1, Jagged1 and NICD in epithelial ovarian carcinomas and a preliminary study on the activity of gamma-secretase in epithelial ovarian carcinoma cell lines].
[Notch signaling pathway blocked by gamma-secretase inhibitor and its effect on the growth and apoptosis of SKOV3 cells].
Carcinoma, Hepatocellular
A small molecule inhibitor of signal Peptide peptidase inhibits Plasmodium development in the liver and decreases malaria severity.
An upstream element containing an ETS binding site is crucial for transcription of the human presenilin-1 gene.
Gamma-secretase complex-dependent intramembrane proteolysis of CD147 regulates the Notch1 signaling pathway in hepatocellular carcinoma.
Inhibition of gamma-secretase affects proliferation of leukemia and hepatoma cell lines through Notch signaling.
Modulation of the gamma-secretase activity as a therapy against human hepatocellular carcinoma.
Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1-Stat3.
Regulation of transcription of the human presenilin-1 gene by ets transcription factors and the p53 protooncogene.
Carcinoma, Intraductal, Noninfiltrating
Mammary stem cells and breast cancer--role of Notch signalling.
Carcinoma, Lobular
Aberrations of Chromosomes 1 and 16 in Breast Cancer: A Framework for Cooperation of Transcriptionally Dysregulated Genes.
Carcinoma, Non-Small-Cell Lung
MiR-574-3p accelerates cell migration and invasion through regulating BACE1 in Non-Small Cell Lung Cancer.
Carcinoma, Ovarian Epithelial
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret Cancer Centre, Chicago and California phase II consortia.
[Expression of Notch1, Jagged1 and NICD in epithelial ovarian carcinomas and a preliminary study on the activity of gamma-secretase in epithelial ovarian carcinoma cell lines].
Carcinoma, Squamous Cell
Epidermal Growth Factor Receptor and Notch Pathways Participate in the Tumor Suppressor Function of {gamma}-Secretase.
Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities.
Presenilin 1 is frequently overexpressed and positively associates with epidermal growth factor receptor expression in head and neck squamous cell carcinoma.
Cardiomyopathy, Dilated
Polymorphisms of presenilin-1 gene associate with dilated cardiomyopathy susceptibility.
Cardiovascular Diseases
Examining Sex Differences in Markers of Cognition and Neurodegeneration in Autosomal Dominant Alzheimer's Disease: Preliminary Findings from the Colombian Alzheimer's Prevention Initiative Biomarker Study.
Cataract
The link between apolipoprotein E, presenilin 1, and kinesin light chain 1 gene polymorphisms and age-related cortical cataracts in the Chinese population.
Cerebellar Ataxia
Presenilin-1 Mutations in Alzheimer's Disease: An Update on Genotype-Phenotype Relationships.
Cerebral Amyloid Angiopathy
A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene.
A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease.
Association of presenilin-1 polymorphism with cerebral amyloid angiopathy in the elderly.
BACE-1 is expressed in the blood-brain barrier endothelium and is upregulated in a murine model of Alzheimer's disease.
Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice.
Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's disease due to a novel presenilin 1 mutation.
Novel presenilin-1 mutation with widespread cortical amyloid deposition but limited cerebral amyloid angiopathy.
Occludin deficiency with BACE1 elevation in cerebral amyloid angiopathy.
Cerebral Amyloid Angiopathy, Familial
Presenilin-1 polymorphism and hereditary cerebral hemorrhage with amyloidosis, Dutch type.
Cerebral Hemorrhage
Amyloid angiopathy in a Volga German family with Alzheimer's disease and a presenilin-2 mutation (N141I).
Presenilin-1 polymorphism and hereditary cerebral hemorrhage with amyloidosis, Dutch type.
Selective expression of presenilin 1 in neural progenitor cells rescues the cerebral hemorrhages and cortical lamination defects in presenilin 1-null mutant mice.
Cerebral Infarction
Glial expression of presenilin epitopes in human brain with cerebral infarction and in astrocytoma.
Presenilin 1 immunostaining using well-characterized antibodies in human tissues.
Cerebrovascular Disorders
Increased blood BACE1 activity as a potential common pathogenic factor of vascular dementia and late onset Alzheimer's disease.
Chlamydophila Infections
Astrocytes infected with Chlamydia pneumoniae demonstrate altered expression and activity of secretases involved in the generation of ?-amyloid found in Alzheimer disease.
Cholangiocarcinoma
Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis.
Choroidal Neovascularization
?-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment.
Gamma-secretase regulates VEGFR-1 signalling in vascular endothelium and RPE.
Coinfection
Characterization of the reconstituted gamma-secretase complex from Sf9 cells co-expressing presenilin 1, nicastrin [correction of nacastrin], aph-1a, and pen-2.
Colitis
Distinct effects of p38alpha deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease.
Requirement of Notch activation during regeneration of the intestinal epithelia.
Colonic Neoplasms
Cleavage of ST6Gal I by radiation-induced BACE1 inhibits golgi-anchored ST6Gal I-mediated sialylation of integrin ?1 and migration in colon cancer cells.
Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.
Gamma-secretase inhibitor does not modulate angiogenesis in colon adenocarcinoma in obese mice.
gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.
Gamma-secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells.
Honokiol in combination with radiation targets Notch signaling to inhibit colon cancer stem cells.
Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease.
Notch inhibits expression of the Krüppel-like factor 4 tumor suppressor in the intestinal epithelium.
The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the Delta1/Notch1 pathway.
Colorectal Neoplasms
Blockade of gamma-secretase activity within the hippocampus enhances long-term memory.
Gamma-secretase inhibition combined with platinum compounds enhances cell death in a large subset of colorectal cancer cells.
Gamma-secretase inhibitor, a potential target therapy for MUC2-positive colorectal carcinoma.
Gamma-secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells.
miRDRN-miRNA disease regulatory network: a tool for exploring disease and tissue-specific microRNA regulatory networks.
Notch signaling in gastrointestinal tract (review).
Presenilin attenuates receptor-mediated signaling and synaptic function.
Presenilin-dependent "gamma-secretase" processing of deleted in colorectal cancer (DCC).
Communication Disorders
Development of molecular tools for diagnosis of Alzheimer's disease that are based on detection of amyloidogenic proteins.
Confusion
Epilepsy and cognitive impairments in Alzheimer disease.
Congenital Abnormalities
Normal brain development in PS1 hypomorphic mice with markedly reduced gamma-secretase cleavage of betaAPP.
Coronary Artery Disease
Male-specific association between a gamma-secretase polymorphism and premature coronary atherosclerosis.
Corticobasal Degeneration
Corticobasal Syndrome in a Family with Early-Onset Alzheimer's Disease Linked to a Presenilin-1 Gene Mutation.
Craniocerebral Trauma
Depletion of GGA1 and GGA3 Mediates Postinjury Elevation of BACE1.
Presenilin-1 polymorphism and amyloid beta-protein deposition in fatal head injury.
Creutzfeldt-Jakob Syndrome
A Common BACE1 Polymorphism Is a Risk Factor for Sporadic Creutzfeldt-Jakob Disease.
CSF BACE1 activity is increased in CJD and Alzheimer disease other dementias.
Development of molecular tools for diagnosis of Alzheimer's disease that are based on detection of amyloidogenic proteins.
Familial Creutzfeldt-Jakob disease in a patient carrying both a presenilin 1 missense substitution and a prion protein gene insertion.
Cri-du-Chat Syndrome
GSK-3 phosphorylates delta-catenin and negatively regulates its stability via ubiquitination/proteosome-mediated proteolysis.
Deglutition Disorders
Dementia, pyramidal system involvement, and leukoencephalopathy with a presenilin 1 mutation.
Dementia
A case of probable non-familial early onset Alzheimer dementia in a Hispanic male.
A novel p.Leu(381)Phe mutation in presenilin 1 is associated with very early onset and unusually fast progressing dementia as well as lysosomal inclusions typically seen in Kufs disease.
A novel presenilin 1 L166H mutation in a pseudo-sporadic case of early-onset Alzheimer's disease.
A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch.
Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins.
Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia.
Alterations of chaperone protein expression in presenilin mutant neurons in response to glutamate excitotoxicity.
AMY plaques in familial AD: comparison with sporadic Alzheimer's disease.
Amyloid angiopathy in a Volga German family with Alzheimer's disease and a presenilin-2 mutation (N141I).
An Overview of ?-Amyloid Cleaving Enzyme 1 (Bace1) in Alzheimer's Disease Therapy Elucidating its Exosite-Binding Antibody and Allosteric Inhibitor.
Analysis of alpha-1 antichymotrypsin, presenilin-1, angiotensin-converting enzyme, and methylenetetrahydrofolate reductase loci as candidates for dementia.
Analysis of apolipoprotein E, alpha1-antichymotrypsin and presenilin-1 genes polymorphisms in dementia caused by normal pressure hydrocephalus in man.
Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome.
Asymptomatic Carriers of Presenilin-1 E318G Variant Show no Cerebrospinal Fluid Biochemical Signs Suggestive of Alzheimer's disease in a Family with Late-onset Dementia.
Atypical dementia associated with a novel presenilin-2 mutation.
Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD.
BACE1 role in Alzheimer's disease and other dementias: from the theory to the practice.
Beta-Secretase 1 Underlies Reactive Astrocytes and Endothelial Disruption in Neurodegeneration.
Biochemical markers in persons with preclinical familial Alzheimer disease.
Biomarkers of Alzheimer disease, insulin resistance, and obesity in childhood.
Cerebrospinal Fluid BACE1 Activity and sA?PP? as Biomarker Candidates of Alzheimer's Disease.
Cognitive decline in patients with familial Alzheimer's disease associated with E280a presenilin-1 mutation: a longitudinal study.
Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease.
CSF BACE1 activity is increased in CJD and Alzheimer disease other dementias.
Decreased Deposition of Beta-Amyloid 1-38 and Increased Deposition of Beta-Amyloid 1-42 in Brain Tissue of Presenilin-1 E280A Familial Alzheimer's Disease Patients.
Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation.
Dementia, pyramidal system involvement, and leukoencephalopathy with a presenilin 1 mutation.
Diagnostic accuracy of CERAD total score in a Colombian cohort with mild cognitive impairment and Alzheimer's disease affected by E280A mutation on presenilin-1 gene.
Disease duration in autosomal dominant familial Alzheimer disease: A survival analysis.
Dopa Responsive Parkinsonism in an Early Onset Alzheimer's Disease Patient with a Presenilin 1 Mutation (A434T).
Early onset autosomal dominant dementia with ataxia, extrapyramidal features, and epilepsy.
Electroacupuncture Mitigates Hippocampal Cognitive Impairments by Reducing BACE1 Deposition and Activating PKA in APP/PS1 Double Transgenic Mice.
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.
Epilepsy and cognitive impairments in Alzheimer disease.
Exacerbation of poststroke dementia by type 2 diabetes is associated with synergistic increases of beta-site amyloid precursor protein-cleaving enzyme activation and beta-amyloid generation in rat brains.
Examining Sex Differences in Markers of Cognition and Neurodegeneration in Autosomal Dominant Alzheimer's Disease: Preliminary Findings from the Colombian Alzheimer's Prevention Initiative Biomarker Study.
Facilitation of glutamate, but not GABA, release in Familial Alzheimer's APP mutant Knock-in rats with increased ?-cleavage of APP.
Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1.
Familial dementia with frontotemporal features associated with M146V presenilin-1 mutation.
Frequency and clinicopathological characteristics of presenilin 1 Gly206Ala mutation in Puerto Rican Hispanics with dementia.
Identification of Somatic Mutations in Dementia-related Genes in Cancer Patients.
Increased blood BACE1 activity as a potential common pathogenic factor of vascular dementia and late onset Alzheimer's disease.
Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.
Magnesium Modulates Amyloid-beta Protein Precursor Trafficking and Processing.
MicroRNA-195 Protects Against Dementia Induced by Chronic Brain Hypoperfusion via Its Anti-Amyloidogenic Effect in Rats.
MiR-9 Regulates the Expression of BACE1 in Dementia Induced by Chronic Brain Hypoperfusion in Rats.
Molecular evidence of presenilin 1 mutation in familial early onset dementia.
Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease.
Neuropsychological profile of a large kindred with familial Alzheimer's disease caused by the E280A single presenilin-1 mutation.
New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism.
No association between a polymorphism in the presenilin 1 gene and dementia with Lewy bodies.
Nodular bilateral amygdala degeneration in demented individuals.
Novel presenilin 1 mutations associated with early onset of dementia in a family with both early-onset and late-onset Alzheimer disease.
Novel Presenilin-1 Mutation (Ala275Ser) Associated With Clinical Features of Dementia With Lewy Bodies.
Octapeptide repeat insertions in the prion protein gene and early onset dementia.
Performance on MMSE sub-items and education level in presenilin-1 mutation carriers without dementia.
Phenotypic Variability in Autosomal Dominant Familial Alzheimer Disease due to the S170F Mutation of Presenilin-1.
Platelets: Peripheral Biomarkers of Dementia?
Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study.
Presenilin 1 and alpha-1-antichymotrypsin polymorphisms in Down syndrome: no effect on the presence of dementia.
Presenilin 2 mutation accelerates the onset of impairment in trace eyeblink conditioning in a mouse model of Alzheimer's disease overexpressing human mutant amyloid precursor protein.
Presenilin gene predisposes to late-onset degenerative but not vascular dementia: a comparative study of PS1 and ApoE genes in a North Indian Cohort.
Presenilin-1 gene intronic polymorphism and late-onset Alzheimer's disease.
Presenilin-1 polymorphism and hereditary cerebral hemorrhage with amyloidosis, Dutch type.
Presenilin-1 polymorphism in patients with Alzheimer's disease, vascular dementia and alcohol-associated dementia in Japanese population.
Presenilin/gamma-Secretase and Inflammation.
Pulse Pressure: An Emerging Therapeutic Target for Dementia.
Reduction of Ca2+ stores and capacitative Ca2+ entry is associated with the familial Alzheimer's disease presenilin-2 T122R mutation and anticipates the onset of dementia.
Refractory epilepsy in PSEN 1 mutation (I83T).
Rescue of Early bace-1 and Global DNA Demethylation by S-Adenosylmethionine Reduces Amyloid Pathology and Improves Cognition in an Alzheimer's Model.
S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10.
Serpents on the road to dementia and death. Accumulating evidence from several studies points to the normal function of presenilin 1 and suggests how the mutant protein contributes to deposition of amyloid plaques in Alzheimer's disease.
Serum Beta Secretase 1 (BACE1) activity increases in patients with mild cognitive impairment.
Single and multiple transgenic mice as models for Alzheimer's disease.
Spastic paraplegia preceding PSEN1-related familial Alzheimer's disease.
The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.
The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease.
Treatment of Alzheimer's Disease: The Legacy of the Cholinergic Hypothesis, Neuroplasticity, and Future Directions.
Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype.
Upregulation of SET Expression by BACE1 and its Implications in Down Syndrome.
Variable phenotype of Alzheimer's disease with spastic paraparesis.
When sporadic disease is not sporadic: the potential for genetic etiology.
Dementia, Vascular
Apolipoprotein E and intronic polymorphism of presenilin 1 and alpha-1-antichymotrypsin in Alzheimer's disease and vascular dementia.
Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation.
Increased blood BACE1 activity as a potential common pathogenic factor of vascular dementia and late onset Alzheimer's disease.
Presenilin-1 polymorphism in Alzheimer's disease and vascular dementia.
Presenilin-1 polymorphism in patients with Alzheimer's disease, vascular dementia and alcohol-associated dementia in Japanese population.
Demyelinating Diseases
Focal demyelination in Alzheimer's disease and transgenic mouse models.
Overcoming failure to repair demyelination in EAE: gamma-secretase inhibition of Notch signaling.
Diabetes Mellitus
The BACE1 inhibitor LY2886721 improves diabetic phenotypes of BACE1 knock-in mice.
Diabetes Mellitus, Type 2
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1.
Associations of Plasma BACE1 Level and BACE1 C786G Gene Polymorphism with Cognitive Functions in Patients with Type 2 Diabetes: A Cross- Sectional Study.
BACE2 plays a role in the insulin receptor trafficking in pancreatic beta-cells.
Exacerbation of poststroke dementia by type 2 diabetes is associated with synergistic increases of beta-site amyloid precursor protein-cleaving enzyme activation and beta-amyloid generation in rat brains.
Polymorphisms of presenilin-1 gene associate with dilated cardiomyopathy susceptibility.
Presenilin-1 Established ER-Ca2+ Leak: a Follow Up on Its Importance for the Initial Insulin Secretion in Pancreatic Islets and ?-Cells upon Elevated Glucose.
The BACE1 inhibitor LY2886721 improves diabetic phenotypes of BACE1 knock-in mice.
[Glucagon-like peptide 1 improves learning and memory abilities of rats with type 2 diabetes].
Disorders of Sex Development
Sex differences in autophagy-mediated diseases: toward precision medicine.
Down Syndrome
Abeta 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis.
Accumulation of Insoluble Amyloid-? in Down's Syndrome is Associated with Increased BACE-1 and Neprilysin Activities.
Activation of the Notch pathway in Down syndrome: cross-talk of Notch and APP.
Alzheimer's disease skin fibroblasts selectively express a bradykinin signaling pathway mediating tau protein Ser phosphorylation.
Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition.
Association between presenilin-1 -48C/T polymorphism and Down's syndrome.
Association between presenilin-1 polymorphism and maternal meiosis II errors in Down syndrome.
Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome.
Characterization of a mouse model overexpressing beta-site APP-cleaving enzyme 2 reveals a new role for BACE2.
Chromosome missegregation and trisomy 21 mosaicism in Alzheimer's disease.
Combined association of Presenilin-1 and Apolipoprotein E polymorphisms with maternal meiosis II error in Down syndrome births.
Down syndrome and beta-amyloid deposition.
Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease.
Elevated expression of beta-site amyloid precursor protein cleaving enzyme 2 in brains of patients with Down syndrome.
Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses.
Expression Profiling of Notch Signalling Pathway and Gamma-Secretase Activity in the Brain of Ts1Cje Mouse Model of Down Syndrome.
Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression.
In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model.
Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome.
Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome.
Insights from modeling the tertiary structure of human BACE2.
Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome.
Partial BACE1 reduction in a Down syndrome mouse model blocks Alzheimer-related endosomal anomalies and cholinergic neurodegeneration: role of APP-CTF.
Presenilin 1 and alpha-1-antichymotrypsin polymorphisms in Down syndrome: no effect on the presence of dementia.
Presenilin-1 exists in the axoplasm fraction in the brains of aged Down's syndrome subjects and non-demented individuals.
Protein expression of BACE1, BACE2 and APP in Down syndrome brains.
The possible effect of microRNA-155 (miR-155) and BACE1 inhibitors in the memory of patients with down syndrome and Alzheimer's disease: Design, synthesis, virtual screening, molecular modeling and biological evaluations.
Upregulation of SET Expression by BACE1 and its Implications in Down Syndrome.
Dysarthria
Dementia, pyramidal system involvement, and leukoencephalopathy with a presenilin 1 mutation.
Novel insertional presenilin 1 mutation causing Alzheimer disease with spastic paraparesis.
Dystonia
Novel insertional presenilin 1 mutation causing Alzheimer disease with spastic paraparesis.
Emergence Delirium
Correlation of Serum BACE1 With Emergence Delirium in Postoperative Patients: A Preliminary Study.
Encephalitis
Gallic Acid is a Dual ?/?-Secretase Modulator that Reverses Cognitive Impairment and Remediates Pathology in Alzheimer Mice.
Encephalomyelitis
Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis.
Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21.
Notch3 inhibition in myelin-reactive T cells down-regulates protein kinase Ctheta and attenuates experimental autoimmune encephalomyelitis.
Overcoming failure to repair demyelination in EAE: gamma-secretase inhibition of Notch signaling.
Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis.
Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21.
Notch3 inhibition in myelin-reactive T cells down-regulates protein kinase Ctheta and attenuates experimental autoimmune encephalomyelitis.
Overcoming failure to repair demyelination in EAE: gamma-secretase inhibition of Notch signaling.
Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitis.
Ependymoma
Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas.
Epilepsy
Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy.
Atypical presentation of a novel Presenilin 1 R377W mutation: sporadic, late-onset Alzheimer disease with epilepsy and frontotemporal atrophy.
BACE1 deficiency causes altered neuronal activity and neurodegeneration.
BACE1 elevation is associated with aberrant limbic axonal sprouting in epileptic CD1 mice.
CA1 hippocampal neuronal loss in familial Alzheimer's disease presenilin-1 E280A mutation is related to epilepsy.
Expression analysis of beta-secretase 1 (BACE1) and its naturally occurring antisense (BACE1-AS) in blood of epileptic patients.
Presenilin-1 mutation Alzheimer's disease: a genetic epilepsy syndrome?
Epilepsy, Temporal Lobe
Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy.
BACE1 elevation is associated with aberrant limbic axonal sprouting in epileptic CD1 mice.
Fatty Liver
Neuronal human BACE1 knockin induces systemic diabetes in mice.
Fibromatosis, Aggressive
Nirogacestat suppresses RANKL-Induced osteoclast formation in vitro and attenuates LPS-Induced bone resorption in vivo.
Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases.
Frontotemporal Dementia
A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch.
Alternative transcripts of presenilin-1 associated with frontotemporal dementia.
Biochemical and Morphological Characterization of the A?PP/PS/Tau Triple Transgenic Mouse Model and Its Relevance to Sporadic Alzheimer's Disease.
Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease.
Dementia mimicking Alzheimer's disease Owing to a tau mutation: CSF and PET findings.
Differential distribution of presenilin-1, Bax, and Bcl-X(L) in Alzheimer's disease and frontotemporal dementia.
Early onset autosomal dominant dementia with ataxia, extrapyramidal features, and epilepsy.
Familial frontotemporal dementia associated with a novel presenilin-1 mutation.
Familial frontotemporal dementia-associated presenilin-1 c.548G>T mutation causes decreased mRNA expression and reduced presenilin function in knock-in mice.
Las noticias de Madrid (News from Madrid).
Mutations in progranulin explain atypical phenotypes with variants in MAPT.
Presenilin-1 Mutations in Alzheimer's Disease: An Update on Genotype-Phenotype Relationships.
Presenilin/gamma-Secretase and Inflammation.
Frontotemporal Lobar Degeneration
Targeting mRNA for Alzheimer's and related dementias.
Genetic Diseases, Inborn
EEG and Granular Osmiophilic Elements in Early-Onset Alzheimer's Disease.
Glioblastoma
?-secretase inhibitor-I enhances radiosensitivity of glioblastoma cell lines by depleting CD133+ tumor cells.
Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch.
Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells.
Gamma-secretase inhibitor DAPT suppresses glioblastoma growth via uncoupling of tumor vessel density from vessel function.
gamma-Secretase is differentially modulated by alterations of homocysteine cycle in neuroblastoma and glioblastoma cells.
MicroRNA-339-5p down-regulates protein expression of ?-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects.
Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase.
Glioma
A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma.
Analysis of presenilin 1 and presenilin 2 expression and processing by newly developed monoclonal antibodies.
Characterization of detergent-insoluble complexes containing the familial Alzheimer's disease-associated presenilins.
Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor.
Gene expression analyses to explore the biomarkers and therapeutic targets for gliomas.
Notch promotes radioresistance of glioma stem cells.
Wild-type TP53 defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs.
Glucose Intolerance
Neuronal human BACE1 knockin induces systemic diabetes in mice.
Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein.
Granulosa Cell Tumor
Effects of an inhibitor of the gamma-secretase complex on proliferation and apoptotic parameters in a FOXL2-mutated granulosa tumor cell line (KGN).
Head Injuries, Closed
Increased expression of the gamma-secretase components presenilin-1 and nicastrin in activated astrocytes and microglia following traumatic brain injury.
Hearing Loss
?-secretase BACE1 is required for normal cochlear function.
Hearing Loss, Noise-Induced
Therapeutic potential of a gamma-secretase inhibitor for hearing restoration in a guinea pig model with noise-induced hearing loss.
Hearing Loss, Sensorineural
Therapeutic potential of a gamma-secretase inhibitor for hearing restoration in a guinea pig model with noise-induced hearing loss.
Heart Failure
BACE1 levels are elevated in congestive heart failure.
Cardiac adenovirus-associated viral Presenilin 1 gene delivery protects the left ventricular function of the heart via regulating RyR2 function in post-ischaemic heart failure.
Heart Septal Defects, Ventricular
Presenilin-1 Polymorphisms Are Not Relevant in Susceptibility to Ventricular Septal Defect: A Case-Control Study.
Hemangioma
Expression of HES and HEY genes in infantile hemangiomas.
Hematologic Neoplasms
Characterization of an atypical gamma-secretase complex from hematopoietic origin.
Hepatitis C
Signal peptide peptidase dependent cleavage of type II transmembrane substrates releases intracellular and extracellular signals.
Hernia, Umbilical
Presenilin genes are downregulated during somitogenesis in the cadmium-induced omphalocele chick model.
Herpes Simplex
Alzheimer's Disease: APP, Gamma Secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and Their Relationships with Herpes Simplex, C. Pneumoniae, Other Suspect Pathogens, and the Immune System.
Overexpression in neurons of human presenilin-1 or a presenilin-1 familial Alzheimer disease mutant does not enhance apoptosis.
Herpes Zoster
The role of intestinal endotoxemia in a rat model of aluminum neurotoxicity.
Hidradenitis Suppurativa
A new nonsense mutation in the POGLUT1 gene in two sisters with Dowling-Degos disease.
Gamma-secretase gene mutations link acne inversa (flexural, scarring acne) with Alzheimer's disease.
Genetic variations in gamma-secretase and PSTPIP1 in hidradenitis suppurativa in Singaporean Chinese.
Hidradenitis suppurativa: haploinsufficiency of gamma-secretase components does not affect gamma-secretase enzyme activity in vitro.
In silico Analysis of Gamma-Secretase-Complex Mutations in Hidradenitis Suppurativa Demonstrates Disease-Specific Substrate Recognition and Cleavage Alterations.
Low prevalence of gamma-secretase complex gene mutations in a large cohort of predominantly Caucasian patients with Hidradenitis Suppurativa.
PRESENILIN 1 Mutations Causing Early-Onset Familial Alzheimer's Disease or Familial Acne Inversa Differ in Their Effects on Genes Facilitating Energy Metabolism and Signal Transduction.
The possible association of hidradenitis suppurativa and Down syndrome: is increased APP expression resulting in impaired Notch signaling the missing link?
Hirschsprung Disease
Identification of Genes Associated with Hirschsprung Disease, Based on Whole-genome Sequence Analysis, and Potential Effects on Enteric Nervous System Development.
HIV Infections
Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease.
Huntington Disease
Apolipoprotein E and presenilin-1 genotypes in Huntington's disease.
Geriatric neurogenetics: oxymoron or reality?
Quantitative interaction proteomics of neurodegenerative disease proteins.
Hydrocephalus
Analysis of apolipoprotein E, alpha1-antichymotrypsin and presenilin-1 genes polymorphisms in dementia caused by normal pressure hydrocephalus in man.
Hydrocephalus and abnormal subcommissural organ in mice lacking presenilin-1 in Wnt1 cell lineages.
Hydrocephalus, Normal Pressure
Analysis of apolipoprotein E, alpha1-antichymotrypsin and presenilin-1 genes polymorphisms in dementia caused by normal pressure hydrocephalus in man.
Hyperalgesia
miR-15b mediates oxaliplatin-induced chronic neuropathic pain through BACE1 down-regulation.
Hypercholesterolemia
Association analysis of genes involved in cholesterol metabolism located within the linkage region on chromosome 10 and Alzheimer's disease.
Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease.
Hyperglycemia
Amyloid-? Production: Major Link Between Oxidative Stress and BACE1.
Contribution of genetic and dietary insulin resistance to Alzheimer phenotype in APP/PS1 transgenic mice.
Elevated circulating amyloid concentrations in obesity and diabetes promote vascular dysfunction.
Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain ?-amyloid through PPAR? activation.
PPAR? Agonist Pioglitazone Reverses Memory Impairment and Biochemical Changes in a Mouse Model of Type 2 Diabetes Mellitus.
Telmisartan Treatment Ameliorates Memory Deficits in Streptozotocin-Induced Diabetic Mice via Attenuating Cerebral Amyloidosis.
Hyperhomocysteinemia
Hyperhomocysteinemia increases beta-amyloid by enhancing expression of gamma-secretase and phosphorylation of amyloid precursor protein in rat brain.
S-adenosylmethionine reduces the progress of the Alzheimer-like features induced by B-vitamin deficiency in mice.
Hyperlipidemias
Elevated circulating amyloid concentrations in obesity and diabetes promote vascular dysfunction.
Hyperlipidemia-induced apoptosis of hippocampal neurons in apoE(-/-) mice may be associated with increased PCSK9 expression.
Polymorphisms of presenilin-1 gene associate with dilated cardiomyopathy susceptibility.
PPAR? Agonist Pioglitazone Reverses Memory Impairment and Biochemical Changes in a Mouse Model of Type 2 Diabetes Mellitus.
Hypersensitivity
Premature death in transgenic mice that overexpress a mutant amyloid precursor protein is preceded by severe neurodegeneration and apoptosis.
Hypertension
Hypertension accelerates the progression of Alzheimer-like pathology in a mouse model of the disease.
Hypertension, Pulmonary
Notch3 signaling promotes the development of pulmonary arterial hypertension.
Propylthiouracil Attenuates Experimental Pulmonary Hypertension via Suppression of Pen-2, a Key Component of Gamma-Secretase.
hypoxanthine phosphoribosyltransferase deficiency
Correction: HPRT Deficiency Coordinately Dysregulates Canonical Wnt and Presenilin-1 Signaling: A Neuro-Developmental Regulatory Role for a Housekeeping Gene?
HPRT deficiency coordinately dysregulates canonical Wnt and presenilin-1 signaling: a neuro-developmental regulatory role for a housekeeping gene?
Hypoxia, Brain
miR-124 Regulates the Expression of BACE1 in the Hippocampus Under Chronic Cerebral Hypoperfusion.
Infarction, Middle Cerebral Artery
Caspase inhibition attenuates accumulation of beta-amyloid by reducing beta-secretase production and activity in rat brains after stroke.
Infections
Astrocytes infected with Chlamydia pneumoniae demonstrate altered expression and activity of secretases involved in the generation of ?-amyloid found in Alzheimer disease.
Author Correction: HIV-1 counteracts an innate restriction by amyloid precursor protein resulting in neurodegeneration.
Cleavage and Sub-Cellular Redistribution of Nuclear Pore Protein 98 by Coxsackievirus B3 Protease 2A Impairs Cardioprotection.
Correlation between HIV-1 seropositivity and prevalence of a gamma-secretase polymorphism in two distinct ethnic populations.
Ets transcription factors ER81 and Elk1 regulate the transcription of the human presenilin 1 gene promoter.
FTY720 Attenuates Infection-Induced Enhancement of A? Accumulation in APP/PS1 Mice by Modulating Astrocytic Activation.
Presence of presenilin 1/2 affects the invasion and replication of Salmonella typhimurium.
Regulation of transcription of the human presenilin-1 gene by ets transcription factors and the p53 protooncogene.
Signal peptide peptidase dependent cleavage of type II transmembrane substrates releases intracellular and extracellular signals.
Insulin Resistance
Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity.
Altered amyloid precursor protein processing regulates glucose uptake and oxidation in cultured rodent myotubes.
Alzheimer's disease And Diabetes: New Insights and Unifying Therapies.
Amyloid-? Induces Hepatic Insulin Resistance In Vivo via JAK2.
Associations of Plasma BACE1 Level and BACE1 C786G Gene Polymorphism with Cognitive Functions in Patients with Type 2 Diabetes: A Cross- Sectional Study.
Biomarkers of Alzheimer disease, insulin resistance, and obesity in childhood.
Can Ketones Help Rescue Brain Fuel Supply in Later Life? Implications for Cognitive Health during Aging and the Treatment of Alzheimer's Disease.
Dicer1-miR-328-Bace1 signalling controls brown adipose tissue differentiation and function.
Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease.
Expression of ?-site APP-cleaving enzyme 1 in the hippocampal tissue of an insulin-resistant rat model of Alzheimer's disease.
Increased ?-site APP cleaving enzyme 1-mediated insulin receptor cleavage in type 2 diabetes mellitus with cognitive impairment.
Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice.
Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein.
The BACE1 inhibitor LY2886721 improves diabetic phenotypes of BACE1 knock-in mice.
The BACE1 product sAPP? induces ER stress and inflammation and impairs insulin signaling.
Toward prevention of Alzheimers disease--potential nutraceutical strategies for suppressing the production of amyloid beta peptides.
Intellectual Disability
Delta-catenin is required for the maintenance of neural structure and function in mature cortex in vivo.
GSK-3 phosphorylates delta-catenin and negatively regulates its stability via ubiquitination/proteosome-mediated proteolysis.
Iron Overload
The Effect of TCM-Induced HAMP on Key Enzymes in the Hydrolysis of AD Model Cells.
Ischemic Attack, Transient
Increased beta-secretase activity and expression in rats following transient cerebral ischemia.
Ischemic Stroke
Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke.
Kidney Diseases
The Notch pathway in podocytes plays a role in the development of glomerular disease.
Leishmaniasis, Cutaneous
Inhibition of gamma-secretase activity without interfering in Notch signalling decreases inflammatory response in patients with cutaneous leishmaniasis.
Leukemia
Effects of gamma-secretase inhibitors on the growth of leukemia cells.
Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T cell Acute Lymphoblastic Leukemia.
Gamma-secretase inhibitors induce erythroid differentiation in erythroid leukemia cell lines.
Gamma-secretase inhibitors suppress the growth of leukemia and lymphoma cells.
Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors.
Inhibition of gamma-secretase affects proliferation of leukemia and hepatoma cell lines through Notch signaling.
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.
NOTCH1-RBPJ complexes drive target gene expression through dynamic interactions with superenhancers.
Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition.
The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
[Inhibitors for Notch and gamma-secretase. Biology of T-cell leukemia]
Leukemia, Lymphoid
Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.
Leukemia, T-Cell
Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia.
[Inhibitors for Notch and gamma-secretase. Biology of T-cell leukemia]
Leukoencephalopathies
Beta-Secretase 1 Underlies Reactive Astrocytes and Endothelial Disruption in Neurodegeneration.
Dementia, pyramidal system involvement, and leukoencephalopathy with a presenilin 1 mutation.
Lewy Body Disease
Enhanced accumulation of phosphorylated alpha-synuclein and elevated beta-amyloid 42/40 ratio caused by expression of the presenilin-1 deltaT440 mutant associated with familial Lewy body disease and variant Alzheimer's disease.
Lissencephaly
Altered morphological and electrophysiological properties of Cajal-Retzius cells in cerebral cortex of embryonic Presenilin-1 knockout mice.
Presenilin-1 deficiency leads to loss of Cajal-Retzius neurons and cortical dysplasia similar to human type 2 lissencephaly.
Lung Neoplasms
Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
MiR-574-3p accelerates cell migration and invasion through regulating BACE1 in Non-Small Cell Lung Cancer.
Rethinking Gamma-secretase Inhibitors for Treatment of Non-small-Cell Lung Cancer: Is Notch the Target?
Lymphoma
Gamma-secretase inhibitors suppress the growth of leukemia and lymphoma cells.
Inhibition of KSHV infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor.
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.
Lymphoma, B-Cell
Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors.
Notch-regulation upon Dll4-stimulation of TGFb-induced apoptosis and gene expression in human B-cell non-Hodgkin lymphomas.
Lymphoma, Primary Effusion
Inhibition of KSHV infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor.
Lymphoma, T-Cell
CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors.
Macular Degeneration
?-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment.
Approaches for detecting lysosomal alkalinization and impaired degradation in fresh and cultured RPE cells: evidence for a role in retinal degenerations.
Malaria
The zymogen of plasmepsin V from Plasmodium falciparum is enzymatically active.
Malformations of Cortical Development
Altered morphological and electrophysiological properties of Cajal-Retzius cells in cerebral cortex of embryonic Presenilin-1 knockout mice.
Presenilin 1 in migration and morphogenesis in the central nervous system.
Presenilin-1 deficiency leads to loss of Cajal-Retzius neurons and cortical dysplasia similar to human type 2 lissencephaly.
Malformations of Cortical Development, Group II
The function of presenilin-1 in amyloid beta-peptide generation and brain development.
Malnutrition
S-adenosyl methionine: A connection between nutritional and genetic risk factors for neurodegeneration in Alzheimer's disease.
Medulloblastoma
Inhibition of neurotrophin receptor p75 intramembran proteolysis by gamma-secretase inhibitor reduces medulloblastoma spinal metastasis.
Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors.
Melanoma
Long-Term Inhibition of Notch in A-375 Melanoma Cells Enhances Tumor Growth Through the Enhancement of AXIN1, CSNK2A3, and CEBPA2 as Intermediate Genes in Wnt and Notch Pathways.
Notch and NOXA-related pathways in melanoma cells.
p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas.
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
memapsin 2 deficiency
?-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects.
Alzheimer's disease neurons fail the acid test.
Axonal and Schwann Cell BACE1 Is Equally Required for Remyelination of Peripheral Nerves.
Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice.
BACE1 controls synaptic function through modulating release of synaptic vesicles.
BACE1 Deficiency Causes Abnormal Neuronal Clustering in the Dentate Gyrus.
BACE1 deficiency causes altered neuronal activity and neurodegeneration.
BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease.
BACE1 regulates the proliferation and cellular functions of Schwann cells.
BACE1-/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization.
Editorial: Implications for BACE1 Inhibitor Clinical Trials: Adult Conditional BACE1 Knockout Mice Exhibit Axonal Organization Defects in the Hippocampus.
Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice.
Presenilin 1 deficiency alters the activity of voltage-gated Ca2+ channels in cultured cortical neurons.
Presenilin 1 deficiency suppresses autophagy in human neural stem cells through reducing ?-secretase-independent ERK/CREB signaling.
Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency.
Presenilin-1 deficiency impairs glutamate-evoked intracellular calcium responses in neurons.
Presenilin-1 deficiency leads to loss of Cajal-Retzius neurons and cortical dysplasia similar to human type 2 lissencephaly.
Presenilins: molecular switches between proteolysis and signal transduction.
Reversing hypomyelination in BACE1-null mice with Akt-DD overexpression.
Memory Disorders
7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease.
?-Asarone Mitigates Amyloidosis and Downregulates RAGE in a Transgenic Mouse Model of Alzheimer's Disease.
A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice.
Alzheimer's therapy targeting the ?-secretase enzyme BACE1: Benefits and potential limitations from the perspective of animal model studies.
Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice.
BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease.
BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice.
BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease.
BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology.
BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions.
BAG-1M co-activates BACE1 transcription through NF-?B and accelerates A? production and memory deficit in Alzheimer's disease mouse model.
Beneficial effects of the ?-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression.
CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease.
Deletion of the Cathepsin B Gene Improves Memory Deficits in a Transgenic Alzheimer's Disease Mouse Model Expressing A?PP Containing the Wild-Type ?-Secretase Site Sequence.
Deletion of the eIF2? Kinase GCN2 fails to rescue the memory decline associated with Alzheimer's disease.
Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice.
Depletion of Caveolin-1 in Type-2 Diabetes Model Induces Alzheimer's disease Pathology Precursors.
Effects of BACE1 haploinsufficiency on APP processing and A? concentrations in male and female 5XFAD Alzheimer mice at different disease stages.
Electroacupuncture Ameliorates Neuroinflammation-Mediated Cognitive Deficits through Inhibition of NLRP3 in Presenilin1/2 Conditional Double Knockout Mice.
Enhanced activity of hippocampal BACE1 in a mouse model of postmenopausal memory deficits.
FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders.
Gastrodin suppresses BACE1 expression under oxidative stress condition via inhibition of the PKR/eIF2? pathway in Alzheimer's disease.
Genetic and pharmacological basis for therapeutic inhibition of beta- and gamma-secretases in mouse models of Alzheimer's memory deficits.
Hyperhomocysteinemia increases beta-amyloid by enhancing expression of gamma-secretase and phosphorylation of amyloid precursor protein in rat brain.
Indirubin-3'-monoxime rescues spatial memory deficits and attenuates beta-amyloid-associated neuropathology in a mouse model of Alzheimer's disease.
Inhibition of GSK3?-mediated BACE1 expression reduces Alzheimer-associated phenotypes.
Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease.
Long-term oral melatonin alleviates memory deficits, reduces amyloid-? deposition associated with downregulation of BACE1 and mitophagy in APP/PS1 transgenic mice.
Marginal vitamin A deficiency facilitates Alzheimer's pathogenesis.
Mechanisms that lessen benefits of ?-secretase reduction in a mouse model of Alzheimer's disease.
miRNA-31 Improves Cognition and Abolishes Amyloid-? Pathology by Targeting APP and BACE1 in an Animal Model of Alzheimer's Disease.
Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer's disease.
Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice.
Phospho-eIF2? level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice.
Picrorhiza kurroa Prevents Memory Deficits by Inhibiting NLRP3 Inflammasome Activation and BACE1 Expression in 5xFAD Mice.
Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain ?-amyloid through PPAR? activation.
Review of synthesis, biological assay and QSAR studies of ?-secretase inhibitors.
Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice.
Synaptic activity prompts gamma-secretase-mediated cleavage of EphA4 and dendritic spine formation.
Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
The Alzheimer's disease beta-secretase enzyme, BACE1.
The Cysteine Protease Inhibitor, E64d, Reduces Brain Amyloid-? and Improves Memory Deficits in Alzheimer's Disease Animal Models by Inhibiting Cathepsin B, but not BACE1, ?-Secretase Activity.
Trans-cinnamaldehyde improves neuroinflammation-mediated NMDA receptor dysfunction and memory deficits through blocking NF-?B pathway in presenilin1/2 conditional double knockout mice.
Transcriptional regulation of the presenilin-1 gene: implication in Alzheimer's disease.
Val97Leu mutant presenilin-1 induces tau hyperphosphorylation and spatial memory deficit in mice and the underlying mechanisms.
Wharton's Jelly-derived mesenchymal stem cells alleviate memory deficits and reduce amyloid-? deposition in an APP/PS1 transgenic mouse model.
Metabolic Syndrome
Dysregulation of SREBP2 induces BACE1 expression.
Las noticias de Madrid (News from Madrid).
Multiple Myeloma
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma.
Multiple Sclerosis
Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves.
Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21.
Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis.
Muscular Diseases
Light and electron microscopic immunolocalization of presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy.
Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis.
Muscular Dystrophies, Limb-Girdle
Geriatric neurogenetics: oxymoron or reality?
Myoclonus
A novel mutation (L250V) in the presenilin 1 gene in a Japanese familial Alzheimer's disease with myoclonus and generalized convulsion.
A novel presenilin 1 duplication mutation (Ile168dup) causing Alzheimer's disease associated with myoclonus, seizures and pyramidal features.
A systematic review of familial Alzheimer's disease: Differences in presentation of clinical features among three mutated genes and potential ethnic differences.
Presenilin-1 Mutations in Alzheimer's Disease: An Update on Genotype-Phenotype Relationships.
Myositis
BACE-1, PS-1 and sAPP? levels are increased in plasma from sporadic inclusion body myositis patients: surrogate biomarkers among inflammatory myopathies.
Increased BACE1 mRNA and noncoding BACE1-antisense transcript in sporadic inclusion-body myositis muscle fibers--possibly caused by endoplasmic reticulum stress.
Light and electron microscopic immunolocalization of presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy.
NOGO is increased and binds to BACE1 in sporadic inclusion-body myositis and in AbetaPP-overexpressing cultured human muscle fibers.
Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis.
Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging.
Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis.
Myositis, Inclusion Body
BACE-1, PS-1 and sAPP? levels are increased in plasma from sporadic inclusion body myositis patients: surrogate biomarkers among inflammatory myopathies.
Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis.
Nasopharyngeal Carcinoma
Tricetin Suppresses Migration and Presenilin-1 Expression of Nasopharyngeal Carcinoma through Akt/GSK-3? Pathway.
Neoplasm Metastasis
Inhibition of neurotrophin receptor p75 intramembran proteolysis by gamma-secretase inhibitor reduces medulloblastoma spinal metastasis.
The expression of presenilin 1 enhances carcinogenesis and metastasis in gastric cancer.
Neoplasms
3,5-bis(2,4-difluorobenzylidene)-4-piperidone, a novel compound that affects pancreatic cancer growth and angiogenesis.
A Miniaturized 1536-Well Format gamma-Secretase Assay *
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret Cancer Centre, Chicago and California phase II consortia.
A secreted type of beta1,6 N-acetylglucosaminyltransferase V (GnT-V), a novel angiogenesis inducer, is regulated by gamma-secretase.
Activating Notch1 mutations in mouse models of T-ALL.
Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model.
ADAMs family members as amyloid precursor protein alpha-secretases.
Allopregnanolone Reverses Bioenergetic Deficits in Female Triple Transgenic Alzheimer's Mouse Model.
An exo-cell assay for examining real-time gamma-secretase activity and inhibition.
Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells.
Antimalarial Drug Artemether Inhibits Neuroinflammation in BV2 Microglia Through Nrf2-Dependent Mechanisms.
Antisense Oligonucleotide Therapeutic Approach for Suppression of Ataxin-1 Expression: A Safety Assessment.
Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.
Behavioral alterations associated with apoptosis and down-regulation of presenilin 1 in the brains of p53-deficient mice.
Beta-Secretase 1 (BACE1) Is Down-Regulated in Invasive Ductal Carcinoma of Breast.
Bisphenol A disrupts Notch signaling by inhibiting gamma-secretase activity and causes eye dysplasia of Xenopus laevis.
Bromotyrosine-derived metabolites from an Indonesian marine sponge in the family Aplysinellidae (Order Verongiida).
CD40/CD40L interaction induces Abeta production and increases gamma-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling.
CD45 deficiency drives amyloid-? peptide oligomers and neuronal loss in Alzheimer's disease mice.
Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies.
Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches.
CTL Attenuation Regulated by PS1 in Cancer-Associated Fibroblast.
Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.
Effects of an inhibitor of the gamma-secretase complex on proliferation and apoptotic parameters in a FOXL2-mutated granulosa tumor cell line (KGN).
Elevated serum HER-2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression.
EpCAM-associated claudin-7 supports lymphatic spread and drug resistance in rat pancreatic cancer.
Epidermal Growth Factor Receptor and Notch Pathways Participate in the Tumor Suppressor Function of {gamma}-Secretase.
Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor.
Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes.
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.
Functional characterization of novel presenilin-2 variants identified in human breast cancers.
Gamma-secretase and the intramembrane proteolysis of Notch.
gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease.
gamma-Secretase in biology and medicine.
Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.
Gamma-secretase inhibitor DAPT suppresses glioblastoma growth via uncoupling of tumor vessel density from vessel function.
Gamma-secretase inhibitor treatment promotes VEGF-A-driven blood vessel growth and vascular leakage but disrupts neovascular perfusion.
Gamma-secretase inhibitor, a potential target therapy for MUC2-positive colorectal carcinoma.
Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor.
Gene expression profiling in cells with enhanced gamma-secretase activity.
Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice.
Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.
GSK-3 phosphorylates delta-catenin and negatively regulates its stability via ubiquitination/proteosome-mediated proteolysis.
High activities of BACE1 in brains with mild cognitive impairment.
Human ROBO1 is cleaved by metalloproteinases and gamma-secretase and migrates to the nucleus in cancer cells.
Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695.
Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation.
Identification of key miRNA-gene pairs in gastric cancer through integrated analysis of mRNA and miRNA microarray.
Increased NF-?B signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.
Increased TNFR1 expression and signaling in injured peripheral nerves of mice with reduced BACE1 activity.
Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis.
Inhibition of ?-secretase activity by a monoclonal antibody against the extracellular hydrophilic loop of presenilin 1.
Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors.
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma.
Inhibition of gamma-secretase by the CK1 inhibitor IC261 does not depend on CK1delta.
Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression.
Interleukin-1 receptor type 1 is a substrate for gamma-secretase-dependent regulated intramembrane proteolysis.
Isorhynchophylline ameliorates cognitive impairment via modulating amyloid pathology, tau hyperphosphorylation and neuroinflammation: Studies in a transgenic mouse model of Alzheimer's disease.
Lack of association between IDE genetic variability and Down's syndrome.
Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease.
MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease.
Metformin may antagonize Lin28 and/or Lin28B activity, thereby boosting let-7 levels and antagonizing cancer progression.
Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis.
Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant.
Nirogacestat suppresses RANKL-Induced osteoclast formation in vitro and attenuates LPS-Induced bone resorption in vivo.
NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production.
Notch inhibition in Kaposi's sarcoma tumor cells leads to mitotic catastrophe through nuclear factor-kappaB signaling.
NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.
NOTCH signaling as a novel cancer therapeutic target.
Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma.
Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials.
Notch signaling, gamma-secretase inhibitors, and cancer therapy.
Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia.
Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma.
Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim.
Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling.
Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide.
Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung.
Palmitate-activated astrocytes via serine palmitoyltransferase increase BACE1 in primary neurons by sphingomyelinases.
Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.
Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.
Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities.
Processing of Notch and amyloid precursor protein by gamma-secretase is spatially distinct.
Protein kinase C regulation of intracellular and cell surface amyloid precursor protein (APP) cleavage in CHO695 cells.
Protein processing mechanisms: from angiotensin-converting enzyme to Alzheimer's disease.
Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements.
Rational targeting of Notch signaling in cancer.
Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases.
Shedding of the p75NTR neurotrophin receptor is modulated by lipid rafts.
T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling.
The botanical origin and antioxidant, anti-BACE1 and antiproliferative properties of bee pollen from different regions of South Korea.
The emerging role of ?-secretases in cancer.
The molecular programme of tumour reversion: the steps beyond malignant transformation.
The novel membrane protein TMEM59 modulates complex glycosylation, cell surface expression and secretion of the amyloid precursor protein.
The role of proteolysis in Alzheimer's disease.
Total synthesis of the dictyodendrins as an arena to highlight emerging synthetic technologies.
TRAF6 promotes TGF?-induced invasion and cell-cycle regulation via Lys63-linked polyubiquitination of Lys178 in TGF? type I receptor.
Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway.
Tumor necrosis factor-alpha-elicited stimulation of gamma-secretase is mediated by c-Jun N-terminal kinase-dependent phosphorylation of presenilin and nicastrin.
Tumor reversion: mesenchymal-epithelial transition as a critical step in managing the tumor-microenvironment cross-talk.
z-Leucinyl-Leucinyl-Norleucinal Induces Apoptosis of Human Glioblastoma Tumor-Initiating Cells by Proteasome Inhibition and Mitotic Arrest Response.
Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss.
Nephrotic Syndrome
The pathogenic role of notch activation in podocytes.
Nervous System Diseases
An Overview of ?-Amyloid Cleaving Enzyme 1 (Bace1) in Alzheimer's Disease Therapy Elucidating its Exosite-Binding Antibody and Allosteric Inhibitor.
BACE1 Levels Correlate with Phospho-Tau Levels in Human Cerebrospinal Fluid.
Can BACE1 Inhibition Mitigate Early Axonal Pathology in Neurological Diseases?
MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1.
Piperazine-substituted chalcones: a new class of MAO-B, AChE, and BACE-1 inhibitors for the treatment of neurological disorders.
The Ever-Changing Morphology of Hippocampal Granule Neurons in Physiology and Pathology.
Neuralgia
miR-15b mediates oxaliplatin-induced chronic neuropathic pain through BACE1 down-regulation.
Neuroblastoma
A natural squamosamide derivative FLZ reduces amyloid-beta production by increasing non-amyloidogenic AbetaPP processing.
A?1-42-mediated down-regulation of Uch-L1 is dependent on NF-?B activation and impaired BACE1 lysosomal degradation.
Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines.
Activation of peroxisome proliferator-activated receptor delta suppresses BACE1 expression by up-regulating SOCS1 in a JAK2/STAT1-dependent manner.
Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage.
AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation.
Aggravation of Alzheimer's disease due to the COX-2-mediated reciprocal regulation of IL-1? and A? between glial and neuron cells.
Akt activity in presenilin 1 wild-type and mutation transfected human SH-SY5Y neuroblastoma cells after serum deprivation and high glucose stress.
Alpha-secretase as a therapeutic target.
Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts.
Alzheimer's disease presenilin-1 exon 9 deletion and L250S mutations sensitize SH-SY5Y neuroblastoma cells to hyperosmotic stress-induced apoptosis.
Alzheimer's disease presenilin-1 expression modulates the assembly of neurofilaments.
Amyloid Beta-Peptide Increases BACE1 Translation through the Phosphorylation of the Eukaryotic Initiation Factor-2?.
Amyloid precursor protein compartmentalization restricts beta-amyloid production: therapeutic targets based on BACE compartmentalization.
An upstream element containing an ETS binding site is crucial for transcription of the human presenilin-1 gene.
Analysis of presenilin 1 and presenilin 2 expression and processing by newly developed monoclonal antibodies.
ApoE isoforms and carboxyl-terminal-truncated apoE4 forms affect neuronal BACE1 levels and A? production independently of their cholesterol efflux capacity.
Aspartyl protease inhibitor pepstatin binds to the presenilins of Alzheimer's disease.
Association of active gamma-secretase complex with lipid rafts.
BACE-1 inhibition prevents the ?-secretase inhibitor evoked A? rise in human neuroblastoma SH-SY5Y cells.
BACE1 (beta-secretase) inhibitory chromone glycosides from Aloe vera and Aloe nobilis.
BACE1 activity impairs neuronal glucose oxidation: rescue by beta-hydroxybutyrate and lipoic acid.
BACE1 and presenilin/?-secretase regulate proteolytic processing of KCNE1 and 2, auxiliary subunits of voltage-gated potassium channels.
Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling.
Ca(2+) stores and capacitative Ca(2+) entry in human neuroblastoma (SH-SY5Y) cells expressing a familial Alzheimer's disease presenilin-1 mutation.
Carnosic acid suppresses the production of amyloid-? 1-42 by inducing the metalloprotease gene TACE/ADAM17 in SH-SY5Y human neuroblastoma cells.
Caspase cleavage of exon 9 deleted presenilin-1 is an early event in apoptosis induced by calcium ionophore A 23187 in SH-SY5Y neuroblastoma cells.
Caspase cleaved presenilin-1 is part of active gamma-secretase complexes.
CD40/CD40L interaction induces Abeta production and increases gamma-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling.
Cellular consequences of the expression of Alzheimer's disease-causing presenilin 1 mutations in human neuroblastoma (SH-SY5Y) cells.
Changes in cholesterol metabolism are associated with PS1 and PS2 gene regulation in SK-N-BE.
Chinese Presenilin-1 V97L mutation enhanced Abeta42 levels in SH-SY5Y neuroblastoma cells.
Cholinergic- and stress-induced signaling activities in cells overexpressing wild-type and mutant presenilin-1.
Cleavage of Alzheimer's amyloid precursor protein by alpha-secretase occurs at the surface of neuronal cells.
Constitutive and cytokine-regulated expression of presenilin-1 and presenilin-2 genes in human neural cell lines.
Design, Synthesis, and Evaluation of Donepezil-Like Compounds as AChE and BACE-1 Inhibitors.
Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template.
Differential effects of transforming growth factor-beta(s) and glial cell line-derived neurotrophic factor on gene expression of presenilin-1 in human post-mitotic neurons and astrocytes.
Disrupted intracellular calcium regulates BACE1 gene expression via nuclear factor of activated T cells 1 (NFAT 1) signaling.
Divalent cation tolerance protein binds to ?-secretase and inhibits the processing of amyloid precursor protein.
Downregulated miR-29c correlates with increased BACE1 expression in sporadic Alzheimer's disease.
Dysregulation of SREBP2 induces BACE1 expression.
Effects of early maternal separation on biobehavioral and neuropathological markers of Alzheimer's disease in adult male rats.
Effects of galantamine on ?-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells.
Engineered Proteolytic Nanobodies Reduce Abeta Burden and Ameliorate Abeta Induced Cyto-toxicity.
Enhanced generation of intracellular Abeta42 amyloid peptide by mutation of presenilins PS1 and PS2.
Ethanol-induced PGE2 up-regulates A? production through PKA/CREB signaling pathway.
Ets transcription factors ER81 and Elk1 regulate the transcription of the human presenilin 1 gene promoter.
Extracellular release of BACE1 holoproteins from human neuronal cells.
Gadd153 and NF-?B Crosstalk Regulates 27-Hydroxycholesterol-Induced Increase in BACE1 and ?-Amyloid Production in Human Neuroblastoma SH-SY5Y Cells.
gamma-Secretase is differentially modulated by alterations of homocysteine cycle in neuroblastoma and glioblastoma cells.
Histone acetyltransferase p300 mediates histone acetylation of PS1 and BACE1 in a cellular model of Alzheimer's disease.
Human neuroblastoma cells transfected with two Chinese presenilin 1 mutations are sensitized to trophic factor withdrawal and protected by insulin-like growth factor-1.
Hypoxia and reoxygenation increased BACE1 mRNA and protein levels in human neuroblastoma SH-SY5Y cells.
IGF-1-induced processing of the amyloid precursor protein family is mediated by different signaling pathways.
Indomethacin Disrupts the Formation of ?-Amyloid Plaques via an ?2-Macroglobulin-Activating lrp1-Dependent Mechanism.
Inhibition of ?-site amyloid precursor protein cleaving enzyme 1 and cholinesterases by pterosins via a specific structure-activity relationship with a strong BBB permeability.
Inhibition of neurite outgrowth by familial Alzheimer's disease-linked presenilin-1 mutations.
Inhibition of prolylendopeptidase does not affect gamma-secretase processing of amyloid precursor protein in a human neuroblastoma cell line.
Intraventricular Delivery of siRNA Nanoparticles to the Central Nervous System.
Leptin attenuates BACE1 expression and amyloid-? genesis via the activation of SIRT1 signaling pathway.
Luteolin Reduces BACE1 Expression through NF-?B and Estrogen Receptor Mediated Pathways in HEK293 and SH-SY5Y Cells.
Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer's disease and related models.
Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
Morphine via nitric oxide modulates beta-amyloid metabolism: a novel protective mechanism for Alzheimer's disease.
Morphological change by overexpression of D385A dominant negative presenilin 1 in human neuroblastoma SH-SY5Y cells.
Multi-target inhibition ability of neohesperidin dictates its neuroprotective activity: Implication in Alzheimer's disease therapeutics.
Muscarine enhances soluble amyloid precursor protein secretion in human neuroblastoma SH-SY5Y by a pathway dependent on protein kinase C(alpha), src-tyrosine kinase and extracellular signal-regulated kinase but not phospholipase C.
N141I mutant presenilin-2 gene enhances neuronal cell death and decreases bcl-2 expression.
Neuronal ?-amyloid generation is independent of lipid raft association of ?-secretase BACE1: analysis with a palmitoylation-deficient mutant.
Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate.
New type of BACE1 siRNA delivery to cells.
Nicergoline stimulates protein kinase C mediated alpha-secretase processing of the amyloid precursor protein in cultured human neuroblastoma SH-SY5Y cells.
Non-proteolytic effect of beta-site APP-cleaving enzyme 1 (BACE1) on sodium channel function.
Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein.
Novel presenilin 1 and 2 double knock-out cell line for in vitro validation of PSEN1 and PSEN2 mutations.
Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2? pathway.
Oxidative stress promotes JNK-dependent amyloidogenic processing of normally expressed human APP by differential modification of alpha-, beta- and gamma-secretase expression.
Oxidative stress up-regulates presenilin 1 in lipid rafts in neuronal cells.
Palmitate Increases ?-site A?PP-Cleavage Enzyme 1 Activity and Amyloid-? Genesis by Evoking Endoplasmic Reticulum Stress and Subsequent C/EBP Homologous Protein Activation.
Palmitate-Induced SREBP1 Expression and Activation Underlies the Increased BACE 1 Activity and Amyloid Beta Genesis.
Phenylbutyric acid rescues endoplasmic reticulum stress-induced suppression of APP proteolysis and prevents apoptosis in neuronal cells.
PI3-K- and PKC-dependent up-regulation of APP processing enzymes by retinoic acid.
PPAR-? agonist regulates amyloid-? generation via inhibiting BACE-1 activity in human neuroblastoma SH-SY5Y cells transfected with APPswe gene.
Presenilin 1 is involved in the maturation of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1).
Presenilin attenuates receptor-mediated signaling and synaptic function.
Presenilin-1 in neuroblastoma cells.
Presenilin-1 mutations alter K+ currents in the human neuroblastoma cell line, SH-SY5Y.
Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration.
Proteasome-mediated effects on amyloid precursor protein processing at the gamma-secretase site.
Regulation of transcription of the human presenilin-1 gene by ets transcription factors and the p53 protooncogene.
Reticulons RTN3 and RTN4-B/C interact with BACE1 and inhibit its ability to produce amyloid beta-protein.
Rosuvastatin reduces caspase-3 activity and up-regulates alpha-secretase in human neuroblastoma SH-SY5Y cells exposed to A beta.
Serum Starvation Induces BACE1 Processing and Secretion.
Sevoflurane But Not Propofol Provided Dual Effects of Cell Survival in Human Neuroblastoma SH-SY5Y Cells.
Statins and the Squalene Synthase Inhibitor Zaragozic Acid Stimulate the Non-Amyloidogenic Pathway of Amyloid-beta Protein Precursor Processing by Suppression of Cholesterol Synthesis.
Surface trafficking of sodium channels in cells and in hippocampal slices.
Systemic administration of fibroblast growth factor-2 (FGF2) reduces BACE1 expression and amyloid pathology in APP23 mice.
Targeting Notch pathway induces growth inhibition and differentiation of neuroblastoma cells.
The expression of the nicotinic acetylcholine receptor ?3 subunit in the brains of patients with Alzheimer's disease and its effects on ?- and ?-secretases and Notch signal transduction in SH-SY5Y cells.
The Molecular Mechanism of Chronic High-Dose Corticosterone-Induced Aggravation of Cognitive Impairment in APP/PS1 Transgenic Mice.
The over-expression of the wild type or mutant forms of the presenilin-1 protein alters glycoprotein processing in a human neuroblastoma cell line.
The presenilin 1 deltaE9 mutation gives enhanced basal phospholipase C activity and a resultant increase in intracellular calcium concentrations.
The transmembrane domain of the Alzheimer's beta-secretase (BACE1) determines its late Golgi localization and access to beta -amyloid precursor protein (APP) substrate.
The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha.
Thiamine deficiency increases beta-secretase activity and accumulation of beta-amyloid peptides.
Transition-state analogue gamma-secretase inhibitors stabilize a 900 kDa presenilin/nicastrin complex.
Two novel presenilin-1 mutations (I249L and P433S) in early onset Chinese Alzheimer's pedigrees and their functional characterization.
Unnatural amino acid-substituted (hydroxyethyl)urea peptidomimetics inhibit gamma-secretase and promote the neuronal differentiation of neuroblastoma cells.
[The effect of two newly Chinese presenilin-1 mutations on the sensitivity to trophic factor withdrawal in human neuroblastoma cells]
Neurodegenerative Diseases
A New Decision Tree to Solve the Puzzle of Alzheimer's Disease Pathogenesis Through Standard Diagnosis Scoring System.
Alternative transcripts of presenilin-1 associated with frontotemporal dementia.
Alzheimer's disease-causing proline substitutions lead to presenilin 1 aggregation and malfunction.
BACE1 and cholinesterase inhibitory activities of compounds from Cajanus cajan and Citrus reticulata: an in silico study.
Dicer1-miR-328-Bace1 signalling controls brown adipose tissue differentiation and function.
Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways.
Familial Alzheimer's disease: oxidative stress, beta-amyloid, presenilins, and cell death.
Fragment-guided approach to incorporating structural information into a CoMFA study: BACE-1 as an example.
Gracilins: Spongionella-derived promising compounds for Alzheimer disease.
Ibuprofen rescues abnormalities in periodontal tissues in conditional presenilin 1 and presenilin 2 double knockout mice.
Increased Inflammatory Response Both in Brain and in Periphery in Presenilins Conditional Double Knock-Out Mice.
Inhibition of gamma-Secretase Activity by Helical beta-Peptide Foldamers.
Multi-Target ?-Protease Inhibitors from Andrographis paniculata: In Silico and In Vitro Studies.
NACP/alpha-synuclein, NAC, and beta-amyloid pathology of familial Alzheimer's disease with the E184D presenilin-1 mutation: a clinicopathological study of two autopsy cases.
Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease.
Neurodegenerative disease and adult neurogenesis.
Synaptic activity prompts gamma-secretase-mediated cleavage of EphA4 and dendritic spine formation.
Synthesis and Pharmacological Evaluation of 8- and 9-Substituted Benzolactam-V8 Derivatives as Potent Ligands for Protein Kinase C, a Therapeutic Target for Alzheimer's Disease.
The potential of natural product vs neurodegenerative disorders: In silico study of artoflavanocoumarin as BACE-1 inhibitor.
Trimethoxylated Halogenated Chalcones as Dual Inhibitors of MAO-B and BACE-1 for the Treatment of Neurodegenerative Disorders.
Widespread neuronal expression of the presenilin-1 early-onset Alzheimer's disease gene in the murine brain.
Neuroinflammatory Diseases
A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-? and neuroinflammation in APP transgenic mice.
AF710B, a Novel M1/?1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer’s Disease.
Ameliorative effect of alendronate against intracerebroventricular streptozotocin induced alteration in neurobehavioral, neuroinflammation and biochemical parameters with emphasis on A? and BACE-1.
Astrocytes & Astrocyte derived Extracellular Vesicles in Morphine Induced Amyloidopathy: Implications for Cognitive Deficits in Opiate Abusers.
Deficiency of Neuronal p38? MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1.
Down-regulated expression of microRNA-338-5p contributes to neuropathology in Alzheimer's disease.
Ethanol-induced PGE2 up-regulates A? production through PKA/CREB signaling pathway.
Gallic Acid is a Dual ?/?-Secretase Modulator that Reverses Cognitive Impairment and Remediates Pathology in Alzheimer Mice.
Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits.
Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models.
Inhibitory effect of ethanol extract of Nannochloropsis oceanica on lipopolysaccharide-induced neuroinflammation, oxidative stress, amyloidogenesis and memory impairment.
Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology.
Neuroprotective effect of 1-Deoxynojirimycin on cognitive impairment, ?-amyloid deposition, and neuroinflammation in the SAMP8 mice.
NF-?B-regulated microRNA-574-5p underlies synaptic and cognitive impairment in response to atmospheric PM2.5 aspiration.
Paeoniflorin Atttenuates Amyloidogenesis and the Inflammatory Responses in a Transgenic Mouse Model of Alzheimer's Disease.
Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Repeated administration of the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) modulates neuroinflammation and amyloid plaque load in mice bearing amyloid precursor protein and presenilin-1 mutant transgenes.
STAT3 inhibition protects against neuroinflammation and BACE1 upregulation induced by systemic inflammation.
Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease.
The BACE inhibitor NB-360 in preclinical models: From ?-amyloid reduction to downstream disease-relevant effects.
The modulatory role of prime identified compounds in Geophila repens in mitigating scopolamine-induced neurotoxicity in experimental rats of Alzheimer's disease via attenuation of cholinesterase, ?-secretase, MAPt levels and inhibition of oxidative stress imparts inflammation.
TSPO ligand PK11195 alleviates neuroinflammation and beta-amyloid generation induced by systemic LPS administration.
Valproic acid potentiates curcumin-mediated neuroprotection in lipopolysaccharide induced rats.
Neurologic Manifestations
Difficult case of a rare form of familial Alzheimer's disease with PSEN1 P117L mutation.
Neuronal Ceroid-Lipofuscinoses
A novel p.Leu(381)Phe mutation in presenilin 1 is associated with very early onset and unusually fast progressing dementia as well as lysosomal inclusions typically seen in Kufs disease.
Neurosyphilis
BACE1 and Other Alzheimer's-Related Biomarkers in Cerebrospinal Fluid and Plasma Distinguish Alzheimer's Disease Patients from Cognitively-Impaired Neurosyphilis Patients.
Niemann-Pick Disease, Type C
Cholesterol-Dependent Energy Transfer between Fluorescent Proteins-Insights into Protein Proximity of APP and BACE1 in Different Membranes in Niemann-Pick Type C Disease Cells.
Obesity
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1.
Bace1-dependent amyloid processing regulates hypothalamic leptin sensitivity in obese mice.
Neuronal human BACE1 knockin induces systemic diabetes in mice.
Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice.
Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein.
Olfaction Disorders
Differential spatial expression of peripheral olfactory neuron-derived BACE1 induces olfactory impairment by region-specific accumulation of ?-amyloid oligomer.
Osteoporosis
Dimorphic effects of Notch signaling in bone homeostasis.
Osteosarcoma
How the NOTCH Pathway Contributes to the Ability of Osteosarcoma Cells to Metastasize.
Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation.
Notch signaling contributes to the pathogenesis of human osteosarcomas.
Tomatidine Represses Invasion and Migration of Human Osteosarcoma U2OS and HOS Cells by Suppression of Presenilin 1 and c-Raf-MEK-ERK Pathway.
Ovarian Neoplasms
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret Cancer Centre, Chicago and California phase II consortia.
Down-regulation of Notch1 by gamma-secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780.
Inhibition of gamma-secretase in Notch1 signaling pathway as a novel treatment for ovarian cancer.
Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion.
PDGFB as a vascular normalization agent in an ovarian cancer model treated with a gamma-secretase inhibitor.
Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.
The Role of Notch and Gamma-secretase Inhibition in an Ovarian Cancer Model.
Pancreatic Neoplasms
Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice.
Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer.
[Suppressive effects of gamma-secretase inhibitor DAPT on the proliferation of pancreatic cancer cells].
Pancreatitis
Loss of Bace1 in mice does not alter the severity of caerulein induced pancreatitis.
Notch signaling is required for exocrine regeneration after acute pancreatitis.
Paraparesis, Spastic
A novel presenilin 1 mutation (V261L) associated with presenile Alzheimer's disease and spastic paraparesis.
A novel presenilin 1 mutation (Y154N) in a patient with early onset Alzheimer's disease with spastic paraparesis.
A novel presenilin-1 mutation (Leu85Pro) in early-onset Alzheimer disease with spastic paraparesis.
A presenilin 1 mutation (Arg278Ser) associated with early onset Alzheimer's disease and spastic paraparesis.
A presenilin 1 mutation (L420R) in a family with early onset Alzheimer disease, seizures and cotton wool plaques, but not spastic paraparesis.
A systematic review of familial Alzheimer's disease: Differences in presentation of clinical features among three mutated genes and potential ethnic differences.
A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1.
Cotton wool plaques in non-familial late-onset Alzheimer disease.
Novel insertional presenilin 1 mutation causing Alzheimer disease with spastic paraparesis.
PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease.
Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities.
Presenilin-1 Mutations in Alzheimer's Disease: An Update on Genotype-Phenotype Relationships.
Pure spastic paraparesis associated with a novel presenilin 1 R278K mutation.
Variable phenotype of Alzheimer's disease with spastic paraparesis.
Variant Alzheimer disease with spastic paraparesis: a rare presenilin-1 mutation.
Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype.
Variant Alzheimer's disease with spastic paraparesis: clinical characterization.
Very early onset Alzheimer's disease with spastic paraparesis associated with a novel presenilin 1 mutation (Phe237Ile).
Widespread white matter and conduction defects in PSEN1-related spastic paraparesis.
Paraplegia
Novel insertional presenilin 1 mutation causing Alzheimer disease with spastic paraparesis.
Spastic paraplegia preceding PSEN1-related familial Alzheimer's disease.
Temporal-spatial expression of presenilin 1 and the production of amyloid-beta after acute spinal cord injury in adult rat.
Parkinson Disease
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1.
Association of a BACE1 Gene Polymorphism with Parkinson's Disease in a Norwegian Population.
Cerebrospinal fluid A?42 levels and APP processing pathway genes in Parkinson's disease.
Downregulation of lncRNA BACE1-AS improves dopamine-dependent oxidative stress in rats with Parkinson's disease by upregulating microRNA-34b-5p and downregulating BACE1.
Lead neurotoxicity: exploring the potential impact of lead substitution in zinc-finger proteins on mental health.
Quantitative interaction proteomics of neurodegenerative disease proteins.
Parkinsonian Disorders
A novel mutation (G217D) in the Presenilin 1 gene ( PSEN1) in a Japanese family: presenile dementia and parkinsonism are associated with cotton wool plaques in the cortex and striatum.
A novel presenilin 1 mutation (Leu418Trp) associated with spasticity, parkinsonism, and white matter lesion in a dominant Alzheimer's family.
Dopa Responsive Parkinsonism in an Early Onset Alzheimer's Disease Patient with a Presenilin 1 Mutation (A434T).
Early onset autosomal dominant dementia with ataxia, extrapyramidal features, and epilepsy.
Multimodal Imaging in a Patient With Alzheimer Disease and Parkinsonism Because of a Presenilin-1 Mutation.
New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism.
Presenilin-1 Mutations in Alzheimer's Disease: An Update on Genotype-Phenotype Relationships.
Sex differences in autophagy-mediated diseases: toward precision medicine.
Peripheral Nerve Injuries
Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves.
Peripheral Nervous System Diseases
Beta secretase activity in peripheral nerve regeneration.
Peritoneal Fibrosis
Preventive effect of Notch signaling inhibition by a gamma-secretase inhibitor on peritoneal dialysis fluid-induced peritoneal fibrosis in rats.
Pheochromocytoma
BACE1 inhibitory activity of fungal endophytic extracts from Malaysian medicinal plants.
Effects of human presenilin 1 isoforms on proliferation and survival of rat pheochromocytoma cell line PC12.
Isoflurane preconditioning inhibited isoflurane-induced neurotoxicity.
Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate.
Role of tyrosine phosphorylation in the antioxidant effects of the p75 neurotrophin receptor.
The transcription factor Yin Yang 1 is an activator of BACE1 expression.
Pick Disease of the Brain
A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques.
Pick bodies in a family with presenilin-1 Alzheimer's disease.
Presenilin-1 expression in Pick's disease.
Pilonidal Sinus
Hidradenitis Suppurativa: Proposal of Classification in Two Endotypes with Two-Step Cluster Analysis.
Pituitary Neoplasms
HIF-1? Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy.
Pneumonia
Gamma-secretase inhibitor reduces allergic pulmonary inflammation by modulating Th1 and Th2 responses.
Polymyositis
BACE-1, PS-1 and sAPP? levels are increased in plasma from sporadic inclusion body myositis patients: surrogate biomarkers among inflammatory myopathies.
Polyradiculoneuropathy
Expression analysis of BDNF, BACE1 and their antisense transcripts in inflammatory demyelinating polyradiculoneuropathy.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Expression analysis of BDNF, BACE1 and their antisense transcripts in inflammatory demyelinating polyradiculoneuropathy.
Pre-Eclampsia
Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.
CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors.
Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia.
Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell lines.
PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.
T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome.
The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines.
Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model.
Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
NOTCH and PI3K-AKT pathways intertwined.
Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases.
Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas.
Pathobiology of acute lymphoblastic leukemia.
PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.
Relapsed T Cell ALL: Current Approaches and New Directions.
T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome.
Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
The challenge of targeting notch in hematologic malignancies.
The notch pathway promotes NF-?B activation through Asb2 in T cell acute lymphoblastic leukemia cells.
The role of NOTCH1 signaling in T-ALL.
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.
Prion Diseases
Prion protein expression alters APP cleavage without interaction with BACE-1.
PrPSc accumulation in neuronal plasma membranes links Notch-1 activation to dendritic degeneration in prion diseases.
Protein Deficiency
NF{kappa}B-dependent Control of BACE1 Promoter Transactivation by A{beta}42.
Renal Insufficiency
The pathogenic role of notch activation in podocytes.
Renal Insufficiency, Chronic
Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and A? expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer's disease: A pilot study.
Retinoblastoma
Presenilin 1 overexpressions in Chinese hamster ovary (CHO) cells decreases the phosphorylation of retinoblastoma protein: relevance for neurodegeneration.
Retinopathy of Prematurity
Gamma-Secretase Inhibitor, DAPT, Prevents the Development of Retinopathy of Prematurity in a Rat Model by Regulating the Delta-Like Ligand 4/Notch Homolog-1 (DLL4/Notch-1) Pathway.
Presenilin-2 (PS2) expression up-regulation in a model of retinopathy of prematurity and pathoangiogenesis.
Sarcoma, Ewing
Inhibition of notch signaling induces neural differentiation in Ewing sarcoma.
Scrapie
A gamma-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains.
Seizures
A novel mutation (L250V) in the presenilin 1 gene in a Japanese familial Alzheimer's disease with myoclonus and generalized convulsion.
A novel presenilin 1 duplication mutation (Ile168dup) causing Alzheimer's disease associated with myoclonus, seizures and pyramidal features.
A presenilin 1 mutation (L420R) in a family with early onset Alzheimer disease, seizures and cotton wool plaques, but not spastic paraparesis.
A presenilin 1 mutation (Ser169Pro) associated with early-onset AD and myoclonic seizures.
A systematic review of familial Alzheimer's disease: Differences in presentation of clinical features among three mutated genes and potential ethnic differences.
Association between BACE1 gene polymorphisms and focal seizures in a Chinese Han population.
BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease.
BACE1-/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization.
BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains.
Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6.
CA1 hippocampal neuronal loss in familial Alzheimer's disease presenilin-1 E280A mutation is related to epilepsy.
Early-Onset Network Hyperexcitability in Presymptomatic Alzheimer's Disease Transgenic Mice Is Suppressed by Passive Immunization with Anti-Human APP/A? Antibody and by mGluR5 Blockade.
Electric Stimulation of Neurogenesis Improves Behavioral Recovery After Focal Ischemia in Aged Rats.
Epilepsy and cognitive impairments in Alzheimer disease.
Epileptic Seizures in AD Patients.
Low brain ascorbic acid increases susceptibility to seizures in mouse models of decreased brain ascorbic acid transport and Alzheimer's disease.
Presenilin-1 Mutations in Alzheimer's Disease: An Update on Genotype-Phenotype Relationships.
Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons.
Seizure protein 6 controls glycosylation and trafficking of kainate receptor subunits GluK2 and GluK3.
Sepsis
Lipopolysaccharide-induced Notch signaling activation through JNK-dependent pathway regulates inflammatory response.
The Role of Secretase Pathway in Long-term Brain Inflammation and Cognitive Impairment in an Animal Model of Severe Sepsis.
Skin Neoplasms
Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development.
Spinal Cord Injuries
Inhibition of Gamma-Secretase Promotes Axon Regeneration After a Complete Spinal Cord Injury.
Nogo BACE jumps on the exosome.
Temporal-spatial expression of presenilin 1 and the production of amyloid-beta after acute spinal cord injury in adult rat.
Treatment with a Gamma-Secretase Inhibitor Promotes Functional Recovery in Human iPSC- Derived Transplants for Chronic Spinal Cord Injury.
Spinocerebellar Ataxias
Early-onset familial Alzheimer's disease related to presenilin 1 mutation resembling autosomal dominant spinocerebellar ataxia.
Geriatric neurogenetics: oxymoron or reality?
Quantitative interaction proteomics of neurodegenerative disease proteins.
Regulation of BACE1 by miR-29a/b in a cellular model of Spinocerebellar ataxia 17.
Squamous Cell Carcinoma of Head and Neck
Presenilin 1 is frequently overexpressed and positively associates with epidermal growth factor receptor expression in head and neck squamous cell carcinoma.
Starvation
Fibroblast growth factor rescues brain endothelial cells lacking presenilin 1 from apoptotic cell death following serum starvation.
Presenilins in the heart: presenilin-2 expression is increased by low glucose and by hypoxia in cardiac cells.
Serum Starvation Induces BACE1 Processing and Secretion.
Stomach Neoplasms
?-Secretase 1 and its Naturally Occurring Anti-Sense RNA are Down-Regulated in Gastric Cancer.
MicroRNA-133a inhibits gastric cancer cells growth, migration, and epithelial-mesenchymal transition process by targeting presenilin 1.
Notch signaling in gastrointestinal tract (review).
The expression of presenilin 1 enhances carcinogenesis and metastasis in gastric cancer.
Stroke
Alzheimer's associated amyloid and tau deposition co-localizes with a homeostatic myelin repair pathway in two mouse models of post-stroke mixed dementia.
Atorvastatin promotes presenilin-1 expression and Notch1 activity and increases neural progenitor cell proliferation after stroke.
DAPT protects brain against cerebral ischemia by down-regulating the expression of Notch 1 and Nuclear factor kappa B in rats.
Development of molecular tools for diagnosis of Alzheimer's disease that are based on detection of amyloidogenic proteins.
Early biomarkers for post-stroke cognitive impairment.
Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation.
Presenilin-1 polymorphism and hereditary cerebral hemorrhage with amyloidosis, Dutch type.
Proliferating Reactive Astrocytes Are Regulated by Notch-1 in the Peri-Infarct Area After Stroke.
Self-renewal and differentiation of reactive astrocyte-derived neural stem/progenitor cells isolated from the cortical peri-infarct area after stroke.
Subarachnoid Hemorrhage
Gamma-secretase inhibitor (GSI1) attenuates morphological cerebral vasospasm in 24h after experimental subarachnoid hemorrhage in rats.
Synucleinopathies
Enhanced accumulation of phosphorylated alpha-synuclein in double transgenic mice expressing mutant beta-amyloid precursor protein and presenilin-1.
Tauopathies
cPLA2 and desaturases underlie the tau hyperphosphorylation offset induced by BACE knock-down in neuronal primary cultures.
Early functional connectivity deficits and progressive microstructural alterations in the TgF344-AD rat model of Alzheimer's Disease: A longitudinal MRI study.
Enhanced accumulation of tau in doubly transgenic mice expressing mutant betaAPP and presenilin-1.
Mutations in progranulin explain atypical phenotypes with variants in MAPT.
Teratocarcinoma
Differential effects of transforming growth factor-beta(s) and glial cell line-derived neurotrophic factor on gene expression of presenilin-1 in human post-mitotic neurons and astrocytes.
Thiamine Deficiency
Thiamine deficiency alters APP but not presenilin-1 immunoreactivity in vulnerable brain regions.
Thymoma
Electroacupuncture ameliorates beta-amyloid pathology and cognitive impairment in Alzheimer disease via a novel mechanism involving activation of TFEB (transcription factor EB).
Toxic Optic Neuropathy
Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of ?-secretase inhibitors.
Trauma, Nervous System
Inhibition of Gamma-Secretase Promotes Axon Regeneration After a Complete Spinal Cord Injury.
Triple Negative Breast Neoplasms
DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer.
Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.
Uterine Cervical Neoplasms
Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes.
[Expression of Notch intracellular domain in cervical cancer and effect of DAPT on cervical cancer cell]
Vascular Diseases
Elevated circulating amyloid concentrations in obesity and diabetes promote vascular dysfunction.
Linking vascular disorders and Alzheimer's disease: Potential involvement of BACE1.
The Alzheimer's disease beta-secretase enzyme, BACE1.
Vascular System Injuries
The Decrease of Uch-L1 Activity Is a Common Mechanism Responsible for A? 42 Accumulation in Alzheimer's and Vascular Disease.
Vasospasm, Intracranial
Gamma-secretase inhibitor (GSI1) attenuates morphological cerebral vasospasm in 24h after experimental subarachnoid hemorrhage in rats.
Whooping Cough
FTY720 Attenuates Infection-Induced Enhancement of A? Accumulation in APP/PS1 Mice by Modulating Astrocytic Activation.
Multiple pathways of apolipoprotein E signaling in primary neurons.
Neurotoxic mechanisms triggered by Alzheimer's disease-linked mutant M146L presenilin 1: involvement of NO synthase via a novel pertussis toxin target.